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Abstract 
 
The family of aminoacyl-tRNA synthetases (aaRS) are essential to all 
living cells.  They are fundamental to setting the genetic code during protein 
synthesis by charging tRNA with a specific amino acid.  As such, they have 
been selected by the pharmaceutical industries as optimal targets.  A new 
class of antimicrobial benzoxaborole compounds was identified as a potent 
inhibitor of leucyl-tRNA synthetase (LeuRS) and therefore of protein 
synthesis.  AN2690 (5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole) 
blocks fungal cytoplasmic LeuRS by trapping tRNALeu in the editing site of 
the enzyme’s CP1 domain.  Some resistant mutations are located outside of 
the CP1 hydrolytic editing active site. Thus, their mode of action was not 
understood.  A combination of X-ray crystallography, molecular dynamics, 
biochemical experiments, and mutational analysis of a distal benzoxaborole-
resistant mutant uncovered a eukaryote-specific tyrosine “switch” that is 
critical to tRNA-dependent post-transfer editing.  The tyrosine “switch” has 
three states that shift between interactions with a lysine and the 3’-hydroxyl 
of the tRNA terminus, to inhibit or promote post-transfer editing.  The 
benzoxaborole’s mechanism of action capitalizes upon one of these editing 
active site states.  Evolution of this tunable editing mechanism in eukaryotic 
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and archaeal LeuRSs is proposed to enable precise control of aminoacylation 
fidelity.    
The aaRSs have also been adapted through evolution for alternate 
functions that are entirely distinct from proteins synthesis.  In E. coli, small 
fractions of LeuRS were identified outside the cytoplasm, in the periplasmic 
space and also associated with the membrane.  Under certain stresses, 
LeuRS and tRNALeu re-located into the media.  In some cases, LeuRS 
appeared to be fragmented with one part associated with the membrane, and 
a second part in the periplasmic space. It is hypothesized that E. coli LeuRS 
plays a non-canonical role as a leucine sensor and cell signaling akin to yeast 
and mammalian cells.  
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Chapter I. Introduction 
I.1 Overview of aminoacyl-tRNA synthetases 
I.1.1 AARS classification. 
Translation of the genetic code requires a group of adaptor molecules called 
aminoacyl-tRNAs.  To attach a particular amino acid to its cognate tRNA, the aminoacyl-
tRNA synthetases (AARSs), an ancient enzyme family, are recruited to generate and 
maintain the pool of accurately aminoacylated aminoacyl-tRNAs (Ibba & Söll, 2000; 
Mascarenhas et al., 2009; Schimmel, 1987). Each amino acid is recognized by a specific 
AARS, but can be linked to more than one tRNA.  This degeneracy, also known as the 
genetic code (Crick et al., 1961), is one of the most important discoveries of the 20th 
century. 
The covalent attachment of amino acid to its cognate tRNA occurs in two steps within 
the aminoacylation active site of the AARSs.  First, the amino acid is activated by ATP to 
form an aminoacyl-adenylate intermediate. Second, the activated amino acid is 
transferred to either the 2’- or 3’-OH of the A76 adenosine at the 3’-end of the tRNA, 
generating the aminoacyl-tRNA (Mascarenhas et al., 2009; Pang et al., 2014). 
Although they share a common mechanism, the AARSs are divided into two classes 
based on active site structure and sequence similarities (Table 1.1) (Arnez & Moras, 
1997; Cusack et al., 1990; Eriani et al., 1990; Ribas de Pouplana & Schimmel, 2001).  
Typically, the cores of class I AARSs are defined by the presence of a Rossmann 
dinucleotide-binding fold (Rould et al., 1989), which was first observed in 
dehydrogenases (Buehner et al., 1974; Rossmann et al., 1974) and mainly composed of 
six parallel β-strands with four flanking α-helixes.  Two signature peptides, “KMSKS” 
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(Lys-Met-Ser-Lys-Ser) (Hountondji et al., 1986) and “HIGH” (His-Ile-Gly-His) 
(Webster et al., 1984), are directly involved in ATP-dependent amino acid activation.  
Class II AARSs usually exist as dimers or tetramers. Their catalytic core is comprised of 
seven antiparallel β-strands linked by multiple helices and loops.  Three semi-conserved 
motifs are identified based on sequence homology, forming a helix-loop-strand (motif 1), 
strand-loop-strand (motif 2) and strand-helix (motif 3) (Cusack et al., 1990; Eriani et al., 
1990).  Motif 1 (gφxxφxxpφφ) plays a critical role in dimerization and is found at the 
interface of the dimer.  Both motif 2 [(F/Y/H)Rx(E/D)(4-12x)(R/H)xxxFxxx(D/E)] and 
motif 3 (λxφgφgφeRφφφφφ) constitute the aminoacylation active site1 (Figure 1.1).   
 
Table 1.1  Classification of AARSs based  
on architectural and  sequence similarity* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Highlighted (in orange color) AARSs contain proofreading activities  
to clear misactivated or mischarged amino acids. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  The abbreviations are: x, variant; φ, hydrophobic; λ, small amino acid.	  
Class I Class II 
Ia IIa 
LeuRS SerRS 
IleRS ThrRS 
ValRS AlaRS 
MetRS GlyRS 
CysRS ProRS 
ArgRS HisRS 
  
Ib IIb 
GlnRS AspRS 
GluRS AsnRS 
LysRS-I LysRS-II 
  
Ic IIc 
TyrRS PheRS 
TrpRS  
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Figure 1.1. Conserved peptides or motifs in the catalytic sites of class I and II 
AARSs. (Left) Crystal structure of E. coli GlnRS in complex with ATP and tRNAGln. 
(PDB ID: 1GTR) (Perona et al., 1993). Conserved HIGH and (K)MSK(S) (actual 
sequence is VMSKR) are highlighted in yellow and green respectively. The terminal 
adenosine ribose of tRNA (A76) approaches ATP via its 2’-hydroxyl group.  (Wright et 
al.) Crystal structure of yeast AspRS in complex with ATP and tRNAAsp. (PDB ID: 
1ASZ) (Cavarelli et al., 1994) Conserved motifs 1, 2 and 3 are highlighted in yellow, 
green and blue respectively.  The terminal adenosine ribose of tRNA approaches ATP by 
its 3’-hydroxyl group. 
 
Because of their distinct structures, the two classes of AARSs catalyze 
aminoacylation via difference mechanisms.  Class I AARS binds ATP in an extended 
conformation and the amino acid is charged at the 2’-OH of tRNA terminal adenosine 
ribose (Perona et al., 1993).  In contrast, the ATP-binding pocket in class II AARS force 
the γ-phosphate group of ATP to bend over its adenine base, allowing the 3’-OH of the 
tRNA’s A76 ribose to be accessible for aminoacylation (Figure 1.1) (Cavarelli et al., 
1994). 
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I.1.2 Mechanism of the aminoacylation 
During protein translation, AARSs ensure a specific amino acid will be covalently 
attached to the 3’-end of its cognate tRNA with high fidelity.  The reaction occurs via two 
steps (Figure 1.2).   
	  
Figure 1.2.  Cartoon illustration of the two-step aminoacylation reaction catalyzed 
by AARSs.  The first step includes the activation of amino acid, forming aminoacyl 
adenylate (AA-AMP) at the aminoacylation active site.  The second step involves the 
transfer of the activated amino acid to the 3’-end of tRNA.	  	  
 
In the first step, the α-carboxylate oxygen group of amino acid attacks the α-
phosphate of ATP, generating a phospho-anhydride linkage between the amino acid and 
AMP.  This AA-AMP intermediate remains in the active site releasing the pyrophosphate 
(PPi).  In the second step, the 2’-OH or 3’-OH group (for class I or class II AARSs, 
respectively) of the tRNA terminal adenosine ribose attacks the carboxyl carbon of AA-
AMP intermediate. The mixed anhydride bond is cleaved and amino acid transferred to 
the 3’-end of the tRNA (Figure 1.3). 	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Figure 1.3.  The two-step aminoacylation reaction catalyzed by class I AARSs.  (Top) 
Step one involves the nucleophilic attack from the α-carboxyl oxygen of the amino acid 
to the α-phosphate group of ATP, forming the aminoacyl-adenylate intermediate (AA-
AMP).  (Bottom) In step two, the 2’-hydroxyl group (specific for class I AARSs) of the 
tRNA terminal adenosine ribose nucleophilically attacks the carboxyl carbon of AA-
AMP, generating the aminoacyl-tRNA (AA-tRNA). 	  
The crystal structure of T. thermophilus leucyl-tRNA synthetase (LeuRS) in complex 
with leucyl-adenylate (5’-O-[N-(leucyl)-sulfamoyl] adenosine); (Leu-AMS) provides 
molecular details of the amino acid and ATP-binding pockets (Cusack et al., 2000). 
Residues Glu540 and Glu574 form hydrogen bonds to the ribose hydroxyls and Met576 
is stacked with the adenine base.  The conserved “KMSKS” and “HIGH” motifs, together 
with Val577 and Met638 shape the adenine base pocket through hydrogen bonds (First & 
Fersht, 1995).  The leucine-binding pocket is mainly defined by Asp80 and His541 via 
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interactions with the amino group and carbonyl oxygen, respectively. To maintain 
specificity, a group of residues constitute the leucine side chain-binding pocket: Met40, 
Phe41, Tyr43, Phe501, Tyr507, His541 and His545 (Figure 1.4) (Cusack et al., 2000).  In 
class II AARSs, motif 2 has been demonstrated to play an important role in transition 
state stabilization when AA-AMP is formed (Cusack, 1997).  Crystal structure analysis 
shows ATP is nestled in a pocket mainly comprised by motif 2 and 3 (Cavarelli et al., 
1994; Stehlin et al., 1997). 
 
Figure 1.4.  Leucine and ATP binding pocket of LeuRS.  Crystal structure of T. 
thermophilus LeuRS with the leucyl-adenylate analog Leu-AMS (5’-O-[N-(leucyl)-
sulfamoyl] adenosine) bound in the aminoacylation active site. (PDB ID: 1H3N)(Cusack 
et al., 2000) Residues with hydrogen bond interactions to Leu-AMS are highlighted in 
yellow.  The backbone region for the conserved HMGH and (K)MSKS regions are 
highlighted in orange and purple cartoon, respectively. Leucine-binding pocket residues 
Met40, Phe41, Tyr43, Phe501, Tyr507, His541 and His545 are colored green.	  
 
I.1.3 Structure of leucyl-tRNA synthetase 
The overall crystal structure of E. coli LeuRS in complex with tRNALeu and leucyl-
adenylate analog (Leu-AMS) provides a comprehensive view of this enzyme (Figure 1.5) 
(Palencia et al., 2012).  Similar to isoleucyl-tRNA synthetase (IleRS) and valyl-tRNA 
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synthetase (ValRS), the connective polypeptide 1 (CP1) domain is inserted into the 
catalytic domain via two flexible β-strands (Cusack et al., 2000; Hou et al., 1991; Starzyk 
et al., 1987).  The CP1 domain provides the enzyme a secondary active site and 
specifically hydrolyzes mischarged tRNAs (Mursinna et al., 2001).  In prokaryotic 
LeuRSs, an additional small domain called the leucine-specific domain (LSD) is inserted 
just upstream of the “KMSKS” loop. It plays a critical role for aminoacylation and may 
aid the translocation of the tRNA 3’-end between the aminoacylation to the editing active 
site (Vu & Martinis, 2007).   
 
Figure 1.5.  Crystal structure of E. coli LeuRS complexed with tRNALeu and Leu-
AMS in the aminoacylation conformation. The overall structure is organized into 
discrete functional domains highlighted with different colors: catalytic domain, cyan; 
anticodon-binding domain, yellow; C-terminal binding domain, pink; CP1 domain, green; 
Zn-binding domain 1, orange (ZBD-2 not shown); and leucine-specific domain, black 
(PDB ID: 4AQ7)(Palencia et al., 2012).  The tRNALeu is drawn as a brown tube.  
Conserved sequences HMGH and KMSKS are highlighted in purple and red, 
respectively. 
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LeuRS also contains two zinc-binding domains (ZBD-1 and ZBD-2).  Ironically, the 
CP1 domain is inserted downstream of the ZBD-1 domain in LeuRS from bacteria and 
the mitochondria of eukaryotes, and upstream in LeuRS from archaea and cytoplasm of 
eukaryotic organisms. The superposition of Pyrococcus horikoshii and Thermus 
thermophilus LeurRS-tRNALeu complexes reveals that the ZBD-1 domain is mobile 
during the aminoacylation reaction (Tukalo et al., 2005).  The closed, ordered position is 
sterically imcompatible with the entry path of the tRNA 3’-end into the catalytic site. 
Nevertheless, in the absence of tRNA, packing of the ZBD-1 domain over the leucyl-
adenylate protects the transient intermediate from premature hydrolysis. Upon tRNA 
binding, coordinated reorientation of the ZBD-1 and the editing domain allows the 
aminoacylation reaction to occur (Tukalo et al., 2005). 
The C-terminal domain (CTD) is in close proximity to the anticodon loop of tRNALeu.  
However, unlike most other class I AARSs, LeuRS does not use its anticodon-binding 
domain (ABD) to recognize specific residues of tRNA anticodon (Asahara et al., 1993; 
Soma et al., 1999).  Rather, it uses a unique C-termianl domain that interacts with the 
elbow of tRNALeu (Palencia et al., 2012). 
I.1.4 AARSs in protein translation 
When released from the AARS active site, correctly charged aminoacyl-tRNA is 
transferred to the ribosomal A site by elongation factor Tu (EF-Tu) (LaRiviere et al., 
2001).  EF-Tu employs a GTP-dependent conformational change to dissociate 
aminoacyl-tRNA from the ternary complex.  Within the ribosome, a nascent polypeptide 
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chain is generated within the P site where amino acids are covalently attached to the 
growing peptide chain from 3’-end of aminoacyl-tRNAs (Figure 1.6) (Ban et al., 2000).   
 
Figure 1.6.  Cartoon representation of protein synthesis pathway.  Aminoacyl-tRNAs 
are synthesized by AARS, transferred by EF-Tu and utilized in the ribosome to 
synthesize polypeptides.  AARS is colored in grey, EF-Tu in yellow and the ribosome in 
orange. Different amino acids are represented by a colored oval, square, star, and circle.  
The L-shaped black bars and straight white bars represent tRNA and mRNA, 
respectively. 	  
 
I.2 Fidelity of aminoacyl-tRNA synthetases 
I.2.1 Editing pathways in AARSs. 
To maintain high fidelity in the protein translation process, cells have developed 
multiple proofreading checkpoints, including tRNA aminoacylation within AARSs 
(Mascarenhas et al., 2009), aminoacyl-tRNA transfer by EF-Tu (LaRiviere et al., 2001), 
and peptide bond synthesis in the ribosome (Ogle et al., 2002; Zaher & Green, 2009) 
(Figure 1.6).  Serving as the first step to match a particular amino acid to its cognate 
tRNA, AARSs are critical to set the genetic code and ensure the high accuracy of protein 
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synthesis.  Defects in AARSs editing can lead to accumulation of misfolded proteins, 
eventually resulting in neurodegenerative diseases (Lee et al., 2006; Nangle et al., 2006) 
or even premature cell death in bacteria (Karkhanis et al., 2007). 
Linus Pauling first predicted the error rate in protein synthesis to be about 1 in 20, 
based on the structural similarity of amino acids, particularly, those that differed by only 
a single methyl group (Pauling, 1958) (Figure 1.7).  However, the error rate for the 
incorporation of valine to isoleucine site in chicken ovalbumin was observed to be around 
1 in 3000 (Loftfield, 1963).  In order to explain this discrepancy, Alan Fersht proposed 
that some AARSs might possess a secondary active site that corrects errors made in the 
primary active site (Fersht, 1977).  
 
Figure 1.7.  Chemical structures of branched chain L-amino acids, methionine and 
norvaline.  The side chain similarities between leucine and other amino acids, as well as 
norvaline, a metabolic intermediate, are challenges for LeuRS to maintain a high 
aminoacylation fidelity.  
 
Alan Fersht’s theory hypothesized that some AARSs, including LeuRS, IleRS and 
ValRS, maintain a high fidelity through a double sieve editing mechanism (Figure 1.8). 
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The first sieve, which is in the aminoacylation active site, excludes structurally dissimilar 
amino acids but allows structurally similar amino acids such as leucine, isoleucine and 
valine to pass.  The secondary hydrolytic active site, which is in the CP1 domain, 
provides a fine sieve to specifically hydrolyze those mischarged amino acid, while 
releasing correctly charged tRNAs as end products (Mursinna et al., 2004; Palencia et al., 
2012). 
	  
Figure 1.8.  The double sieve model and its corresponding regions within E. coli 
LeuRS. Two separate active sites with distinct recognition strategies significantly 
enhance fidelity in aminoacylation.  The first (coarse) sieve is colored in yellow while the 
second (fine) sieve is colored in green. The cartoon on the right is adapted from Mursinna 
and Martinis, 2004. 	  	  
Out of twenty AARSs, nine have been reported to possess editing activities, which 
include LeuRS (Englisch et al., 1986; Mursinna et al., 2004), IleRS (Baldwin & Berg, 
1966), ValRS (Fersht & Kaethner, 1976), methionyl-tRNA synthetase (MetRS) (Fersht & 
Dingwall, 1979) (class I AARSs) and alanyl-tRNA synthetase (AlaRS) (Tsui & Fersht, 
1981), phenylalanyl-tRNA synthetase (PheRS) (Yarus, 1972), prolyl-tRNA synthetase 
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(ProRS) (Beuning & Musier-Forsyth, 2000), lysyl-tRNA synthetase (LysRS) 
(Jakubowski, 1999) and threonyl-tRNA synthetase (ThrRS) (Dock-Bregeon et al., 2004) 
(class II AARSs). 
Depending on the molecules or types of bonds to be hydrolyzed, two editing 
pathways have been identified (Sarkar et al., 2011; Williams & Martinis, 2006). Pre-
transfer editing and post-transfer editing occur before or after the transfer of amino acid 
to tRNA, respectively (Figure 1.9).  In pre-transfer editing, the mis-activated amino acid 
is cleaved to generate free amino acid and AMP.  In contrast, post-transfer editing cleaves 
the ester bond of mischarged tRNA, leading to the release of non-cognate amino acid and 
free tRNA.  The predominance of pre- or post-transfer editing is enzyme-specific 
(Martinis & Boniecki, 2010).  For example, E. coli LeuRS is mainly dependent on post-
transfer editing (Englisch et al., 1986), while yeast cytoplasmic LeuRS has an amino 
acid-dependent shift between two editing pathways (Sarkar & Martinis, 2011).  
 
Figure 1.9.  Two editing pathways in AARSs.  Post-transfer editing hydrolyzes 
mischarged tRNA to form free amino acid and tRNA while pre-transfer editing leads to 
hydrolysis of mis-activated amino acid to generate free amino acid and AMP. 
 
E. coli LeuRS in complex with tRNALeu crystal structures clearly show two distinct 
conformations for aminoacylation or editing (Palencia et al., 2012) (Figure 1.10).  For 
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instance, the 3’-end of tRNALeu is either buried in the aminoacylation active site, or 
transfered to the CP1 domain’s post-transfer editing pocket.  This dynamic editing 
process ensures optimal orientation of AARS to catalyze aminoacylation or editing 
reactions. 
 
Figure 1.10.  Two conformations of E. coli LeuRS-tRNALeu complex. The 3’-end of 
the tRNA is buried in the aminoacylation core (left) or transferred to the CP1 domain’s 
editing pocket (Wright et al.) (PDB ID: 4AQ7, 4ARC) (Palencia et al., 2012). The CP1 
domain is colored in cyan while the rest of LeuRS is colored in yellow. Blue tubes 
represent tRNALeu.  
 
I.2.2 Post-transfer editing 
Post-transfer editing is the primary editing mechanism used by many AARSs to 
preserve high fidelity in protein synthesis.  For example, in class I AARSs, LeuRS, IleRS 
and ValRS utilize the CP1 domain to catalyze post-transfer editing.  Sequence alignment 
indicates that the most conserved region within the LeuRS CP1 domain is the threonine-
rich region, or “T-rich region”(Mursinna et al., 2001).  Both in vitro (Zhai & Martinis, 
2005) and computional analyses (Boero, 2011; Hagiwara et al., 2010) have supported 
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that the first two neighboring threonines within this region collaborate to stabilize the 
intermediate state when the mischarged tRNA is hydrolyzed (Zhao et al., 2015) (Figure 
1.11).  The first and second threonine sustains the interactions with the carbonyl group 
oxygen and the 3’-hydroxyl group of the tRNA terminal adenosine ribose, respectively.  
The last threonine (also named the editing site discrimination residue) defines the shape 
of the editing pocket to ensure that the correctly charged leucyl-tRNALeu is not 
hydrolyzed (Mursinna et al., 2001). 
 
Figure 1.11. Two threonines within bacterial LeuRS editing domain facilitate post-
transfer editing in a water-dependent manner.  a. The intermediate state of post-
transfer editing reaction with critical interactions highlighted in dashed lines.  b. 
Sequence alignment of the LeuRS CP1 threonine-rich region with conserved, 
homologous and divergent amino acids colored in blue, red and yellow/green, 
respectively. The left figure is adapted from Hagiwara et al 2010.  Abbreviations are as 
follows: Ec, Escherichia coli; Bs, Bacillus subtilis; Tt, Thermus 
thermophilus; Hp, Helicobacter pylori; Sa, Staphylococcus aureus; Se, Salmonella 
enterica; Sp, Streptococcus pneumonia; and Sc-mit, Saccharomyces 
cerevisiae mitochondrial.  Ca, Candida albicans; Sc, Saccharomyces cerevisiae; 
Ce, Caenorhabditis elegans; Hs, Homo sapiens; Ab, Aciduliprofundum boonei; 
Mm, Methanosarcina mazei; Ph, Pyrococcus horikoshii; Si, Sulfolobus islandicus; and c, 
cytoplasmic. 
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The crystal structure of T. thermophilus LeuRS complexed with the post-transfer 
editing analog, 2’-(L-norvalyl) amino-2’-deoxyadenosine (Nva2AA), provides molecular 
details of the post-transfer editing pocket (Lincecum et al., 2003). The three conserved 
threonine residues within the T-rich region forms critical hydrogen bond interactions with 
the analog.  A universally conserved Asp347 stabilizes the α-amino group of the amino 
acid group (Lincecum et al., 2003) (Figure 1.12).   
 
Figure 1.12. Editing pocket within the LeuRS CP1 domain.  The post-transfer editing 
substrate analog 2’-(L-norvalyl) amino-2’-deoxyadenosine (Nva2AA) bound in the 
editing active site of the T. thermophilus LeuRS CP1 domain (PDB ID: 
1OBC)(Lincecum et al., 2003).  The conserved threonine-rich region is highlighted in 
green and critical residues are colored in yellow. 
 
The structural dynamics of LeuRS between the aminoacylation and editing 
conformations implicate the importance of relocalization of the tRNA 3’-end in post-
transfer editing. The two flexible β-strands that link the CP1 domain to the main LeuRS 
	   16	  
body can facilitate post-transfer editing, probably due to their specific interactions with 
tRNA (Betha et al., 2007).  A “translocation peptide” within the CP1 domain has also 
been reported.  When it is mutated, the translocation of the tRNA 3’-end to the editing 
active site is bypassed and product is directly released (Hellmann & Martinis, 2009). 
Class II AARSs also utilize post-transfer editing to maintain aminoacylation fidelity. 
For example, ThrRS hydrolyzes mischarged seryl-tRNAThr at a specific site in the N-
terminal domain and discriminates against valine using a unique zinc ion (Dock-Bregeon 
et al., 2000).  AlaRS’s editing domain is weakly related to the N-terminal domain of 
ThrRS but is unrelated to that found in class I AARSs (Beebe et al., 2003; Dock-Bregeon 
et al., 2004; Dock-Bregeon et al., 2000).  Bacterial ProRS posesses a novel insertion 
domain (INS) domain to specifically hydrolyze Ala-tRNAPro (Wong et al., 2002) while 
PheRS has evolved a secondary tRNA binding domain (B2 domain) to hydrolyze Tyr-
tRNAPhe (Roy & Ibba, 2006). 
In bacterial ProRS, both alanine and cysteine can be activated and charged to 
tRNAPro. The INS domain is responsible to specifically hydrolyze Ala-tRNAPro in cis 
(Wong et al., 2002). However, it lacks a cysteine-specific editing function. Another free-
standing protein called Ybak has been shown to clear mischarged Cys-tRNAPro in trans 
through formation of a ternary (ProRS:Ybak:tRNA) complex (An & Musier-Forsyth, 
2005; Ruan & Söll, 2005). Therefore, Ybak acts as a “third sieve” to enhance ProRS 
fidelity in aminoacylation.  Other genome-encoded trans-editing factors such as AlaXP 
(Chong et al., 2008) and ProXP (Liu et al., 2015) are also reported to prevent 
mistranslation. 
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I.2.3 Pre-transfer editing  
Pre-transfer editing hydrolyzes misactivated AA-AMP prior to transfer of the amino 
acid group to tRNA.  Several mechanisms have been proposed, which include enzyme-
catalyzed hydrolysis of noncognate adenylate when it is formed in the aminoacylation 
active site (pathway 1) and selective release of noncognate adenyate to the surrounding 
solution, followed by non-enzymatic hydrolysis (pathway 2) (Figure 1.13). These pre-
transfer editing pathways have been shown to be dependent and independent of tRNA. In 
addition, a tRNA-dependent pre-transfer editing pathway (pathway 3) has been 
hypothesized based on fluorescence probe studies that show AA-AMP is transferred from 
the aminoacylation site to the CP1 domain based editing site to be hydrolyzed 
(Hendrickson et al., 2002; Nomanbhoy et al., 1999).  It was postulated that an initial 
post-transfer editing-triggered conformational change allowed the transfer of AA-AMP 
(Bishop et al., 2002) (Figure 1.13). 
	  
Figure 1.13. Scheme of pre- and post-transfer editing pathways.  The aminoacylation 
fidelity is maintained by pre-transfer (red) and post-transfer editing (green).  
Abbreviations are: E (enzyme, or aminoacyl-tRNA synthetase), AA (amino acid), AA-
AMP (aminoacyl adenylate), AA-tRNA (aminoacyl tRNA).  The figure is adapted from 
Mascarenhas and Martinis, 2009. 
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I.3 Aminoacyl-tRNA synthetases as pharmaceutical targets 
I.3.1 AARSs as antibiotic targets 
AARSs, which are an ancient family of enzymes that universally exist in all life 
forms, have long been focused upon as antimicrobial drug targets (Tao & Schimmel, 
2000b).  Drugs mimicking the substrates or intermediates of pathogen’ AARSs provide 
an ideal screening pool for the drug development industry.  Due to the structural and/or 
mechanistic differences of prokaryotic and eukaryotic AARSs, drug optimizations can be 
designed to specifically target enzymes that are critical to the pathogenic species.  For 
example, mupirocin (or pseudomonic acid), as a natural product of Pseudomonas 
fluorescens (Fuller et al., 1971), is a potent inhibitor of bacterial IleRS (Hughes & 
Mellows, 1978).  It resembles the isoleucyl-adenylate intermediate and inhibits binding 
of both ATP and isoleucine (Hughes & Mellows, 1978) (Figure 1.14). 
 
Figure 1.14. Chemical structures of mupirocin and isoleucyl adenylate (Ile-AMP). 
 
Halofuginone, isolated from a Chinese herb Chang-Shan, has been used to treat 
malaria for over 2000 years (Koepfli et al., 1947).  Clinical trials also show its potential 
as a therapeutic in cancer and fibrotic diseases treatment (de Jonge et al., 2006; Pines et 
al., 2003).  The crystal structure of human ProRS in the presence of halofuginone 
revealed that the drug mimics proline on one side and the 3’-end of tRNA on the other. In 
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this way, halofuginone inhibits both proline and tRNA binding to ProRS (Zhou et al., 
2013) (Figure 1.15). 
	  
Figure 1.15. Chemical structure of halofuginone.  The structure in red rectangle 
mimics the 3’-end of tRNA while the structure in green rectangle resembles proline. 
 
I.3.2 Antifungal drug AN2690 in onychomycosis treatment 
Instead of inhibiting substrate binding in the aminoacylation active site, AN2690 (5-
fluoro-1,3-dihydroxy-2,1-benzoxaborole) forms an adduct with the 2’- and 3’-hydroxyl of 
the tRNA terminal adenosine ribose in the CP1 domain active site (Rock et al., 2007) 
(Figure 1.16).  This adduct mimics the aminoacylated tRNA, traps the complex in its 
editing conformation, blocks aminoacylation and thus protein synthesis in the pathogenic 
organism.  It has been approved by the FDA with registered name Kerydin, to treat 
onychomycosis, a fungi-based disease of the toenail. 
 
Figure 1.16.  Antifungal AN2690 and AN3018 react with cis-diols of AMP to form 
mimic of tRNALeu-drug adduct. 
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The co-crystal structure of C. albicans LeuRS in complex with AN3018-AMP 
(Figure 1.16) reveals that the adduct shares the non-cognate amino acid binding pocket in 
the CP1 domain (Seiradake et al., 2009).  Interestingly, some spontaneous resistance 
mutants of LeuRS were isolated. Most of these mutations were located in the conserved 
regions of the editing pocket (Rock et al., 2007).  Critical residues in adduct binding 
include Thr316, Arg318, Thr321, Leu404 and Asp422 (Figure 1.17).  Residues Thr316, 
Arg318, Thr321 within the conserved T-rich region and the universally conserved residue 
Asp422 form direct interactions with AN2690.  Leu404 stabilizes the adenine ring from 
the opposite direction. 
 
Figure 1.17.  AN3018-AMP binding pocket in C. albicans LeuRS CP1 domain. 
Critical residues that form hydrogen bonds to AN3018-AMP are highlighted in yellow. 
(PDB ID: 2WFG) (Seiradake et al., 2009) 
 
 
I.3.3 AARSs-related diseases 
Multiple diseases have shown an intrinsic relation to AARSs including neuronal 
dysfunction or loss-of-function, HIV infection and cancer (Park et al., 2008).  For 
example, Charcot-Marie-Tooth (CMT) disease constitutes a group of peripheral 
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neuropathies such as muscular weakness and atrophy in the distal extremities, impaired 
sensation and diminished deep-tendon reflexes (Antonellis et al., 2003). Glycyl-tRNA 
synthetase (GlyRS) (Antonellis et al., 2003) and tyrosyl-tRNA synthetase (TyrRS) 
(Jordanova et al., 2006) have been implicated in cases where their coding genes have 
inherited mutations.  In GlyRS, two CMT-causing mutations are close to a “kissing” 
contact across the dimer interface (Nangle et al., 2007). Even though the CMT phenotype 
is not correlated with aminoacylation activity, most of the mutant proteins could affect 
dimer formation and lead to defective distribution in the neurons.  A recent report shows 
that CMT-causing GlyRS mutations have an altered conformation (He et al., 2015).  It 
binds to neuropilin 1 (Nrp1) receptor competitively, which interferes the cognate binding 
of vascular endothelial growth factor (VEGF) to Nrp1. 
AARSs are also involved in cancer development. It was reported that LysRS could be 
recruited to the plasma membrane to stabilize a 67-kDa laminin receptor (67LR), which 
is implicated in cancer metastasis (Kim et al., 2014). A small compound that inhibits the 
LysRS-67LR interaction but not the catalytic activity of LysRS results in suppressed 
metastasis in mouse models. 
During HIV infection, human LysRS is also selectively packaged into HIV and 
appears to be a critical factor in tRNA packaging (Cen et al., 2001).  Since tRNALys,3 
serves as the reverse transcription primer, it is packaged into HIV-1 with other human 
tRNALys isoacceptors (Mak & Kleiman, 1997).  Human LysRS is the only known cellular 
enzyme that recognizes all tRNALys species specifically and overexpression of LysRS 
enhances tRNALys packaging (Gabor et al., 2002).  
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I.4 Alternative functions of leucyl-tRNA synthetases 
I.4.1 AARS evolution 
Throughout a long evolutionary history, AARSs, have also acquired alternate 
functions that are separate from aminoacylation (Pang et al., 2014).  To ensure a high 
fidelity during protein synthesis, some AARSs evolved a secondary active site to clear 
errors in the aminoacylation process.  For example, the CP1 domain in E. coli LeuRS 
selectively hydrolyzes mischarged tRNA but exclude leucyl-tRNA in its editing pocket 
(Starzyk et al., 1987). Other secondary functions of AARSs include mitochondrial RNA 
splicing (Lambowitz & Perlman, 1990), transcriptional regulation (Putney & Schimmel, 
1981), translational regulation (Romby et al., 1996), cell signaling (Wakasugi, Slike, 
Hood, Ewalt, et al., 2002; Wakasugi, Slike, Hood, Otani, et al., 2002), etc. (Figure 1.18). 
Neurospora crassa mitochondrial TyrRS as well as Saccharomyces cerevisiae 
mitochondrial LeuRS facilitate group I intron splicing (Akins & Lambowitz, 1987; 
Herbert et al., 1988; Labouesse, 1990).  N. crassa TyrRS binds to its intron RNA mainly 
through a small N-terminal domain (Paukstelis et al., 2008) while the splicing activity of 
S. cerevisiae LeuRS is dependent on the CP1 domain and its linker peptides to the main 
body of the enzyme (Sarkar et al., 2012) as well as the C-terminal domain (Hsu et al., 
2006).  The E. coli AlaRS regulates its own gene transcription by binding specifically to 
a palindromic sequence that flanks the gene’s promotor site (Putney & Schimmel, 1981).  
The E. coli ThrRS represses its own translation by competing with ribosome binding to 
its mRNA’s operator region (Romby et al., 1996). 
AARSs are also involved in cell signaling pathways.  For example, human TyrRS is 
secreted during apoptosis (Wakasugi & Schimmel, 1999). The full-length enzyme can 
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then be split into N- and C- terminal fragments with either interleukin-8 like cytokine or 
chemotaxis activity.  Human LeuRS has been reported to serve as an intracellular leucine 
sensor that activates Rag GTPase, which in turn mediates the signal to the mammalian 
target of rapamycin (mTOR) kinase (Bonfils et al., 2012; Han et al., 2012). 
Multiple AARSs have been observed to regulate angiogenesis via distinct 
mechanisms.  Secreted TyrRS (Wakasugi & Schimmel, 1999), TheRS (Williams et al., 
2013) and TrpRS (Wakasugi, Slike, Hood, Otani, et al., 2002) function extracellularly by 
interacting with cell receptors and inducing different responses such as inflammation, 
migration and cell-cell contacts.  Seryl-tRNA synthetase (SerRS), which has a nucleus 
localization signal (NLS), is directed to the nucleus and blocks c-Myc binding to the 
VEGFA promoter, thus suppresses the expression of vascular endothelial growth factor A 
(VEGFA) and downstream angiogenesis and vascular development (Shi et al., 2014; Xu 
et al., 2012).  Upon interferon γ (IFNγ) treatment, glutamyl-prolyl-tRNA synthetase 
(EPRS) is released from the multi-synthetase complex by phosphorylation and binds to 
3’-untranslated region (UTR) of angiogenic genes’ mRNAs (Jia et al., 2008). 
 
Figure 1.18.  Non-canonical functions of AARSs.  AARSs adapted to encompass 
secondary roles in addition to their aminoacylation function. 
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I.4.2 Yeast mitochondrial LeuRS facilitates group I intron splicing 
In fungal mitochondria, two aminoacyl-tRNA synthetases, LeuRS (Herbert et al., 
1988; Lambowitz & Perlman, 1990) and TyrRS (Akins & Lambowitz, 1987) are required 
to facilitate group I intron splicing in S. cerevisiae and N. crassa respectively.  In yeast 
mitochondria, bI4 intron-encoded bI4 maturase and nucleus-encoded yeast mitochondrial 
LeuRS (ymLeuRS) independently bind to the bI4 and aI4α group I introns. The two 
proteins facilitate intron splicing in the genes encoding cytochrome b and the α subunit 
of cytochrome oxidase (cob and cox1α, respectively) (Akins & Lambowitz, 1987) 
(Figure 1.19). The splicing activity of ymLeuRS is harbored by the C-terminal domain 
(Hsu et al., 2006) as well as the CP1 domain (Rho & Martinis, 2000), which diverged to 
accommodate both RNA splicing and amino acid editing (Boniecki et al., 2009; Sarkar et 
al., 2012). 
 
Figure 1.19.  Schematic illustration of LeuRS-assisted group I intron splicing within 
yeast mitochondria. Two group I introns, bI4 and aI4α, are spliced from cob and cox1α  
genes respectively with assistance from bI4 maturase (encoded by the ORF in intron bI4) 
and yeast mitochondrial LeuRS (ymLeuRS).   
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I.4.3 Human cytoplasmic LeuRS as leucine sensor in MTOR pathway 
The mammalian target of rapamycin (mTOR) kinase, which regulates protein translation, 
cell growth and autophagy, senses intracellular amino acid level through LeuRS.  LeuRS 
binds to Rag GTPase in an amino acid-dependent manner, which in turn activates 
mTORC1 pathway (Bonfils et al., 2012; Han et al., 2012) (Figure 1.20).  Another amino 
acid signal mediator upstream of mTORC1 is the class III PI-3-kinase Vps34 and LeuRS 
was identified as the amino acid sensor to activate Vps34 (Yoon & Chen, 2014).  The 
results also suggest that the leucine sensing function of LeuRS is independent of its tRNA 
aminoacylation activity. 
 
Figure 1.20.  Cartoon of LeuRS-dependent leucine sensing in the mTORC1 
pathway.  The cascade of signaling pathway includes: LeuRS senses the intracellular 
leucine level; LeuRS activates Rag GTPase, which in turn switches on the mTORC1 
pathway.  The cartoon is adapted from Han et al 2012. 
 	  
In mammalian cells, LeuRS has been shown to act as a leucine sensor, upstream of 
mTOR pathways (Bonfils et al., 2012; Han et al., 2012).  We wondered if bacterial 
LeuRS could also play a similar leucine-sensing role.  Surprisingly, we found E. coli 
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LeuRS and tRNALeu could dynamically re-localize from cytoplasm, where protein 
synthesis occurs, to the periplasmic space and media upon certain stresses.  Due to the 
tRNA-induced migration effect on human colon cells, we hypothesize that E. coli LeuRS 
and tRNALeu may play essential signaling roles in human microbiome.  This also might 
provide opportunities for therapeutic development. 
As a housekeeping protein in protein synthesis, LeuRS is considered a promising 
drug target.  An antifungal drug AN2690 was reported to specifically block 
aminoacylation of LeuRS in fungus pathogens.  Based on an AN2690-resistance mutant 
that is located outside of the drug-binding pocket, we discovered a novel editing 
mechanism in eukaryotic and archaeal LeuRS (Zhao et al., 2015).  The mechanistic 
distinction for editing between bacterial and non-bacterial LeuRS could be employed to 
design new generations of oxaborole-based antibiotics. 	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Chapter II.  Materials and Methods 
 
II.1 Materials 
Oligonucleotide primers were synthesized by Integrated DNA Technologies, Inc. 
(Coralville, IA).  Radiolabeled [14C]-leucine and [32P]-pyrophosphate were purchased 
from Perkin Elmer (Waltham, MA).  [3H]-isoleucine was acquired from Amersham 
Pharmacia Biotech (Piscataway, NJ).  Restriction enzymes were procured from New 
England Biolabs (Ipswich, MA). Cloned Pfu DNA polymerase and dNTP mix obtained 
from Stratagene (La Jolla, CA).  E. coli strain Rosetta (DE3), BL21 (DE3) and DH5α 
were also purchased from Stratagene. 
II. 2 Mutagenesis 
Site directed mutagenesis was carried out via polymerase chain reaction (PCR).  Each 
50 μl PCR mixture contained 25 ng of template plasmid, 125 ng of each forward and 
reverse primer, 10 mM of dNTPs, and 2.5 U Pfu DNA polymerase (Stratagene) in 
commercially prepared buffer.  The reaction mixtures were heated to 95 °C for 3 min, 
and then DNA was amplified by PCR for 16 cycles under condition:  95 °C for 30 s, 
53 °C for 1 min, and 72 °C for 20 min.  Each PCR mixture was then digested with 
20 units of Dpn1 and then used for transformation of DH5α strain of E.coli.  The DNA 
sequences of the mutated genes were confirmed by UIUC core sequencing facility using 
customized primers. 
III.3 Protein expression and purification 
Mutant and wild-type plasmids were used to transform E. coli strain Rosetta 2 (DE3) 
or BL21 (DE3).  A single colony for the latter was transferred to 3 ml LB medium that 
containing appropriate antibiotics and incubated at 37 °C overnight.  The overnight 
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culture was then transferred to 1 L LB culture with selective antibiotics and grown at 
37 °C, until the OD600 reached 0.6-0.8.  An aliquot of 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) was added to induce protein expression at room 
temperature overnight.  The cells were harvested by centrifugation at 6000 rpm for 
15 min in a Beckman Coulter centrifuge JLA10.5 rotor and stored at -80 °C. 
The cell pellet was thawed on ice, re-suspended in 10 ml equilibrium buffer 20 mM 
Tris, 500 mM NaCl, 10 mM imidazole, pH 8.0 and then sonicated at 40% power for 
4 min using a Vibra Cell sonicator, followed by centrifugation at 12,000 rpm in the 
Beckman Coulter centrifuge JA17 rotor for 30 min at 4 °C.  The lysate was combined 
with His-Select Nickel Affinity Gel (Sigma-aldrich) that had been pre-equilibrated with 
equilibration buffer.  The gel and lysate were mixed gently at 4 °C for 2 h, followed by a 
flow through a BIO-RAD 10 ml column at 4 °C.  The gel was washed with 30 ml 
equilibration buffer.  The fusion-protein with an N-terminal six-histidine tag was eluted 
in equilibration buffer that contained optimized level of imidazole.  The protein product 
was concentrated using an Ultracel tube (Amicon, Bedford, MA) to 500 μl and further 
dialyzed against 20 mM Tris, pH 8.0, 100 mM NaCl, 5% glycerol using a 3500 MWCO 
Slide-A-Lyzer Dialysis Cassette (Thermo, Rockford, IL).  Superdex 200 (or superdex 75) 
gel filtration column connected with FPLC (AKTA purifier, GE) was equilibrated in the 
same buffer followed by sample injection. Tubes showing high absorpition at A280 were 
collected and concentrated.  The final concentration was determined by a Cary-50 Bio 
spectrophotometer at 280 nm using the estimated extinction coefficient by the ExPASy 
Protparam tool (http://web.expasy.org/protparam/).  
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II. 4 Preparation and purification of in vitro transcribed tRNA 
The gene for C. albicans tRNAleuUAA was amplified by polymerase chain reaction 
(PCR) using C. albicans genomic DNA and cloned downstream of a T7 RNA polymerase 
promoter into the Bam HI and Hind III sites of pUC57 (Genescript, Piscataway, NJ) 
yielding pHZCatRNAUUA.  The in vitro transcription template was generated by 
digesting 450 μg pHZCatRNAUUA with 100 U BstN1 in a 1ml overnight reaction at 
65 °C. The transcription reaction mixture contained 40 mM Tris (pH 8.1), 80 mg/ml 
PEG8000, 5 mM Dithiothreitol, 50 μg/ml bovine serum albumen, 0.01% Triton X-100, 
2 mM spermidine, 30 mM MgCl2, 7.5 mM NTPs, 4 U/ml pyrophosphatase (NEB, 
Ipswich, MA), 0.04 unit/ul RNase inhibitor (Bioline, Taunton, MA), 450 μg/ml DNA 
template, and 2 μM T7 RNA polymerase (Betha et al., 2007). The reaction mixture was 
incubated at 42 °C for 3 hours, followed by addition of 2 μM purified T7 RNA 
polymerase, then incubated for another 3 hours.  The RNA product was ethanol-
precipitated, purified on a 10% polyacrylamide gel that contained 8 M urea.  The tRNA 
band was detected by UV light, excised and the gel crushed, followed by extraction in an 
Elutrap Electroelution system (Whatman, UK) 200 V for 3 hours.  The tRNA was 
ethanol-precipitated, washed twice by 70% ethanol, vaccum-dried and resuspended in 
RNase free water (Acros Organics, New Jersey).  A Chroma Spin-30 column (Clontech 
Inc., CA) was used to further purify tRNA from NTPs.  The final concentration was 
determined by a Cary-50 Bio Spectrophotometer (Varian, Santa Clara, CA) using an 
extinction coefficient 871000 M-1 cm-1 (Puglisi & Tinoco, 1989). 
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II. 5 Aminoacylation assays 
Each aminoacylation reaction mixture contained 60 mM HEPES (pH 7.5), 30 mM 
MgCl2, 1 mM DTT, 40 μM [14C]-leucine (6.4 μCi/mL), 4 μM tRNALeu, 100 nM LeuRS 
and initiated by adding 4 mM ATP.  To measure kinetic parameters, tRNA was varied 
from 0.5 μM to 50 μM and the initial velocities were measured.  At specific time points, 
5 μl aliquots were quenched by transferring to Grade 3 qualitative filter pads (Whatman, 
Clifton, NJ) that were pre-soaked with 5% trichloroacetic acid (TCA) and dried.  The 
pads were washed for 8 min with cold 5% TCA three times and one time with cold 70% 
ethanol.  The pads were dried, put into 20 mL disposable scintillation vials (RPI Corp.) 
and quantified in a Beckman LS 6500 multi-purpose scintillation counter (Beckman 
Coulter, Inc., Fullerton, CA). Kinetics data was analyzed by GraphPad 4 (GraphPad 
Inc.,CA) and Sigma Plot 10.0 (Systat Software Inc., CA). 
II. 6 Isolation of mischarged tRNA and deacylation assays 
An aliquot of 8 μM in vitro transcribed C. albicans tRNALeu was aminoacylated with 
[3H]-isoleucine (300 μCi/mL) by 5 μM D422A mutant C. albicans LeuRS (Pang & 
Martinis, 2009) with 60 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM DTT, 4 mM ATP at 
37 °C for 3 h.  The reactions were quenched with 0.18% acetic acid.  Protein was 
removed by extraction with a phenol/chloroform/isoamyl alcohol mixture (125:24:1; 
Fisher Biotech, Fair Lawn, NJ) that had been pre-equilibrated to pH 4.3.  The mischarged 
tRNA was ethanol precipitated at -80 °C overnight.  The dried pellet was re-suspended in 
50 mM KPi, pH 5.0.  Hydrolytic editing assays were carried out in 60 mM HEPES, pH 
7.7, 10 mM MgCl2, and 8 μM misaminoacylated tRNALeu and initiated by 100 nM 
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enzyme.  Each reaction was quenched at specific time points and processed as described 
above. 
II. 7 Inorganic pyrophosphate (PPi) exchange assays 
Each reaction contains 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM DTT, 1 mM 
[32P]-pyrophosphate, 1 μM to 300 μM leucine or 10 μM to 8 mM isoleucine, 0.5 μM 
enzyme (for leucine) or 2 μM enzyme (for isoleucine).  The reaction was initiated by 
adding 1 mM ATP.  Aliquots were quenched at 20 sec, 40 sec, 60 sec, 80 sec on thin 
layer chromatography (TLC) plate (DC-Fertigfolien Polygram Cel 300 PEI/UV254, 
Macherey-Nagel, Germany) that were pre-run with water.  Each plate was put in 50 ml 
running buffer: 750 mM KH2PO4, pH 3.5, until the buffer front reached the top of the 
plate.  The plates were dried and exposed to Fujifilm (BAS cassette2 2040) for 20 min.  
The exposed Fujifilms were read by Storm 840 phosphorimager (Amersham Pharmacia 
Biotech).  The density of each signal was quantified by ImageQuant 5.2 (GE Healthcare). 	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Chapter III. Analysis of the resistance mechanism of a benzoxaborole inhibitor 
reveals insight into the leucyl-tRNA synthetase editing mechanism
III.1 Introduction1 
The discovery of the anti-fungal AN2690 (5-fluoro-1,3-dihydro-1-hydroxy-2,1-
benzoxaborole) and its novel mechanism of action launched a new frontier for 
antimicrobial development that is centered on the oxaboroles (Baker et al., 2006; Barak 
& Loo, 2007; Elewski & Tosti, 2014; Rock et al., 2007).  These boron-containing 
compounds bind to a secondary active site in leucyl-tRNA synthetase (LeuRS), which is 
located in the protein synthesis enzyme’s CP1 domain and is responsible for amino acid 
editing.  When the terminal ribose at the 3’ end of tRNA binds to this hydrolytic site, the 
boron forms an adduct with the ribose cis diols to crosslink tRNA substrate to the enzyme 
and inactivate it.  The cross-linked LeuRS-substrate complex can not turnover to carry 
out its aminoacylation activity that is critical to cell maintenance and survival. 
LeuRS is a member of the essential family of aminoacyl-tRNA synthetases (aaRS).  
Each aaRS is specific for a single standard amino acid.  In a canonical aminoacylation 
active site, the enzyme activates amino acid in an ATP-dependent mechanism that forms 
aminoacyl-adenylate.  The amino acid is then transferred to tRNA via an aminoacyl link 
to either the 2’ or 3’ hydroxyl of the terminal ribose (Figure 3.1) (Ibba & Söll, 2000; 
Mascarenhas et al., 2009). In about half of the aaRSs, a hydrolytic site for quality control 
is located in a separate domain to clear misactivated amino acids in order to circumvent 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Adapted from with permission from Zhao, H., Palencia, A., Seiradake, E., Ghaemi, Z., 
Cusack, S., Luthey-Schulten, Z., & Martinis, S. (2015). Analysis of the resistance 
mechanism of a benzoxaborole inhibitor reveals insight into the leucyl-tRNA synthetase 
editing mechanism. ACS Chem. Biol., 10(10), 2277-2285.  Copyright (2015) American 
Chemical Society.  Copyright release form is on Page 169.	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translation of statistical errors during protein synthesis (Figure 1.11) (Mascarenhas et al., 
2009). 
 
Figure 3.1 LeuRS two-step aminoacylation and hydrolytic editing reactions.  LeuRS 
carries out pre- and post-transfer editing within the Rossmann fold and the CP1 domain, 
respectively. 
 
The aaRSs were first used as a clinical target for antibiotics when a natural product 
pseudomonic acid was discovered to inhibit isoleucyl-tRNA synthetase (IleRS) and 
subsequently marketed as mupirocin to treat topical Staphyolococcus aureus infections 
(Fuller et al., 1971; Tao & Schimmel, 2000a). Pseudomomic acid interacts with the 
synthetic active site to inhibit amino acid activation (Hughes & Mellows, 1978; Silvian et 
al., 1999; Yanagisawa et al., 1994). In contrast, AN2690 binds to the secondary 
hydrolytic site and inactivates aminoacylation by forming an adduct with the tRNA-
enzyme complex (Figure 1.17) (Rock et al., 2007).  This novel anti-fungal was recently 
approved as a new therapeutic to treat onychomycosis.  A novel benzoxaborole has also 
demonstrated efficacy in combatting complicated infections caused by some Gram-
negative bacteria (Hernandez et al., 2013). 
Resistance mutations to AN2690 have been identified in Candida albicans (Rock et 
al., 2007).  Most are located in the hydrolytic active site of the CP1 domain.  However, 
some are distal to the catalytic site and their resistance mechanisms are unclear.  For 
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example, mutation of a conserved lysine residue (K510E) was selected at least 9 Å away 
from the bound drug molecule (Figure 3.2).  We hypothesized that the distally located 
Lys510 plays a role in amino acid editing within the CP1 domain.  Mutational analysis of 
this region combined with X-ray crystallography, molecular dynamics (MD) and 
metadynamics simulations, as well as biochemical experiments uncovered a three-state 
tyrosine switch in the editing mechanism that the AN2690 capitalized upon to cross-link 
the enzyme-bound tRNA.  It also implicated an evolutionary partition that distinguished 
archaeal and eukaryotic mechanisms for editing from bacteria. 
 
Figure 3.2  C. albicans LeuRS K510 mutation leads to benzoxaborole resistance.  
a. Crystal structure of C. albicans cytoplasmic LeuRS with AN3018-AMP bound 
(Seiradake et al., 2009) (PDB ID: 2WFG) and Lys510 resistance site 
highlighted. b. Sequence alignment of eukaryotic and archaeal LeuRS with Lys510 
marked by an arrow.  Abbreviations are: Ca, Candida albicans; Sc, Saccharomyces 
cerevisiae; Ce, Caenorhabditis elegans; Hs, Homo sapiens; Ab, Aciduliprofundum 
boonei; Mm, Methanosarcina mazei; Ph, Pyrococcus horikoshii; Si, Sulfolobus 
islandicus; and c, cytoplasmic. 
 
III.2 Experimental procedures 
III.2.1 Materials 
Modified nucleotide bases, including cordycepin 5’-triphosphate sodium salt (3’-
dATP; Sigma-Adrich, St. Louis, MO), 3’-amino-3’-deoxyadenosine-5’-O-triphosphate 
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(3’-NH2-dATP; Biolog Life Science Institute, Bremen, Germany), and 3’-O-
methyladenosine-5’-triphosphate (3’-OMe-dATP; TriLink BioTechnologies, San Diego, 
CA) were purchased from commercial sources. 
Plasmid pHZCaWT expressing C. albicans cytoplasmic LeuRS from a gene insert 
that was cloned into the Nhe I and Xho I restriction sites of pET21b was a gift from 
Anacor Pharmaceuticals.  Plasmid pCaCP1WT expressing C. albicans cytoplasmic 
LeuRS CP1 domain (residues 280-530) was cloned into the NcoI and XhoI restriction 
sites of pET21d as previously reported (Seiradake et al., 2009). 
III.2.2 Mutagenesis and purification of Candida albicans LeuRS and the isolated           
CP1 domain 
Site directed mutagenesis was carried out via PCR.  The plasmid pHZCaLRSWT 
encoding the wild type C. albicans cytoplasmic LeuRS was used as the template to 
introduce desired mutations to generate the plasmids pHZCaK510A, pHZCaK510D, 
pHZCaK510E, pHZCaK510R, pHZCaD422A, pHZCaY487E, pHZCaY487A, 
pHZCaY487F, pHZCaT316S, pHZCaT316V, encoding the mutant K510A, K510D, 
K510E, K510R, D422A, Y487E, Y487A, Y487F, T316S, T316V, respectively.  Plasmid 
pHZCaY487F was then used as a template in another PCR reaction to introduce a second 
T316V mutation, which created the plasmid pHZCaY487F/T316V encoding the double 
mutant Y487F/T316V.  Similarly, the plasmid pCaCP1WT was utilized as a template to 
generate plasmids pCaCP1K510A, pCaCP1K510E, encoding LeuRS CP1 domain 
K510A, K510E mutant, respectively.  Detailed mutagenesis process was described in 
Chapter II. 
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For protein expression, mutant and wild-type plasmids encoding C. albicans LeuRS 
and its CP1 domain were used to transform E. coli strain Rosetta 2 (DE3) (Stratagene) 
and BL21 (DE3) (Stratagene), respectively.  A single colony for the latter was transferred 
to 3 ml LB medium that contained 100 μg/ml ampicillin (Ap). In the case of the full-
length gene expression 30 μg/ml chloramphenicol (Cm) was also added, and each culture 
incubated at 37 °C overnight.   
Protein expression and purification were carried out as Chapter II described.  The 
protein product was concentrated using an Ultracel-50K or -10K tube (Amicon, Bedford, 
MA) to 500 μl.  The final concentration for full-length LeuRSs were determined by Cary-
50 Bio spectrophotometer using an extinction coefficient 144510 M-1 cm-1.  The LeuRS 
CP1 domain was further dialyzed and separated by Superdex 75 gel filtration column.  
The final concentration for isolated CP1 domain was determined by Cary-50 Bio 
Spectrophotometer with extinction coefficient 28100 M-1 cm-1.  
III.2.3 Protein crystallization and structure determination 
A stock concentration of 34 mg/ml LeuRS K510A mutant was stored in 20 mM Tris, 
pH 8.0, 100 mM NaCl, and 5% glycerol before crystallization.  Buffer 20 mM Tris, 
200 mM NaCl, pH 7.5 was used to dilute protein to 15 mg/ml for crystallization in its apo 
form.  The AN2690-AMP-K510A LeuRS CP1 domain complex was formed using 
30 mg/ml protein, 7.5 mM AMP, and 1 mM AN2690.  Protein crystals were grown in 
hanging drops of 1 μl protein solution and 1 μl of crystallization solution in the well.  The 
apo form of the K510A LeuRS mutant was crystalized in 0.2 M ammonium acetate, 
0.1 M sodium acetate trihydrate, pH 4.0, 24% PEG 3350 overnight at 16 °C.  The 
AN2690-AMP K510A LeuRS CP1 domain complex was crystalized in 0.2 M sodium 
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acetate, 0.1 M HEPES sodium pH 7.4, 30% PEG 2000 overnight at 16 °C.  Crystals were 
frozen in cryoprotectant solution containing 20% glycerol.  The AN2690-AMP wild-type 
LeuRS CP1 domain complex was crystallized at a similar condition as previously 
described (Seiradake et al., 2009). 
Diffraction data was collected at the European Synchrotron Radiation Facility (ESRF, 
Grenoble, France) and at the Advanced Photon Source (APS, Argonne National 
Laboratory, Chicago, USA) and were integrated with XDS and scaled with XSCALE 
(Kabsch, 1993) or with HKL2000 (Otwinowski & Minor, 1997) respectively. Further 
data analysis was performed with the CCP4 suite (Bailey, 1994). The structure was 
solved by molecular replacement with PHASER (McCoy et al., 2005) using the C. 
albicans LeuRS editing domain as a model (PDB: 2WFE). Manual adjustments in COOT 
(Emsley & Cowtan, 2004) were used to correct the position of certain residues and to find 
solvent molecules. The final models were refined using REFMAC5. Interfaces were 
analysed with the PISA server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html). 
Structure quality was analysed with MOLPROBITY 
(http://molprobity.biochem.duke.edu/), showing all residues in allowed regions (>97%).  
Structure depictions were constructed with VMD (Humphrey et al., 1996). 
III.2.4 AN2690-resistance assays 
In AN2690-resistance assays, 0.5 mM AN2690 was pre-incubated in the reaction 
mixture containing 500 nM LeuRS at room temperature for 20 min.  Other procedures are 
the same as aminoacylation assays. 
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III.2.5 Circular dichroism 
Purified C. albicans LeuRS CP1 domain were dialyzed into 20 mM Tris, 20 mM 
KH2PO4, 100 mM NaCl, pH 7.0 and the LeuRS CP1 domain diluted to 20 μM.  Far-UV 
CD spectra from 200 to 250 nm were measured in a JASCO J-715 spectropolarimeter 
equipped with a JASCO PTC343 cooling unit. A total of 50 accumulations were 
integrated and corrected using a trace that measured only the buffer.  Spectra for the wild 
type LeuRS CP1 domains were obtained at temperatures of 19.4 °C, 28.8 °C, 38.5 °C, 
48.1 °C, and 57.6 °C.  Spectra for the K510A mutant LeuRS CP1 domains were obtained 
at temperatures of 19.3 °C, 29.0 °C, 38.6 °C, 48.1 °C, and 57.7 °C. 
III.2.6 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) was performed using LeuRS CP1 domain wild-
type, K510E mutant, or K510A mutant against AN2690-AMP at 25 °C by an ITC200 
system (MicroCal, GE Healthcare). Wild-type protein and mutants were dialyzed against 
the titration buffer (50 mM HEPES-KOH, 30 mM KCl and 30 mM MgCl2, pH 8.0). 
Compound AN2690 and AMP were also prepared in the same buffer.  A 60 μM protein 
solution was in the presence of 10 mM AMP in the calorimetric cell and titrated using 26 
stepwise injections of 1.5 μL each with the compound AN2690 plus AMP.  AN2690 
solutions were placed in the syringe at 0.7 to 3 mM (depending on the expected affinity) 
along with 10 mM AMP. The heat generated after each ligand injection was measured 
base on the integral of the calorimetric signal. The resultant binding isotherms were 
analyzed by a nonlinear least-squares fit of the experimental data to a single site model 
(Turnbull & Daranas, 2003; Wiseman et al., 1989) using Microcal Origin 7.0 software. 
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Experiments were duplicated and variability estimated to be 5% in the binding enthalpy 
and 10% for both the binding affinity and the number of sites. 
III.2.7 Standard MD simulations 
The coordinates of T. thermophilus LeuRS CP1 domain (TtCP1) bound to the post-
transfer editing substrate analog 2’-(L-norvalyl) amino-2’-deoxyadenosine (Nva2AA) 
(PDB entry: 2BTE) was used to construct Ile-AMP in the editing active site.  To build the 
Ile-AMP bound to CaCP1, The coordinates for the T. thermophilus and C. albicans 
LeuRS CP1 domain (PDB entry: 2WFG) were structurally aligned to introduce Ile-AMP 
to the latter.  In particular, two conserved threonine-rich (residues 316 to 326), and GTG 
(residues 407 to 423) regions were used for the alignment, in order to move Ile-AMP to 
C. albicans LeuRS editing site.  To aid the assignment of amino acid side-chain 
protonation states, the program PROPKA (Bas et al., 2008) was performed to calculate 
the pKa.  The K510E mutation was introduced by Mutate in psfgen (Humphrey et al., 
1996).  Potassium ions were added at a distance of 6.5 Å to the system by Ionize to 
neutralize the system.  The system was solvated with 8 Å of TIP3P water molecules by 
Grubmuller Solvate (Grubmuller et al., 1996), then solvated with TIP3P water molecules 
in VMD to ensure the minimum distance between any protein/ligand atoms and the side 
of the box was 12 Å.  The total volume of the system was  ~ 70 × 80 × 80 Å3 with a total 
of ~ 4.0 × 104 atoms.   
We performed two sets of standard MD simulations of the C. albicans LeuRS CP1 
wild-type and K510E mutant forms in complex with Ile-AMP for a total of 120 ns.  All 
simulations were performed using the CHARMM 27 parameter set (MacKerell et al., 
1998) and NAMD 2.9 (Phillips et al., 2005).  To apply the NPT ensemble, the 
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temperature was set at 298 K by Langevin dynamics with a damping constant of 5 ps-1. 
The pressure was maintained at 1 atm by applying a Langevin piston (Feller et al., 1995).  
The bonded, nonbonded, and electrostatic interactions were recorded at time steps of 1, 2, 
and 4 fs, respectively.  The switching and cutoff distances were set respectively at 10 and 
12 Å for nonbonded interactions.  The Particle Mesh Ewald (de Jonge et al.) method 
(Darden et al., 1993) with a grid density of at least 1 Å-3 was used to compute the long-
range electrostatic interactions,.  The stepwise minimization and thermalization of the 
system were performed as described previously (Eargle et al., 2008).  Each system was 
equilibrated and run for an extended time of 30 ns. 
III.2.8 Well-tempered metadynamics simulation (WTmeta) 
Metadynamics (Barducci et al., 2008; Laio & Parrinello, 2002) aims at helping the 
system to escape from its local minima and determines the underlying free energy surface 
as a function of a carefully chosen set of reaction coordinates (Collective variables). 
Collective variables (CVs) are explicit functions of the system coordinates that represent 
the degrees of freedom of the system along which rare events are happening. In 
Metadynamics an additional history-dependent bias, in the form of a Gaussian is added to 
the system’s potential:   
 
𝑉!(𝑆, 𝑡) = 𝑤   exp − 𝑆 − 𝑠(𝑡!) !2𝛿𝑠!!!!!!!,!!!,…  
where, w is the Gaussians height, 𝛿𝑠 is the Gaussian width, 𝜏G is the time interval for the 
Gaussian deposition and s(t) = S(x(t)) is the value of the collective variable at time t. It is 
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assumed in metadynamics that for a sufficiently long simulation, 𝑉!(𝑆, 𝑡) provides an 
estimate of the underlying free energy (Laio & Gervasio, 2008): lim!    !𝑉! 𝑆, 𝑡 ~− 𝐹(𝑆) 
WTmeta is a variant of metadynamics in which, to facilitate the free energy barrier 
crossing CVs are simulated at a higher temperature, which is raised by Δ𝑇  (bias 
temperature) with respect to the system temperature. Unlike conventional metadynamics, 
the summation of bias potentials does not exactly compensate F(S). In this case, the free 
energy of the system along a CV, S, is obtained by: 
𝐹 𝑆, 𝑡 = −𝑇 + Δ𝑇Δ𝑇   𝑉!(𝑆, 𝑡) 
In the course of the simulation the Gaussian heights at a given value of S reduce 
exponentially according to  
𝑤 = 𝜔 exp −𝑉! 𝑠, 𝑡𝛥𝑇 𝜏!  
where 𝜔 is the initial bias deposition rate. Introduction of this form, prevents the risk of 
overfilling of the free energy regions in long simulations (Barducci et al., 2008).  In 
addition, hill heights that are close to zero is an indication that the simulation can be 
stopped. 
We applied WTmeta to explore the free energy landscape of Tyr rotamer states that 
have been observed in MD simulations using the version implemented in NAMD 2.9. We 
performed two sets of simulations on Ile-AMP in complex with wild-type CaCP1 and 
K510E mutant form. The CVs in both simulations were the distance between the Tyr487 
hydroxyl group of CaCP1 and the 3’-hydroxyl group of substrate Ile-AMP ribose and the 
root mean square deviation (RMSD) of the backbone of α-helix (sequence 476 to 489) 
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and side chain atoms of Tyr487.  The bias temperature was 2980 K, the initial deposition 
rate of Gaussians was 0.02 kcal/(molps), with a width along CV1 of 0.5 Å and along CV2 
of 0.25 Å. Quartic walls were applied to limit the sampling region of the CV space. In 
wild-type (K510E mutant) simulation, along CV1 a wall was set at a value of 14 (11.5) Å 
and along CV2 at 2.3 (2.3) Å with force constants of 12 (12) kcal/mol Å2 and 20 (12) 
kcal/mol Å2, respectively.  
 
III.3 Results 
III.3.1 Distal Lys510 is a resistance site for oxaborole inhibition of Candida albicans 
LeuRS.  
Spontaneous mutations in the yeast cytoplasmic LeuRS CP1 editing domain were 
isolated in varied concentrations of AN2690 (Rock et al., 2007; Sarkar et al., 2011). 
These mutations lacked resistance to other common anti-fungal drugs supporting a 
unique mechanism of action for the oxaborole family of inhibitors (Sarkar et al., 2011). 
Comparison to crystal structures of LeuRS bound to AN2690 showed that the LeuRS 
editing site was targeted for resistance (Rock et al., 2007).  In addition, a conserved 
lysine residue outside of the editing site in yeast LeuRS was selected.  Since this site is 
distal to the editing site (Figure 3.2a), its mechanism of action for resistance to AN2690 
(64-fold increased resistance in vivo), as well as a putative role in amino acid editing 
were unclear.  Because this lysine is found across eukaryote cytoplasmic and archaeal 
LeuRSs (Figure 3.2b), we hypothesized that it could play a role in post-transfer editing.  
Using a cloned LeuRS gene from the pathogen C. albicans, we introduced the 
resistance mutation (K510E) at the conserved lysine resistance site.  In addition, we 
substituted an alanine (K510A) to probe the oxaborole mechanism of action and the 
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enzyme target’s resistance mechanism. The wild-type C. albicans LeuRS and each 
mutant and their CP1 domains were expressed recombinantly in Escherichia coli with an 
N-terminal six-histidine fusion and purified by nickel affinity chromatography.  Circular 
dichroism of the CP1 domains of the wild type and mutant LeuRS proteins supported that 
the mutations did not impact the overall structures (Figure 3.3).  
 
Figure 3.3  Circular dichroism supports that LeuRS resistance mutant maintains 
protein structure at elevated temperatures. 
 
We also cloned the gene for C. albicans tRNALeu UUA that would be critical to the 
oxaborole inhibition mechanism.  We introduced a T7 promoter and in vitro transcribed 
tRNALeu using T7 RNA polymerase (Sampson & Uhlenbeck, 1988). Purified C. albicans 
tRNALeu and LeuRS wild-type or mutant protein were combined in leucylation assays.  
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Each mutant LeuRS aminoacylated leucine similarly to the wild-type LeuRS (Figure 
3.4a, Table 3.1).   
 
Figure 3.4  Lys510 mutants of C. albicans LeuRS confer tRNALeu-dependent AN2690 
resistance.  a. Leucylation activity.  b.  AN2690 inhibition of C. albicans LeuRS 
aminoacylation.  Open symbols indicate presence of AN2690. c. LeuRS deacylation of 
Ile-tRNALeu.  Abbreviations are as follows: WT (▲, triangle); K510A (▼, inverted 
triangle); K510D (n, square); K510E (u, diamond); K510R (●, circle); No enzyme ( , 
pentagon).  Error bars are based on reactions repeated at least in triplicate. 
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A concentration of 0.5 mM AN2690 was pre-incubated with the reaction mixture 
(Rock et al., 2007) and [14C]-Leu-tRNALeu was measured at different time points.  
Incorporation of the K510A and K510E mutations into the pathogen C. albicans LeuRS 
conferred resistance to AN2690 in LeuRS aminoacylation assays (Figure 3.4b). 
 
Table 3.1  Kinetic parameters* of C. albicans LeuRS and resistant mutants charging 
tRNALeu. 
 
LeuRS kcat (sec-1) KM (µM) kcat / KM (mM-1 sec-1) Relative kcat / KM  
WT 0.29 ± 0.05    5 ± 1 58 1 
K510A 0.24 ± 0.08    6 ± 0.5 43 0.8 
K510E 0.26 ± 0.03    5 ± 1 50 0.9 
Note:  tRNA was varied from 0.5 μM to 50 μM and the initial velocities were measured at 15, 30, 45, 
60 seconds.  Each data set was averaged from at least three independent measurements. 
*apparent parameters 
 
Because AN2690 targets the editing active site of LeuRS, we also tested for quality 
control by the C. albicans enzyme. As would be expected, the wild-type C. albicans 
LeuRS readily deacylated mischarged C. albicans Ile-tRNALeu (Table 3.2, Figure 3.4c).   
Although the deacylation activity of the K510E resistance mutation was decreased 
compared to wild-type, it retained significant activity supporting that it could maintain 
quality control of translation at some level in the pathogen.  In contrast, the editing 
activity of the K510A mutant LeuRS was dramatically reduced. We also created a K510R 
and K510D mutation to test mutations that would be respectively homologous at these 
sites for the wild-type and resistant LeuRS.  The K510R LeuRS mutant retained 
deacylation activity compared to the wild-type, while the K510D mutation activity was 
even less than the selected K510E resistance mutant.  We hypothesized that this drug 
resistance mutant had selected a critical editing site, which balanced combatting AN2690, 
whilst maintaining sufficient quality control. 
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Table 3.2 Pyrophosphate exchange assays indicate that isoleucine has 
high tendency to be mischarged by LeuRS. 
 
III.3.2 K510A LeuRS mutation traps a critical tyrosine in an oxaborole-resistant 
rotamer state.   
 
Figure 3.5  Structures of oxaborole-AMP drug binding to C. albicans LeuRS CP1 
domain.   Crystal structure superposition of apo wild-type LeuRS CP1 domain 
(Seiradake et al., 2009) (PDB ID: 2WFE) binding to AN3018-AMP (Seiradake et al., 
2009) (a; PDB ID: 2WFG) or AN2690-AMP (b; PDB ID: 5AGJ).  c. Comparison of apo 
K510A mutant LeuRS CP1 domain (PDB ID: 5AGH) and binding to AN2690-AMP 
(PDB ID: 5AGI).  Drug-bound and apo LeuRS are yellow and cyan, respectively. 
AN3018-AMP, AN2690-AMP, Tyr487, and Lys510 are in “licorice” format.  Red arrows 
mark the movement (1.5 or 0.9 Å) of the I4ae helix, which was measured by the change 
in distance of the α-carbon of the Val477 in the overlapped structures. 
 
The co-crystal structure of C. albicans LeuRS CP1 domain bound to AN3018-AMP 
has been solved previously (Figure 3.2, 3.5a; PDB ID: 2WFE, 2WFG) (Seiradake et al., 
2009).  The oxaborole resides largely in the amino acid binding pocket of the editing 
active site, while the AMP mimics the 3’ terminus of the tRNA that forms a dative bond 
with the boron atom.   Here, we co-crystallized the wild-type C. albicans LeuRS CP1 
!
Substrate kcat (sec-1) KM (mM) kcat/KM 
(mM-1sec-1) 
Discrimination 
Factor 
Leucine 12.5 ± 0.2 0.025 ± 0.002 5.0 × 102 1 
Isoleucine 3.7 ± 0.2 0.70 ± 0.09 5.3 94 
Valine 1.2 ± 0.3 12 ± 5 0.1 5000 
Methionine 0.8 ± 0.2 12 ± 5 0.07 7500 
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editing domain with AN2690-AMP and determined the structure of the complex at 2.0 Å 
resolution (Figure 3.5b, Table 3.3) (Seiradake et al., 2009).   In both of the oxaborole-
bound structures that represent the LeuRS-inhibitor complex (I-state), the hydroxyl group 
of the Tyr487 ring binds to the phosphate group of the AMP adduct.  As observed 
previously, there is also a second rotamer form, where Tyr487 interacts with Lys510 
(Seiradake et al., 2009). 
Table 3.3.  Data collection and refinement statistics 
Candida albicans 
CP1 LeuRS 
Wild type 
+ AN2690–AMP 
K510A mutant 
+ AN2690–AMP 
K510A mutant 
unliganded 
Data collection    
Space group P212121 P212121 C2 
Cell dimensions      
a, b, c (Å) 42.95, 59.62, 97.15 42.17, 58.43, 95.16 89.35, 41.10, 67.26 
    α, β, γ  (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 106.71, 90.00 
Resolution (Å)a 50-2.0 (2.00-2.05) 50-1.47 (1.47-1.51)  64-1.81 (1.81-1.85) 
Rsym 11.5 (48.1) 5.5 (48.4) 5.9 (38.3) 
I / σI 9.7 (3.0) 9.2 (4.3) 4.9 (4.3) 
CC (1/2)    
Completeness (%) 99.7 (97.4) 99.3 (91.2) 90.4 (64.4) 
Redundancy 4.0 (3.9) 9.1 (8.8) 4.9 (4.3) 
    
Refinement    
Resolution (Å) 2.0 1.47 1.81 
No. reflections 
work/free 16451/880 35180/2033 18676/998 
Rwork / Rfree 0.178 / 0.245 0.199 / 0.218 0.165 / 0.218 
No. atoms    
Protein 2033 2063 1945 
Ligand 33 [AN2690-AMP] 33 [AN2690-AMP] - 
Water/other 197 249/ 12 (2 x glycerol) 147 / 8(2 x acetate) 
B-factors    
Protein 19.0 19.3 27.2 
Ligand 14.4 10.8 - 
Water/other 29.5 23.6 / 19.2 38.1 / 28.1 (acetate) 
R.M.S. deviations    
Bond lengths (Å) 0.009 0.004 0.011 
Bond angles (°) 1.496 1.192 1.441 
            a Values in parentheses are for highest-resolution shell. 
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Tyr487 resides in the I4ae α-helix that “caps” the editing active site of C. albicans 
LeuRS by closing over it.  In yeast, a separate mutation that confers resistance, in which 
an apartate was substituted by either a glycine or asparagine, was proposed to disrupt a 
hinging mechanism for the cap (Sarkar et al., 2011).  This α-helix cap is comprised of a 
peptide insert that is found only in eukaryotes and archaea (Fukunaga & Yokoyama, 
2005; Sarkar et al., 2011; Seiradake et al., 2009), and missing in bacterial LeuRSs 
(Figure 3.6) (Cusack et al., 2000; Palencia et al., 2012).  Comparison with the structure 
of the apo CP1 domain from C. albicans LeuRS (Figure 3.5a) showed that the α-helix 
cap moves 1.5 Å toward the oxaborole upon its binding to the editing site (Seiradake et 
al., 2009).  Concomitantly, the conserved Tyr487 transitions between two rotamer states 
to interact with the inhibitor in the I-state (Figure 3.5a).  Crystal structures of LeuRS 
from human (Seiradake et al., 2009) as well as Pyrococcus horikoshii (Fukunaga & 
Yokoyama, 2005) also support that the tyrosine has two rotamer conformations (Figure 
3.6).   
 
Figure 3.6  Structures of LeuRS CP1 domains highlight archae and eukaryote-
specific 4Iae helix insert.  The LeuRS CP1 domains are colored in cyan, with the I4ae 
helix and Tyr487 shown in yellow and red respectively, when present.  The protein data 
base deposited structures are:  P. horikoshii, PDB ID: 1WKB, H. sapiens, PDB ID: 
2WFD, C. albicans, PDB ID: 2WFE, T. thermophilus, PDB ID: 1H3N and E. coli, PDB 
ID: 4AQ7. 
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In the absence of the oxaborole-AMP adduct, Tyr487 interacts electrostatically with 
Lys510 (K-state; Figure 3.5a).  A nearby phenylalanine (Phe491) stabilizes the tyrosine 
via π-π interactions.  Because Lys510 is an oxaborole resistance site, we hypothesized 
that the Tyr487 – Lys510 interaction played a critical role in the mechanism of resistance.  
We determined that the KD for binding of AN2690-AMP to the C. albicans LeuRS CP1 
domain was increased significantly from 0.7 + 0.3 µM for the wild-type enzyme to 21 + 3 
µM and 46 + 6 µM for the K510E and K510A mutant LeuRSs, respectively (Table 3.4).  
Isothermal calorimetry indicated that the change in binding was largely driven by 
entropic factors (Figure 3.7, 3.8).  We wondered if the entropy loss correlated to a 
restriction in the tyrosine rotamer states.  
 
Figure 3.7  Isothermal titration calorimetry (ITC) shows K510 mutant LeuRS CP1 
domain has a lower binding affinity to AN2690-AMP.   ITC was performed using 
LeuRS CP1 domain wild-type (a), K510E mutant (b), or K510A mutant (c) against 
AN2690-AMP at 25 °C by an ITC200 system (MicroCal, GE Healthcare). The upper 
panel shows the binding isotherms for the titration experiment and the bottom panel 
shows the fitted curve.  This experiment was performed by Andres Palencia, EMBL. 
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Figure 3.8  ITC-derived thermodynamic parameters obtained for the binding of 
AN2690-AMP to wild-type C. albicans LeuRS and mutants.  Error bars represent the 
standard deviation (<5%) of at least two independent experiments.  This analysis was 
performed by Andres Palencia, EMBL. 
 
 
Table 3.4 Thermodynamic parameters measured by isothermal titration 
calorimetry. 
 
We screened for crystallization conditions for the Lys510 mutants of LeuRS in the 
presence and absence of the oxaborole inhibitor.  Both the apo and AN2690-AMP bound 
forms of K510A C. albicans CP1 domain crystallized at 1.8 Å and 1.5 Å respectively, via 
hanging drops in an overnight incubation at 16 °C (Table 3.3).  In both apo and AN2690-
AMP bound forms, the side chain of Tyr487 is locked into the “K-state” by occupying 
space vacated by the lysine side chain in the mutant Lys510A LeuRS (Figure 3.5c). 
Tyr487’s failure to form a hydrogen bond with AN2690-AMP in conjunction with 
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restricted movement of the α-helix that it resides, is consistent with its weaker KD for 
drug binding.  
 
Figure 3.9  Ile-AMP substrate mimic used in simulations. 
 
An Ile-AMP analog of the mischarged tRNA molecule was built (Figure 3.9) and 
modeled into the editing site based on structural overlap between C. albicans LeuRS 
(Seiradake et al., 2009) (PDB ID: 2WFG) and T. thermophilis LeuRS that is bound to the 
mischarged norvaline-tRNALeu (Tukalo et al., 2005) (PDB ID: 2BTE).  This bound Ile-
AMP overlapped with the AN2690 inhibitor complex in having a hydrogen bond bridge 
between its phosphate moiety and Tyr487.  We probed the rotamer transitions of Tyr487 
using MD via NAMD (Phillips et al., 2005).  In four sets of simulations for the C. 
albicans LeuRS, Tyr487 transiently maintained its interaction with the phosphate group 
of Ile-AMP, that mimics the bound oxaborole-AMP of the I-state for ~10 ns.  Over the 
combined 60 ns time course of MD for the wild-type LeuRS CP1 domain, the K-state 
rotamer was sampled where Tyr487 interacted with Lys510 and Phe491 similar to the 
static crystal structure of apo LeuRS.  An additional rotamer state called “S” emerged in 
the presence of the Ile-AMP editing substrate where Tyr487 forms a hydrogen bond with 
the 3’ hydroxyl group of the ribose of the editing substrate.  In the mutant K510E LeuRS, 
MD only showed the K-state and S-state, even though Lys510 has been substituted by a 
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glutamate residue.  Similar to the I-state that binds the oxaborole-AMP inhibitor and 
transiently interacts with the phosphate moiety of Ile-AMP, the 4Iae α-helix shifts closer 
toward the editing pocket (Figure 3.10, 3.11).   
 
Figure 3.10  MD-computed states of C. albicans LeuRS CP1 domain with Ile-AMP. 
a. MD of  C. albicans LeuRS CP1 domain (PDB: 2WFG) initially docked to Ile-AMP 
yields three states in which Tyr487 interacts with the ribose 3’ hydroxyl group (“S”, left), 
phosphate (“I”, middle), and the Lys510 resistance site as well as Phe491 (“K”, right). 
 
 
Figure 3.11  Four independent standard MD simulations sampled three 
conformational states of wild-type (left) and K510E resistance mutant (Wright et al.) 
of C. albicans LeuRS CP1 domain based on distances between the Tyr487 hydroxyl 
group and 3’ hydroxyl group of Ile-AMP ribose.  The “S,” “I,” and “K” states are 
defined respectively by distances of ~3, ~5, and ~9 Å. 
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We compared the free energy landscape of wild-type and K510E mutant LeuRS CP1 
domains by employing well-tempered metadynamics (Barducci et al., 2008; Laio & 
Parrinello, 2002) (WTmeta) along two collective variables (CVs).  The first CV was the 
distance between the Tyr487 hydroxyl group of the C. albicans LeuRS CP1 domain and 
the 3’-hydroxyl group of substrate Ile-AMP ribose.  The second CV was the root mean 
square deviation (RMSD) of the side chain atoms of Tyr487 and the backbone atoms of 
the shifting 4Iae α-helix, where Tyr487 resides.  After about 100 ns, the simulation 
converged (Figure 3.12, 3.13).   
 
Figure 3.12  Metadynamics simulation samples three states identified by MD. 
 
 
Figure 3.13  The free energy differences between rotamer states K and I are plotted 
over the course of the simulation for the wild-type (WT, blue line) and K510E 
mutant (red line) LeuRS. The K state was defined by the value of 8 Å < CV1 < 9.5 Å; 
CV2 > 1.1 Å and the I state was defined by 4 Å < CV1 < 5.5 Å; 0.4 Å < CV2 < 0.6 Å. 
The minima of the free energy in each region are considered for each point in time. The  
ΔG for the wild-type and mutant LeuRS respectively reached a plateau after 170 ns and 
130 ns, resulting in the convergence of the simulations.  Zhaleh Ghaemi performed this 
analysis. 
	   54	  
 
The reaction pathway for the wild-type LeuRS CP1 domain transitioned from the K to S 
state via the intermediate I-state (Figure 3.14, 3.15).   
 
Figure 3.14  Free energy map of wild-type (top; simulation time of 200 ns) and 
K510E (bottom; simulation time of 160 ns) CP1 domain with Ile-AMP bound at 120 
ns indicates relationship of “S,” “I,” and “K” states.  X- and Y- axes represent 
CV1 and CV2, respectively.  
 
 
Figure 3.15  Three-dimensional free energy landscapes for wild-type (left) and 
K510E mutant (Wright et al.) LeuRS CP1 domain with Ile-AMP bound. 
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Similar metadynamics studies incorporated the K510E mutant and revealed that the 
K-state dominates for this LeuRS resistance mutant (Figure 3.14, 3.15). We estimated 
that the free energy difference (∆G) for the K-state and I-state of the K510E LeuRS 
mutant is stabilized by ~3 kcal/mol with respect to the wild-type. (Figure 3.13)  This 
difference correlates well with the ITC measurements described above that determined 
2.0 kcal/mol difference in the ΔG of binding (Table 3.3).   
 
III.3.3 Collaboration of amino acid neighbors for LeuRS post-transfer editing 
diverge between bacteria and eukaryotes. 
 
Figure 3.16 Editing active site model of C. albicans and T. thermophilus bound with 
Ile-AMP.  a.  MD model of C. albicans LeuRS editing site with Ile-AMP bound shows 
Tyr487 and Thr316 respectively interact with ribose 3’ hydroxyl group of Ile-AMP ribose 
and carbonyl oxygen.  b. Two conserved threonines in T. thermophiles LeuRS structure 
stabilize Ile-AMP in editing site.   
 
Our computational investigations implied that Tyr487 might play a mechanistic role 
in post-transfer editing through its interaction with the ribose 3’ hydroxyl group (Figure 
3.16a).  This tyrosine is conserved in eukaryotes, but located in a peptide insert (I4ae) 
that is completely missing in bacteria (Figure 3.17) (Seiradake et al., 2009).  
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Figure 3.17  Sequence alignment of eukaryotic and archaeal LeuRS with Lys487 
highlighted by arrow.  (Abbreviations described in Figure 3.2.) 
 
 
In contrast, a bacterial-conserved threonine residue (Thr248 in E. coli and T. 
thermophilus) in a completely different region of the CP1 domain interacts with the 3’ 
ribose hydroxyl (Figure 3.16b) (Hagiwara et al., 2010; Palencia et al., 2012; Tukalo et al., 
2005). Remarkably, this threonine resides in a peptide region that is conserved amongst 
all three kingdoms, but is only capitalized upon by bacteria for interactions with the 
substrate’s hydroxyl group.  This threonine-rich peptide is critical for substrate binding, 
discrimination, and hydrolysis during the editing reaction (Zhai & Martinis, 2005).  
However, eukaryotes have substituted this threonine (Thr248) in this otherwise conserved 
peptide with leucine (Figure 3.18). 
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Figure 3.18  Sequence alignment of LeuRS CP1 threonine-rich region in LeuRS with 
conserved, homologous, and diverged amino acids highlighted in blue, red, and 
yellow respectively. Green delineates the conserved bacterial threonine site that has 
diverged compared to eucaryotes and archae.  Abbreviations are indicated in Figure 3.2 
and as follows: Ec, Escherichia coli; Bs, Bacillus subtilis; Tt,Thermus 
thermophilus; Hp, Helicobacter pylori; Sa, Staphylococcus aureus; Se, Salmonella 
enterica; Sp, Streptococcus pneumonia; and Sc-mit, Saccharomyces 
cerevisiae mitochondrial.   
 
Based on experimental (Zhai & Martinis, 2005) and computational QM/MM 
investigations (Boero, 2011; Hagiwara et al., 2010), Thr247 along with a neighboring 
threonine (Thr248) within the highly conserved threonine-rich region of the bacterial 
LeuRS CP1 editing domain were hypothesized to collaborate to stabilize the transition 
state during ester bond cleavage of misacylated tRNALeu (Figure 3.16b). The first 
threonine (Thr247) interacts via a hydrogen bond with the carbonyl oxygen atom of the 
aminoacyl group of mischarged tRNA.  This carbonyl oxygen also forms a hydrogen 
bond with a nearby water molecule in a bipartite interaction (Boero,	  2011;	  Hagiwara	  et	  
al.,	  2010).	  	  As described above, the neighboring threonine (Thr248) interacts with the 3’ 
hydroxyl group of the terminal adenosine ribose of tRNA (Figure 3.16b).  These 
neighboring bacterial threonines sustain a network of hydrogen bonds that stabilize a 
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high-energy state in the hydrolytic mechanism (Hagiwara et al., 2010).  Individual 
mutation of each bacterial threonine residue had minimal effects on deacylation activity, 
but a double mutation of the threonine neighbors to valine abolished hydrolytic activity 
of LeuRS (Zhai & Martinis, 2005).  We performed a 30 ns MD simulation using the 
bacterial T. thermophilus LeuRS CP1 domain bound to Ile-AMP.  Thr248 predominantly 
interacts with the 3’ hydroxyl group of the tRNA terminal adenosine ribose (Figure 
3.19a) while the interaction between Thr247 and the substrate’s carbonyl oxygen was 
frequently sampled (Figure 3.19b). 
 
Figure 3.19  Critical threonine-substrate interactions are stable in molecular 
dynamics simulations.  In a 30 ns non-biased molecular dynamics simulation of T. 
thermophilus LeuRS CP1 domain (PDB ID: 2BTE) bound to Ile-AMP, the distance 
between the (a) Thr247 side chain hydroxyl oxygen and Ile-AMP carbonyl oxygen as 
well as the (b) Thr248 side chain hydroxyl oxygen and Ile-AMP 3’-hydroxyl oxygen are 
measured  c. In a 30 ns non-biased molecular dynamics simulation of the C. albicans 
LeuRS CP1 domain (PDB ID: 2WFG) with Ile-AMP bound in the S state, the distance 
between the Thr316 side chain hydroxyl oxygen and Ile-AMP carbonyl oxygen atom was 
measured. 
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Significantly, MD simulations that we describe above for the S state suggest that 
Tyr487 of C. albicans LeuRS mimics the role of the second “threonine collaborator” in 
bacteria LeuRSs that is missing in eukaryotes.  Tyr487 forms a hydrogen bond to the 3’ 
ribose hydroxyl, but approaches the bound editing substrate mimic from its opposite side 
compared to the bacterial threonine (Figure 3.16a).  This is because Tyr487 resides in the 
eukaryote-specific I4ae peptide insert that is distant from the conserved threonine-rich 
peptide.  Of the Tyr487 substitutions that selectively introduced alanine, phenylalanine or 
glutamic acid, only the Y487E mutant exhibited small effects on deacylation (Figure 
3.20), reminiscent of the minor effect when the downstream  threonine neighbor was 
singularly mutated in bacterial LeuRS (Zhai & Martinis, 2005).   
 
Figure 3.20  Deacylation activity of Tyr487 C. albicans LeuRS mutants. Symbols 
are: wild-type (▲, triangle); Y487E (▼, inverted triangle); Y487F (n, square); Y487A 
(u, diamond); and no enzyme ( , pentagon). 
 
Primary sequence alignments indicated that the downstream threonine neighbor in 
bacteria has been replaced by leucine in eukaryotes (Figure 3.18). To identify hydroxyl-
bearing candidates that could serve as a putative collaborative residue with tyrosine, we 
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compared the three-dimensional structures of the CP1 domain editing sites. We 
hypothesized that Thr316 of C. albicans LeuRS structurally overlaps with the first 
threonine neighbor (Thr247) of T. thermophilus LeuRS for deacylation (Figure 3.16a) 
and could collaborate with Tyr487.  Significantly, Thr316 is also aligned in the primary 
sequence with the critical threonine neighbor in bacteria (Figure 3.18).  Our MD 
simulation result also supported that Thr316 interacted with the Ile-AMP carbonyl group 
(Figure 3.19c).  
 
Figure 3.21 Deacylation activity of Thr316 C. albicans LeuRS 
mutants.  Abbreviations are: wild-type (▲, triangle); Y487F/T316V (◀, left-pointing 
triangle); T316V (▶, right-pointing triangle); T316S (●, circle); Y487F (★ , star); 
and no enzyme ( , pentagon). 
 
Similar to the Tyr487 mutations in C. albicans LeuRS, single mutations of Thr316 to 
valine and serine only had minimal effects on deacylation (Figure 3.21).  However, a 
double mutation of Y487F and T316V that removed both hydroxyl groups from these 
side chains in C. albicans LeuRS abolished editing, consistent with the bacterial LeuRS 
mechanism (Zhai & Martinis, 2005).  This supports that bacteria and eukaryotes have 
separately adapted to rely on different structural elements to facilitate post-transfer 
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editing while maintaining fidelity.  Whereas bacteria utilize two neighboring threonine 
residues, eukaryotes depend on one threonine and a tyrosine, more distant in the primary 
protein sequence, to structurally converge in the active site and collaboratively facilitate 
deacylation.    
 
III.3.4 Substrate-assisted mechanism for LeuRS post-transfer editing relies on 3’ 
hydroxyl groups of mischarged tRNA.  
 
 
Figure 3.22 tRNA analogs were prepared using E. coli CCA-adding enzyme by 
exchanging in vitro transcribed C. albicans tRNALeu(Sampson & Uhlenbeck, 1988) 
terminal adenosine with either 3’-dATP, 3’-OCH3-dATP, or 3’-NH2-dATP. 
 
Computational QM/MM investigations (Boero, 2011; Hagiwara et al., 2010) 
suggested that, in bacterial LeuRS, the 3’ hydroxyl group of tRNA is important to a 
network of hydrogen bonds that facilitates hydrolysis of mischarged tRNALeu.  If this is 
the case, then we rationalized that modifications of the hydroxyl group at this site, which 
hinder its interactions with the collaborative tyrosine, would impact deacylation activity.  
We used E. coli tRNA nucleotidyltransferase to exchange the terminal adenosine of C. 
albicans tRNALeu transcript with a hydrogen (tRNA-3’-H), amine (tRNA-3’-NH2) and 
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methoxy (tRNA-3’-OCH3) group (Figure 3.22) (Minajigi & Francklyn, 2008; Nordin & 
Schimmel, 2002).  Each of these tRNAs were mischarged with isoleucine and recovered 
for deacylation assays.   
 
Figure 3.23 Deacylation activity by wild-type C. albicans LeuRS of Ile-tRNALeu that 
contains modifications of the A76 ribose 3’-hydroxyl group.  Symbols are: tRNA-3’-
OH (▲, triangle); tRNA-3’-NH2 (n, square); tRNA-3’-OCH3 (u, diamond); and tRNA-
3’-H (▼, inverted triangle). 
 
In each case, modification at the 3’ hydroxyl group impeded deacylation activity 
relative to the wild type mischarged tRNALeu (Figure 3.23).  Introduction of an amine 
(tRNA-3’-NH2) resulted in the most significant decrease in deacylation.  However, it is 
likely that this 3’ amine group attacks the carbonyl carbon of the mischarged isoleucine to 
promote an intramolecular shift of the amino acid, yielding a stable peptide linkage 
(Fraser & Rich, 1973; Ramesh et al., 1999; Sprinzl & Cramer, 1975) at the 3’ position 
that is not readily hydrolyzed by LeuRS (Figure 3.24).    
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Figure 3.24 Predicted intra-molecular electron transfer between 3’-amine and 
carbonyl of linked amino acid leads to enrichment of non-hydrolizable amide 
isomer.  R’= tRNALeu-C-C; R = non-cognate amino acid side chain. 
 
As expected, replacement of the 3’ hydroxyl group with a bulky methoxy group 
displaces the bound water molecule to substantially decrease deacylation activity.  The 3’ 
deoxyATP replacement at the tRNA 3’ end maintained some deacylation activity, albeit 
decreased relative to the wild-type tRNALeu.   Similar to substitutions of serine by alanine 
that replaced a critical hydroxyl group in the active site of the protease subtilisin (Carter 
& Wells, 1990), we hypothesize that the void resulting from complete elimination of the 
ribose hydroxyl group could be filled by a water molecule. This water molecule would 
enable at least limited deacylation by re-establishing the hydrogen bond network to 
promote hydrolysis.  
 
III.4 Discussion 
The oxaboroles have emerged as a whole new class of anti-microbials that uniquely 
targets essential LeuRS enzymes via their amino acid editing site.  This boron-dependent 
mechanism is substrate-assisted, requiring the free cis-diols of the tRNA’s 3’ end to trap a 
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tightly bound RNA-protein complex (Rock et al., 2007).  Specificity by LeuRS for the 
fused oxaborole benzyl ring is likely facilitated by a roomy editing site that evolved 
specifically to flexibly accommodate multiple non-cognate amino acids (such as 
isoleucine and norvaline) that LeuRS misactivates (Karkhanis et al., 2006).  This 
contrasts with closely related aaRSs, such as IleRS and ValRS, which edit by similar 
mechanism that requires a universally conserved aspartic acid for quality control, but 
singularly target single amino acids that are smaller (Mascarenhas et al., 2009).  Thus, 
design of effective oxaborole inhibitors for other editing aaRSs would likely require a 
smaller chemical scaffold to confer suitable specificity.  
 
Figure 3.25 Mechanistic divergence of LeuRS post-transfer editing. T. thermophilus 
(green; residues 245-248, 335-347) and C. albicans (yellow; 314-317, 410-422) LeuRS 
CP1 domains are structurally aligned in the modelled substrate-bound state.  The 
eukaryotic I4ae helix insert is purple.  Key amino acids for editing from C. albicans and 
T. thermophilus LeuRS are colored black and red respectively.  
 
A combination of biochemical, structural, and computational work determined that 
the LeuRS undergoes subtle conformational shifts in its editing site that profoundly 
influence the potency of the mechanism of action for the oxaborole.  While revealed by a 
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distal resistance mutation, drug interactions are dependent on a mobile tyrosine residue 
that migrates between three states.  The resting state of LeuRS is comprised of mixed 
populations of the tyrosine states (Seiradake et al., 2009).  However, it is clear that the 
conserved tyrosine switch adopts specific conformations with distinct interactions as it 
cycles through the LeuRS reaction.   
The tyrosine switch is proffered by a later evolutionary addition of a helical insert 
within the CP1 editing domain that is found only in archeal and eukaryotic LeuRSs.  It is 
completely missing in bacterial LeuRSs (Figure 3.25).  Rather, the editing mechanism for 
bacterial LeuRSs is dependent on a conserved threonine residue that is also utilized in 
IleRS and ValRS.  Akin to the tyrosine switch, this threonine has been hypothesized to 
interact with the 3’ hydroxyl of the bound tRNA ribose that plays an important chemical 
role in the editing mechanism. Remarkably, the bacterial LeuRS threonine and 
eukaryotic/archeal LeuRS tyrosine approach the bound tRNA ribose from nearly opposite 
sides in its editing complex to confer the hydrogen bond to the 3’ hydroxyl.  While the 
first LeuRS-specific oxaborole (AN2690) discovered was a potent anti-fungal, this 
mechanistic difference could provide another avenue to exploit the oxaboroles as anti-
bacterials.  A second generation of oxaboroles that capitalize upon the threonine 
interaction in bacterial LeuRSs might likewise be used to inhibit IleRS and ValRS.  At 
least in the case of LeuRS, the mechanistic distinctions of the editing reaction could 
further enhance species-specificity of an antibiotic that treats a spectrum of bacterial 
diseases. 
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Chapter IV.  E. coli LeuRS is transported to the periplasmic space via a 
SecDF-dependent mechanism and secreted at early-stationary phase 
IV.1 Introduction 
Non-translational functions of AARSs can be activated by different mechanisms. 
These include: amino acid binding-triggered cell signaling (Bonfils et al., 2012; Han et 
al., 2012; Ko et al., 2001); post-translational modification-associated conformational 
changes (Ofir-Birin et al., 2013); inclusion of new domains in the gene (Guo et al., 
2010); splice variants (Lo et al., 2014) and proteolytic fragments (Wakasugi & 
Schimmel, 1999) carrying novel functions.  For mammalian AARSs, these alternate 
conformations, even if subtle, can result in relocalization of the full-length protein or its 
fragments to other compartment to confer their alternate functions (Fu et al., 2012; Lee et 
al., 2004; Yannay-Cohen et al., 2009)  
One of the first examples was human TyrRS.  This housekeeping protein is 
proteolyzed into two cytokine-like fragments under apoptotic conditions and secreted 
from apoptotic tumor cells as a signal transducer (Wakasugi & Schimmel, 1999).  Both 
TyrRS (Fu et al., 2012) and SerRS (Xu et al., 2012) have been shown to have a fraction 
to cycled to the nucleus. The nucleus-localized SerRS regulates VEGFA expression, 
which controls vessel development in vertebrates (Xu et al., 2012). Tumor necrosis factor 
α (TNF-α) and VEGF-treated endothelial cells secrete ThrRS, which then stimulates cell 
migration and angiogenesis (Williams et al., 2013). Human LysRS is secreted upon TNF-
α treatment to induce cell immune response (Park et al., 2005), whereas GlyRS can be 
secreted by macrophages to inhibit ERK-activated tumorigenesis (Park et al., 2012).  
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Because many mammalian AARSs have been shown to migrate and relocalize to the 
other compartments, we wondered if bacterial AARS might also migrate under specific 
conditions.  For example, in some cyanobacteria species, an inserted membrane-binding 
CAAD domain in GluRS, IleRS, LeuRS and ValRS anchors these housekeeping proteins 
to the thylakoid membrane (Olmedo-Verd et al., 2011).  During differentiation, newly 
synthesized ValRS is directed to the thylakoid-rich region in a CAAD domain-dependent 
mechanism.   
In E. coli, LeuRS was reported to redistribute to the cytoplasmic membrane upon 
certain stresses (Williamson, 1993).  LeuRS has been shown to be critical to nutritional 
stress responses in mammalian and yeast cells.  Using its leucine-binding pocket, LeuRS 
can sense the intracellular leucine level and render the signal to TOR1 (target of 
rapamycin 1) on the lysosomal membrane (Bonfils et al., 2012; Han et al., 2012).  We 
hypothesized that LeuRS might play similar sensor roles in bacterial systems. Our 
investigation in E. coli determined that under leucine deprivation, small fractions of 
LeuRS relocalized from the cytoplasm, where it performs its primary housekeeping 
function. 
IV. 2 Experimental procedures 
IV.2.1 Materials.   
Cyanogen bromide (CNBr)-activated-Sepharose 4B resin (No. C9142) and Optiprep 
(60%; D1556) density gradient medium were purchased from Sigma-Aldrich. E. coli 
strains MG1655 (Guyer et al., 1981), JC1552 (Williamson, 1993) and SX1025 
(Taniguchi et al., 2010) were obtained from Coli Genetic Stock Center (CGSC) at Yale 
University.  E. coli strain DY330 (parent strain of SX1025) was a gift from Dr. A. Emili, 
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(University of Toronto) (Butland et al., 2005).  E. coli strain JP135 and JP91 were gifts 
from Dr. J. Pogliano (UCSD) (Pogliano & Beckwith, 1994). Recombinant E. coli 
glucose-6-phosphate dehydrogenase was obtained from Atgen (South Korea) 
(Cat#GPD0905). 
Table 4.1 Procurement of antibodies. 
Antibody Vendor / Lab Catalog No. / Reference 
Goat α-G6PDH Pierce Antibodies, 
Rockford, IL 
PA1-85474 
Rabbit α-MBP Pierce Antibodies PA1-989 
Rabbit α-OmpA Antibody Research Corp. 
St. Charles, MO 
No. 111120 
Rabbit α-AlaRS Pierce Antibodies PA5-29496 
Rabbit α-ProRS K. Musier-Forsyth,  
Ohio State University 
Purified for this work 
Rabbit α-SecY serum T. Rapoport,  
Harvard University 
(E. Park & Rapoport, 2012) 
Rabbit α-SecD J. Beckwith,  
Harvard Medical School 
(Pogliano & Beckwith, 1994) 
Rabbit α- SecF J. Beckwith,  
Harvard Medical School 
(Pogliano & Beckwith, 1994) 
Chicken α-SecD A. Driessen,  
University of Groningen 
(Nouwen & Driessen, 2002) 
Chicken α- SecF A. Driessen,  
University of Groningen 
(Nouwen & Driessen, 2002) 
Rabbit α-SecY A. Driessen, U Groningen (van der Sluis et al., 2002) 
Rabbit α-SecA F. Yap,  
Saint Louis University 
(Das et al., 2012) 
Mouse- α-YFP BioLegend Inc. 
San Diego, CA 
MMS-118P 
Mouse-α-S3 Developmental Studies 
Hybridoma Bank, 
University of Iowa 
No.373C9C3A1 
Normal rabbit IgG Santa Cruz Biotech. 
Dallas, TX 
sc-2027 
Normal chicken IgY Santa Cruz Biotech. sc-2718 
Rabbit α-Goat HRP KPL Inc., 
Washington DC 
13-13-06 
Goat α-Rabbit HRP KPL Inc. 074-1506 
Goat α-Mouse HRP KPL Inc. 074-1806 
Goat α-Chicken HRP KPL Inc. 14-24-06 
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IV.2.2 Preparation of LeuRS-specific antibody   
Recombinant LeuRS CP1 domain (CP1Leu) from E. coli (encoded by pBETeCP1-13-
6) was purified as described (Betha et al., 2007) and provided to Pierce Custom Antibody 
Services (ThermoFisher) to develop an antibody in rabbit.  After 72 days of inoculation 
in a rabbit, the polyclonal antibody against E. coli LeuRS CP1 domain α-CP1Leu was 
purified from the rabbit serum by antigen-affinity chromatography as follows below 
(Figure 4.1).   
 
Figure 4.1 Purified α-CP1Leu antibody contains IgG proteins. Rabbit antiserum and 
purified α-CP1Leu IgG were separated by SDS-PAGE and stained with Coomassie Blue 
dye.  The reduced IgG heavy chain and light chain are labeled. 
 
Purified E. coli LeuRS CP1 domain was incubated with thrombin (GE Healthcare, 
27-0846-01) at room temperature for 2.5 hours to cleave the N-terminal six-histidine 
fusion tag in 20 mM Tris, 100 mM NaCl, pH 8.0.  Phenylmethylsulfonyl fluoride 
(PMSF) was added at 1 mM to terminate the cleavage reaction and the mixture was 
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loaded onto a pre-equilibrated His-Select Nickel Affinity column (Sigma).  Recombinant 
fusion-free CP1 domain was further purified by size-exclusive chromatography using a 
120 ml Superdex 75 column [in bicarbonate buffer (0.2 M NaHCO3, pH 8.9)], and then 
incubated with 2 ml CNBr resin (0.4 g) that had been activated by 1 mM HCl for 10 min 
(Urh et al., 2009).  The resin bound to CP1Leu was washed twice with 10 ml bicarbonate 
buffer and blocked with 100 mM ethanolamine for 1 hour followed by three 10 ml 
bicarbonate buffer washes.  The CP1Leu affinity column was incubated with rabbit 
antiserum that contained α-CP1Leu in 1X PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) for 24 hours at 4 °C.  The mixture was loaded into 
an empty 10 ml Poly-Prep column (Biorad, Cat. #731-1550), and then washed three times 
with 10 ml 1X PBS containing 500 mM NaCl.  The antibody was eluted with 0.2 M 
acetic acid, pH 2.7, 500 mM NaCl, dialyzed against 1X PBS, and concentrated using 
Ultracel 3K cut-off tubes (Amicon, UFC900324).  Glycerol was added to 50% final 
volume for storage at -20 °C. The final concentration of antibody was determined to be 
0.92 mg/ml based on its absorbance at 280 nm using extinction coefficient 1.36 L/gcm-1 
(Johnstone & Thorpe, 1988). 
The purified α-CP1Leu antibody selectively recognized the full-length LeuRS and the 
isolated CP1Leu domain but not ΔCP1 LeuRS that is missing its CP1 domain (Boniecki et 
al., 2008) (Figure 4.2a).  E. coli strain SX1025 (Taniguchi et al., 2010) contains an 
endogenously expressed yellow fluorescent protein (YFP) fused to the C-terminus of 
LeuRS.  LeuRS-YFP was constructed from E. coli DY330 (Butland et al., 2005).  Both 
strains were grown in LB media overnight.  Cell lysates were separated on a 4-20% 
gradient SDS-PAGE gel and followed by Western blot with α-CP1Leu.  As expected, the 
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LeuRS-YFP fusion was detected at 130 kD, while the full-length LeuRS protein from the 
parent strain is at 100 kD.  This demonstrates that α-CP1Leu discriminates LeuRS from 
closely related proteins such as ValRS and IleRS (Figure 4.2b). 
 
Figure 4.2 Purified α-CP1Leu antibody has high specificity to E. coli LeuRS and its 
CP1 domain.  a. Full-length LeuRS, ΔCP1 LeuRS and isolated CP1 domain from LeuRS 
(CP1Leu) proteins were separated by SDS-PAGE, and analyzed either by staining with 
Coomassie Blue or Western blot using α-CP1Leu antibody. A minor band at 37 kD shown 
in the “CP1” lane of Western blot was likely due to antibody cross-recognition.  c. E. coli 
strain DY330 and SX1025 (containing LeuRS-YFP) were grown overnight, lysed and 
analyzed by Western blot using α-CP1Leu or α-YFP antibodies. Molecular weight markers 
are indicated in kD. 
 
  
IV.2.3 Sub-fractionation of E. coli cells 
E. coli was grown in either rich LB (BP1426, Fisher Scientific) or M9 minimal 
media.  M9 media was supplemented with 50 μg/ml essential amino acids including 
lysine, tryptophan, threonine, methionine, histidine, valine, isoleucine, leucine, 
phenylalanine, arginine, thymine and pyridoxine (Reusser et al., 1957).  Strain MG1655 
(Guyer et al., 1981) was treated with increasing levels of chloramphenicol at OD600 = 
	   72	  
0.92.  Cells were grown for 1.5 hours and harvested by centrifugation at 5000g.  Leucine 
auxotrophic strain JC1552 (Williamson, 1993) (Figure 4.3) was grown in M9 media 
supplemented with each of the 10 amino acids to OD600 = 0.50.  Cells were harvested by 
centrifugation and resuspended in M9 media with essential amino acids as well as 2, 20, 
200 μM leucine for 1.5 hours before harvest.  
 
Figure 4.3  Leucine/arginine auxotrophic E. coli strain JC1552 failed to grow on 
agar plates without leucine or arginine.  Six E. coli strains streaked on M9 agar plate 
supplemented with 10 essential amino acids (left) at 37 °C overnight. The media in the 
middle and right plate are respectively missing leucine and arginine.  The genotypes of 
the six E. coli strains are: 1. JW5807-2 (Δ(araD-araB)567, ΔleuB780::kan, 
ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514); 2. JW5606-1 (Δ(araD-
araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, ΔilvE721::kan, Δ(rhaD-rhaB)568, hsdR514); 
3. JW3745-2 (Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, ΔilvA723::kan, 
Δ(rhaD-rhaB)568, hsdR514); 4. JC1552 (leuB6(Am), fhuA2::IS2, lacY1, glnX44(AS), 
gal-6, λ-, trp-31, hisG1, argG6, rpsL104, malT1(λR), xyl-7, mtlA2, metB1); 5. BW25113 
(Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514); 6. 
MG1655 (λ-, rph-1).  Detailed information on each strain can be found at 
http://cgsc.biology.yale.edu.   
 
E. coli cultures were grown to specific OD600 values before cells were harvested at 
5000 g (or 6025 rpm in Beckman JA17 rotor) for 10 min.  Sub-fractionation of E. coli to 
separate and recover outer membrane vesicles (OMVs), periplasm, cytoplasm and 
membrane were carried out according to previously published protocols (Choi et al., 
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2011; Thein et al., 2010b) with the following significant adaptations (Figure 4.4).  About 
0.35 g E. coli cells were incubated in 10 ml ice-cold buffer A [30 mM 
hydroxymethylaminomethane (Tris), 20% sucrose, 1 mM ethylenediaminetetraacetic acid 
(EDTA), pH 8.0] for 5 min.  The cells were spun down at 10,000g (or 8520 rpm in 
Beckman JA-17 rotor) for 10 min and resuspended in 5 ml ice-cold 5 mM MgCl2 to 
introduce osmotic shock.  After incubation on ice for 10 min with intermittent vortexing, 
spheroplasts (E. coli cells without periplasm and most outer membrane) were pelleted at 
10,000 g for 10 min.  Spheroplasts were washed with 5 mM MgCl2, spun at 10000 g for 
10 min and stored at -80 °C.   
 
Figure 4.4  Scheme of E. coli sub-fractionation and media analysis. Detailed methods 
are found in Section IV.2.4 and IV.2.5.  Published protocols (Choi et al., 2011; Levin, 
1996; Thein et al., 2010b) were adapted for optimal sub-fractionation of E. coli and 
media analysis.  Outer membrane vesicle is abbreviated as OMV. 
 
The supernatant (4.6 ml) containing the periplasmic space fraction was supplemented 
with 10 μl protease inhibitor cocktail (Sigma, P8465) and 92 µl of 1 M Tris, pH 7.5.  This 
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fraction was then purified from the supernatant by ultracentrifugation at 200,000g (or 
45,000 rpm in a Beckman SW 60 Ti rotor) for 2 hours to remove outer membrane debris. 
(Levin, 1996; Schlegel et al., 2013)   
The frozen spheroplasts were thawed on ice and resuspended in 4 ml 1X PBS, as well 
as a supplement with 100 μl protease inhibitor cocktail, 2 μl 1 M dithiothreitol (DTT) and 
10 μl phosphatase inhibitor cocktail (Santa Cruz Biotech, sc-45044).  The spheroplasts 
were homogenized three times by French Press (Thermo Spectronic, FA-078) at 1500 psi, 
followed by centrifugation at 20,000g (or 12049 rpm in Beckman JA-17 rotor) for 30 min 
to pellet cell debris.  The supernatant was subjected to ultracentrifugation at 200,000g for 
4 hours at 4 °C to separate cytoplasm from the total membrane (Thein et al., 2010b). The 
cytoplasm fraction was directly recovered from the supernatant and the pellet was washed 
three times with 4 ml 1X PBS, followed by ultracentrifugation at 200,000g for 30 min.  
The total membrane-containing pellet was resuspended in 4 ml 1X PBS, which was 
supplemented with 2% Triton X-100 and 10 mM MgCl2 (Filip et al., 1973; Schnaitman, 
1971).  After at least 2 hours incubation, the solution was ultracentrifuged at 200,000g for 
1 hour and the supernatant containing the combined outer and inner membrane was 
recovered. 
Each of the periplasm, cytoplasm and total membrane fractions were aliquoted, flash-
frozen with liquid nitrogen and stored at -80 °C before use.  The concentration of total 
protein for each fraction was determined using the Biorad DC protein assay (500-0116). 
Gradient dilutions ranging from 1 to 8 fold were incubated with the DC protein assay 
reagents and absorption measured at 750 nm.  The protein concentrations were calculated 
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according to the standard curves that linearly correlated BSA concentrations ranging 
from 50 ng/µl to 1500 ng/µl. 
E. coli MG1655 cells were inoculated in 2 ml LB media and grown at 37 °C  
overnight.  Cells from 1 ml culture were spun down, washed twice with 1ml fresh LB 
media and resuspended in 100 ml fresh LB media.  When OD600 of the culture reached to 
specific values, 50 ml media was collected from the E. coli culture by centrifugation at 
5000 g for 10 min.  The cell-free supernatant was concentrated 10-fold using Ultracel 3K 
cut-off tubes (Amicon).  The concentrated media was then filtered through a 0.2 μm 
membrane (Corning, 431220) to remove remaining whole cell contaminants.  The filtered 
media was centrifuged at 150,000 g (or 40,000 rpm in Beckman SW 60 Ti rotor) for 3 
hours to pellet outer membrane vesicles (OMVs).  The pellet containing the OMVs were 
resuspended in 200 μl sterile 1X PBS or alternatively in 0.5 ml 50% Optiprep/1X PBS 
buffer. In the latter case, the sample was applied to the bottom of a step-density gradient 
that was prepared by gently stacking 0.5 ml 45%, 0.5 ml 40%, 0.5 ml 35%, 0.5 ml 30%, 
0.5 ml 25%, 0.5 ml 20% and 0.7 ml 10% Optiprep/PBS.  After ultracentrifugation at 
200,000 g (or 45,000 rpm in Beckman SW 60 Ti rotor) for 20 hours at 4 °C, 12 fractions 
of equal volume were collected from the top of the centrifuge tube (Choi et al., 2011). 
Both E. coli JP91 and JP135 (Pogliano & Beckwith, 1994) were grown in 0.5 L LB 
media supplemented with 0.0002% arabinose overnight.  Cells were recovered by 
centrifugation, washed twice by fresh LB media, and resuspended in LB media 
containing 0.0002% arabinose or 0.2% glucose to induce or inhibit SecDF expression, 
respectively. When the OD600 reached to 0.5-0.6, cells were harvested and sub-
fractionated as described above.   
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IV.2.4 Western blot analysis and immunoprecipitation 
The total protein concentration was measured for each fraction and 1 µg protein was 
loaded onto mini-protean TGX 4-20% gradient gels (Biorad, 456-1096).  Proteins were 
separated via electrophoresis according to their molecular weight and transferred to 
polyvinylidene fluoride (PVDF) membranes (Biorad, 162-0177) in 1X Towbin’s buffer 
[25 mM Tris, 192 mM glycine, 20% (v/v) methanol, 0.02% SDS, pH 8.3] (Towbin et al., 
1979). Each membrane was blocked at room temperature for 2 hours using 3% BSA, 
1X PBST (PBS containing 0.2% Tween20) before incubation with primary antibodies 
(Table 4.2) at 4 °C overnight.  The membrane was washed twice in 1X PBST before 
incubating with a secondary antibody at room temperature (RT) for 45 min followed by 
another four washes.  Each membrane was incubated with substrate (Pierce ECL plus 
western blotting, 80196) for 3 min before imaging in a Biorad ChemiDoc MP imaging 
system using ImageLab 4.0.1 software.   
Table 4.2 Dilution ratios of antibodies in Western blot*. 
Primary Antibodies  Dilution Ratio Secondary antibodies Dilution Ratio 
Rabbit a-CP1Leu 1,000 Goat α-Rabbit  10,000 
Goat α-G6PDH 1,000 Rabbit α-Goat  1,000 
Rabbit α-MBP 5,000 Goat α-Rabbit  10,000 
Rabbit α-OmpA 10,000 Goat α-Rabbit  10,000 
Rabbit α-AlaRS 10,000 Goat α-Rabbit  10,000 
Rabbit α-ProRS 2,000 Goat α-Rabbit  10,000 
Rabbit α-SecY serum 5000 Goat α-Rabbit  10,000 
Rabbit α-SecD 200 Goat α-Rabbit  10,000 
Rabbit α-SecF 500 Goat α-Rabbit  10,000 
Chicken α-SecD 2,000 Goat α-Chicken  10,000 
Chicken α-SecF 2,000 Goat α-Chicken  10,000 
Rabbit α-SecY 1,000 Goat α-Rabbit  10,000 
Rabbit α-SecA 5,000 Goat α-Rabbit  10,000 
Mouse- α-YFP 1,000 Goat α-Mouse  10,000 
Mouse-α-S3 1,000 Goat α-Mouse  10,000 
    * Optimal dilution ratios for using Pierce ECL plus substrate. 
	   77	  
Immuno-precipitation was carried out using Pierce Direct IP kit (No. 26148) 
according to the manufacture’s instructions.  We compared the affinity of our customized 
α-E. coli CP1Leu to antibodies that were obtained to recognize other AARSs and 
standards.  These included α-human cytoplasmic AlaRS, α-Rhodopsudomonas palustris 
ProRS and α-Leuconostoc mesenteroides G6PDH antibodies.  Purified E. coli proteins 
and the E. coli cytoplasmic fraction that contained endogenous proteins were tested via 
Western blot analysis (Figure 4.5).  The α-CP1Leu antibody exhibited the highest binding 
affinity to its target protein. However, because antibodies against AlaRS, ProRS and 
G6PDH were not raised against E. coli proteins, they cross-reacted with E. coli protein 
targets with lower affinities. 
 
Figure 4.5 LeuRS antibody α-CP1Leu is highly sensitive compared to antibodies 
against ProRS, AlaRS and G6PDH.  Purified E. coli LeuRS, ProRS, AlaRS and 
G6PDH (10 ng; 2 ng; 0.4 ng) as well as 100 ng crude proteins recovered from the E. coli 
cytoplasm (Cyto) (LB media, OD600 = 0.5) were separated by 4-20% gradient denatured 
gel. Antibodies (1:1000 dilution ratio) were applied to detect respective proteins.  The 
western blot membranes were incubated in either moderate substrate (ECL plus) or 
sensitive substrate (Supersignal West Femto) before exposure. Primary antibody types 
are labeled above each membrane.  Detected protein bands are indicated by “*”. 
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IV.2.5 Protein analysis via liquid chromatography and mass spectrometry   
Proteins recovered from immunoprecipitations or E. coli subcellular fractions were 
separated by 4-20 % gradient denatured gel.  A specific band was cut from the gel and 
introduced to trypsinization. Trypsin (proteomics grade, G-Biosciences) was dissolved in 
25 mM ammonium bicarbonate and added at a estimated ratio of 1:20 (trypsin:protein) 
and digested in a CEM microwave reactor at 55 °C for 30 min.  Digested peptides were 
lyophilized for LC/MS.   
A Dionex Ultimate 3000 RSLCnano was connected directly to a Thermo LTQ-Velos-
ETD pro mass spectrometer.  The Acclaim 300 C-18 nano-column 75 µm x 150 mm 
(particle size 3 Å) with an Acclaim Guard column was used at a flow rate of 300 nl/min.  
Approximately 1-2 µg digested peptides were in 5% acetonitrile and 0.1% formic acid. A 
gradient from 100% A (water + 0.1% formic acid) to 60% B (acetonitrile + 0.1% formic 
acid) was used (in 60 min).  Data collection was conducted using the “Big Five” protocol 
(the top five most abundant ions were sequenced) (Thermo, San Jose, CA), MS/MS data 
were collected using collision-induced dissociation (CID).   
Raw data were collected by Xcalibur software (Thermo, San Jose, CA) and processed 
using in-house software Mascot Distiller and Mascot Server.  Resultant peptides 
sequences were searched against NCBI-NR or Uniprot protein databases.  Proteins 
identified that were below the ions score with extensive homology p > 0.05 (p is the 
probability that the observed match is a random event) were discarded.  
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IV.3 Results 
IV.3.1 Small fractions of E. coli LeuRS reside at the membrane and in the 
periplasmic space. 
Previously, Williamson (1993) determined that E. coli LeuRS associated with the 
membrane under certain nutritional and antibiotic stresses.  We hypothesized that LeuRS 
might be an important signaling molecule in E. coli, similar to LeuRS-dependent TOR1 
activities in yeast and mammalian cells (Bonfils et al., 2012; Han et al., 2012).  We 
developed a customized high-affinity antibody that targeted the E. coli LeuRS CP1 
domain to probe for novel interactions that are coupled to stress responses.  We also 
developed a sub-fractionation method for E. coli to carefully segregate total membrane, 
the periplasmic space and the cytoplasm.  MG1655 strain was used as a model because it 
approximates wild-type E. coli with minimal genetic manipulations (Guyer et al., 1981). 
E. coli strain MG1655 was grown to early log phase (OD600 = 0.5) and sub-
fractionated to separate proteins from the periplasmic space, cytoplasm and membrane 
(Figure 4.4).  We optimized a sub-fractionation method (Thein et al., 2010b) to separate 
periplasm, cytoplasm and membrane. Osmotic shock was first applied to the harvested 
cell pellet to release crude periplasm that contained a small fraction of outer membrane.  
The crude periplasm was ultracentrifuged at 200,000 g to obtain purified periplasm from 
the supernatant.  Spheroplasts that only consist of cytoplasm and membrane (inner 
membrane and most outer membrane) were then homogenized and centrifuged to remove 
any insoluble cell debris.  The cytoplasm was separated from total membrane by 
ultracentrifugation at 200,000 g and the latter was dissolved in a buffer containing 2% 
Triton X100 detergent (Figure 4.4).  Coomassie staining showed distinct banding patterns 
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for each of the three fractions representing the periplasmic space, cytoplasm and total 
membrane (Figure 4.6a).  
 
Figure 4.6  Small fractions of E. coli LeuRS reside within the periplasmic space and 
membrane. a. E. coli strain MG1655 was harvested at OD600 ~0.5, sub-fractionated and 
analyzed by Western blot using different antibodies.  Purified AlaRS and ProRS proteins 
were included as positive controls.  Antibodies against G6PDH, MBP and SecF detect 
their respective target protein in the cytoplasm, periplasmic space and total membrane. b. 
Sub-fractionated E. coli displayed distinct protein spectra in the periplasmic space (P), 
cytoplasm (C) and membrane (M) fractions.  About 1 µg of each fraction was separated 
by a 4-20% gradient gel and strained with Coomassie Blue. 
 
Western blot analysis demonstrated that LeuRS was predominantly localized in the 
cytoplasm, and small fractions of LeuRS were detected in the membrane, consistent with 
a previous report by Williamson (Williamson, 1993) (Figure 4.6b).  Surprisingly, LeuRS 
was also identified in the periplasmic space.  Antibodies against maltose binding protein 
(MBP), glucose 6-phosphate dehydrogenase (G6PDH) and SecF were completely 
separated as biomarkers to confirm fractions respectively for the periplasm, cytoplasm 
and membrane.  Surprisingly, AlaRS had a substantial fraction localized to the 
membrane. ProRS was found only in the cytoplasm. 
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Once we established that LeuRS was associated with the membrane, we probed for 
membrane-associated LeuRS changes upon cell stresses.  In contrast to a previous report 
(Williamson, 1993), LeuRS dissociated from the membrane as chloramphenicol 
increased (Figure 4.7).  LeuRS that resided in the cytoplasm was recovered at similar 
concentrations as chloramphenicol increased.  Likewise G6PDH and SecY were present 
at similar levels in the soluble and membrane fractions, respectively. 
 
Figure 4.7 Endogenous E. coli LeuRS dissociates from membrane upon 
chloramphenicol treatment.  E. coli Strain MG1655 was grown in LB media at 37 °C to 
log phase. At OD600 ~0.9, increasing concentrations of chloramphenicol were added, 
followed by 1.5 hours growth prior to harvest. No treatment is represented by “-”.  
G6PDH and SecY were used as biomarkers for the cytoplasm and membrane, 
respectively. 
 
An auxotrophic E. coli strain for leucine, as well as arginine, JC1552 was employed 
to test the effects of nutritional stresses (Williamson, 1993).  E. coli JC1552 was grown in 
M9 minimal media that contained 50 μg/ml leucine and arginine.  At early log phase 
(OD600=0.5), cells were shifted to concentrations of 2-200 µM leucine or arginine media 
(Williamson, 1993).  As expected, the E. coli growth rate slowed at lower levels of 
leucine (Figure 4.8c,d).  The E. coli cells were grown under limiting leucine or arginine 
for 1.5 hours and then harvested by centrifugation.  Sub-fractionation of E. coli cells 
isolated proteins from periplasm, cytoplasm and membrane.  In contrast to a previous 
report (Williamson, 1993), Western blot analysis using α-CP1Leu clearly showed a 
decrease of membrane-associated LeuRS upon leucine or arginine starvation (Figure 
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4.8a,b).  It is possible that LeuRS is localized with the ribosome that is bound to the 
membrane.  However, Western blot analysis of ribosomal protein S3 showed no 
significant changes under either leucine or arginine starvation stress.  Thus, we 
hypothesize that LeuRS dissociation is uncoupled from any putative interactions with 
membrane-bound ribosome (Herskovits & Bibi, 2000; Luirink et al., 2012).  
 
Figure 4.8 Endogenous LeuRS of E. coli dissociates from membrane under leucine 
and arginine starvation stress. a. E. coli strain JC1552 (leucine and arginine 
auxotrophic) cells were grown in M9 minimal media (supplemented with 10 amino acids 
including leucine and arginine) to early log phase before shifting to media with low 
leucine or arginine media.  Cells were allowed to grow for an additional 1.5 hours before 
harvest and the membrane fractions were recovered.  Equal amounts (1 µg) of proteins 
recovered from membranes were separated by a 4-20% gradient gel and analyzed by 
Western blot.  A band at about 45 kD was detected using α-CP1Leu.  SecY was used as the 
biomarker for the membrane fractions. Ribosomal protein S3 indicated the level of 
membrane-bound ribosome. b. Quantification of the membrane-localized LeuRS band in 
Western blot.  “Pre” represents the level of membrane-localized LeuRS at  OD600 = 0.5 
before switching. c. The recorded OD600 after switching to low leucine media growth of 
JC1552 cells for 1.5 hours. Results were based on three independent experiments.  d. 
Growth curves of JC1552 cells in liquid media that contained low levels of leucine at 37 
°C. e. The periplasmic space samples under leucine starvation stress were analyzed by 
Western blot using α-CP1Leu and α-MBP antibodies.  A band at about 52 kD was 
detected using α-CP1Leu.  MBP was used as the biomarker for the periplasmic space 
fractions. 
	   83	  
It is possible that as LeuRS dissociates from the membrane, it is recycled to the 
cytoplasm or periplasmic space.  Significantly, as leucine concentration decreased, the 
levels of LeuRS increased in the periplasmic space (Figure 4.8e). In addition, the level of 
a 52 kD protein band recognized by α-CP1Leu also increased.  We hypothesize that the 
extra “52 kD” protein may be generated from LeuRS by proteolysis.  Both full-length 
LeuRS and its fragment appeared to be enriched in the periplasmic space in response to 
leucine starvation. 
 
IV.3.2  LeuRS relies on SecDF for translocation to the periplasmic space. 
Translocation of LeuRS from the cytoplasm to the periplasmic space would require 
protein translocation pathways, such as the Sec and Tat system to pass across the inner 
membrane (Wickner & Schekman, 2005).  We carried out immunoprecipitation (IP) 
assays using the isolated E. coli membrane fraction with α-CP1Leu. The 
immunoprecipitated proteins were speculated on an SDS-PAGE gel (Figure 4.9a) and 
recovered for mass spectrometry analysis (Appendix 1). Amongst the candidates, SecD 
and SecF were detected (Figure 4.9). While the role of SecD and SecF in translocation is 
unclear (Beckwith, 2013), this suggested that LeuRS might rely on the multi-protein Sec 
translocon to access to the periplasmic space.  
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Figure 4.9 LeuRS immunoprecipitated with E. coli SecD and SecF. Pierce direct IP 
kit was used.  Either rabbit normal IgG (as control) or α-CP1Leu was coupled to the IP 
resin and incubated with the E. coli membrane fraction (OD600 = 0.5, grown in LB 
media). Elutions that contained immunoprecipitated proteins were separated on a 4-20% 
SDS-PAGE gel (a). Recovered proteins were digested with trypsin and analyzed by mass 
spectrometry.  Peptide signals of SecD (b) and SecF (c) were detected with high 
significance.  The score was generated by Mascot software with extensive homology (p < 
0.05) threshold equals to 45. 
 
In E. coli, most secretory proteins pass through the cytoplasmic membrane via the 
Sec translocon, which consists of the essential SecYEG core channel, ATP-dependent 
motor protein SecA, SecB chaperon and an auxiliary membrane protein SecDF 
(Lycklama & Driessen, 2012).  Typically, a nascent protein binds to the SecB chaperone 
to prevent its folding (Weiss et al., 1988). This SecB-nascent protein complex is 
recognized by SecA and transferred to the SecYEG complex. The SecA protein is an 
ATPase that provide energy for the export process and remains bound to SecYEG during 
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translocation (Sardis & Economou, 2010). The channel complex SecYEG is the central 
player and translocates unfolded proteins through its hydrophilic interior (Lycklama & 
Driessen, 2012). Functionally, in vitro reconstitution analysis determined that the 
minimal translocase requires only SecYE and SecA (Brundage et al., 1990). SecD and 
SecF are non-essential to the reconstituted translocase (Akimaru et al., 1991; Brundage et 
al., 1990).  However, in vivo SecDF knock-out strains are severely defective in protein 
translocation (Pogliano & Beckwith, 1994). 
We obtained antibodies for several proteins of the Sec translocon including SecA and 
SecY, as well as SecD and SecF to test directly for interactions between LeuRS and 
specific proteins in the Sec translocon (Figure 4.10).  Immunoprecipitation experiments 
with either SecD or SecF were significantly enriched with LeuRS, compared to ribosomal 
protein S3 controls that had similar levels, supporting direct interactions between LeuRS 
and SecD, as well as LeuRS and SecF.  Interestingly, SecA was also enriched, suggesting 
that it might also play a role in translocating LeuRS.  However, no direct interactions 
were detected between SecY and LeuRS.  We hypothesize that the LeuRS translocation 
process does not require SecY but utilizes a novel SecDF-dependent mechanism, which 
also requires SecA hydrolysis of ATP to provide energy. 
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Figure 4.10 Western blot on IP elutions revealed that SecA, SecD, SecF, but not 
SecY, binds to LeuRS on the cell membrane.  Ribosomal protein S3 was used as the 
loading control due to its high level in the membrane fraction.  Results using chicken α-
SecD, rabbit α-SecY (A. Driessen) and rabbit α-SecF (J. Beckwith) are shown above.  
Western blot results using rabbit α-SecY serum (T. Rapoport) and chicken α-SecF (A. 
Driessen) generated the same results. 
 
To test our hypothesis, the SecDF knock-out strain JP91 of E. coli and its parent 
strain JP135 (Pogliano & Beckwith, 1994) were sub-fractionated to analyze the levels of  
LeuRS in the cytoplasm, periplasmic space and membrane.  In the E. coli JP91 strain, the 
SecDF operon is regulated by the arabinose-controlled PBAD promoter (Guzman et al., 
1992).  Expression of SecDF was induced by adding arabinose to the media (Figure 
4.11a).  Alternatively, SecDF expression was inhibited by adding glucose, which led to a 
cold-sensitive phenotype (Figure 4.11a).  In the absence of arabinose, the export-
defective JP91 cells are more vulnerable to bleach compared to JP135, probably due to 
lack of some membrane structural proteins that had to be translocated by the Sec 
translocon (Figure 4.11b).   
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Figure 4.11  Cold-sensitive SecDF knockout strain JP91 was vulnerable to bleach.  a. 
The SecDF-knockout E. coli strain JP91 and its parent strain JP135 were grown on LB 
agar plate that was supplemented with or without 0.2% arabinose (Ara), at 30 °C or 37 °C 
overnight.  b. Early log phase LB culture (50 ml) of E. coli strain JP135 or JP91 
supplemented with either arabinose (Ara) or were treated with 5ml 10% bleach. The 
picture was taken immediately after adding bleach.  Dark color indicates significant cell 
death.  All three cultures turned dark after 2 min of bleach treatment. 
 
Both E. coli strains JP91 and JP135 were grown to OD600 ~ 0.5 in LB media 
supplemented with arabinose or glucose, and then harvested and sub-fractionated.  As 
would be expected, in the presence of glucose only, low levels of SecD and SecF were 
expressed in the E. coli strain JP91 (Figure 4.12a).  Based on the incredibly low number 
of molecules of SecDF estimated to be 20-40 molecules/cell (Kudva et al., 2013), this 
would significantly reduce the concentration of SecDF compared to the rest of the Sec 
translocon proteins.  The depletion of SecDF in E. coli JP91’s translocation machinery 
resulted in a difference in the protein spectra of the periplasmic space (Figure 4.12b).  In 
particular, the levels of MBP, an abundant protein in the periplasmic space, decreased 
significantly.  Likewise, the levels of LeuRS were decreased in the periplasmic space of 
SecDF-depleted JP91 strain.  In contrast, the overall LeuRS levels remain unchanged in 
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the whole cell lysate (Figure 4.12c). We hypothesize that LeuRS translocation is 
mediated through the Sec system but in a SecDF-dependent manner. 
 
Figure 4.12 SecDF knockout cells contain low levels of LeuRS in the periplasmic 
space. E. coli strain JP135 (parent) and JP91 (SecDF-) were grown to OD600=0.5 in LB 
media that was supplemented with arabinose or glucose. Harvested cells were sub-
fractionated into the periplasmic space, cytoplasm and membrane.  Recovered proteins 
(1 µg) from the membrane fraction (a), periplasmic space (b) and the whole cell lysate (c) 
were separated by a 4-20% SDS-PAGE gel (Biorad) and analyzed by Western blot.  Total 
protein of membrane fractions were stained by Coomassie Blue dye while the total 
protein of periplasmic space fractions were stained by a more sensitive silver staining kit 
(Invitrogen, LC6070).  In panel b, the arrow labeled band was identified as MBP by mass 
spectrometry. 
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IV.3.3  LeuRS is secreted into the LB media at early stationary phase. 
Because LeuRS was enriched in the periplasmic space upon leucine starvation, we 
wondered if this LeuRS translocation process was triggered by the nutritional levels of 
the media or E. coli growth phases.  To compare the LeuRS sub-cellular distribution in 
different types of media, the E. coli strain MG1655 was grown in either enriched LB 
media or M9 minimal media to early log phase (OD600 = 0.5).  The harvested cells were 
sub-fractionated to recover proteins from the periplasmic space, cytoplasm and 
membrane. Compared to the levels of LeuRS in the cytoplasm and membrane fractions 
when E. coli was grown in LB media, the M9 media-grown E. coli maintained similar 
levels of LeuRS in these fractions. The levels of AlaRS and ProRS were also determined 
in the same fractions.  Both had consistent expressions in LB and M9 media.  In 
particular, ProRS remained located to the cytoplasm, where protein synthesis occurs.  
Interestingly, AlaRS co-fractionated with the membrane.  We wondered if AlaRS was 
associated with the membrane-bound ribosome and proteins.  Surprisingly, the levels of 
LeuRS in the periplasmic space were decreased dramatically when E. coli was growing in 
M9 versus LB media (Figure 4.13).  Similar to LeuRS, the periplasm fraction of S3 was 
completely depleted in M9 media.   
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Figure 4.13  LeuRS dynamically re-distributed in different media.  E. coli strain 
MG1655 was grown to early log phase in LB and M9 media and sub-fractionated. An 
aliquot of 1 µg of protein from sub-fractionated periplasm (P), cytoplasm (C) and 
membrane (M) fractions was separated by SDS-PAGE.  Endogenous proteins were 
detected by Western blot.  Antibodies to G6PDH, MBP, SecF and OmpA were employed 
to detect respective target proteins as markers for the cytoplasm, periplasmic space, inner 
and outer membrane.  The density of each full-length LeuRS band was quantified by 
Image Lab software (Biorad).  Relative densities are labeled below each full-length 
LeuRS band. 
 
The antibodies to E. coli LeuRS are specific for its internal CP1 domain.  In both 
enriched LB and minimal M9 media, a low molecular weight band was detected by α-
CP1Leu at 45 kD in the membrane-bound fraction. The intensity of the “45 kD” band 
increased in the membrane specifically upon leucine starvation (Figure 4.8a). 
Significantly, a faint band at 52 kD appeared in the periplasmic space, while a band for 
the full-length LeuRS was completely missing (Figure 4. 8d, 13). 
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We hypothesize that LeuRS is cleaved within the CP1 domain under certain 
conditions.  It is possible that the “45 kD” and “52 kD” protein comprise the full-length 
LeuRS that has a molecular weight of about 97 kD (Figure 4.14a).  It is possible that E. 
coli LeuRS is cleaved at the putative “AxA” motif by the signal peptidase of Sec 
translocon (labeled in red, Figure 4.14a) of the alanine-rich CP1 domain (Payne et al., 
2012).  In this case, the two protein fragments are differently degraded under distinct 
conditions, suggesting that the stable fragments might play a role in cell signaling.  
Alternatively, the two fragments may overlap in the N-terminus of the LeuRS (Figure 
4.14b) and are activated via different proteases and/or protein partners.  Either way, the 
emergence of the 45 and 52 kD band under different nutritional limitations suggests that 
LeuRS may be processed as part of a signaling and stress response. 
 
Figure 4.14  Proposed LeuRS fragments based on Western blot result.  a. E. coli 
LeuRS may be cleaved within the CP1 domain to generate an N-terminal “45 kD” 
fragment in the membrane and a C-terminal “52 kD” fragment in the periplasmic space. 
The cleavage site may be overlapped at the N-terminus (b). 
 
The media-dependent re-distribution of intracellular LeuRS also provided excellent 
controls to ensure that the LeuRS observed in the periplasmic space is due to efficient 
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sub-fractionation.  This was reinforced by several control markers (G6PDH, MBP, SecF 
and OmpA) that tracked specifically to their appropriate compartments. 
Our data shows that LeuRS and fragments of LeuRS shift between the cytoplasm, 
membrane and periplasmic space.  It is unclear whether LeuRS is associated with just the 
inner membrane via SecDF as described above or possibly the outer membrane too. It 
also remains unclear whether the putative 45 kD LeuRS is associated with the inner 
membrane or outer membrane or both.  Because of the dynamic distribution of LeuRS 
between the periplasmic space, cytoplasm and membrane, especially in the periplasmic 
space, we wondered if LeuRS could also be secreted into the growth media.  E. coli cells 
were grown in LB or M9 media and harvested at early log, log and early stationary 
phases (Figure 4.15a, Table 4.3).  The supernatants that comprised the media were 
recovered and concentrated, followed by 0.2 µm filtration to remove any whole cell 
contamination.  The media fractions were further purified by separating E. coli OMVs via 
ultracentrifugation.  
Table 4.3  Samples of growth media for E. coli strain MG1655. 
Media LB enriched media M9 minimal media 
Sample Early log Log Early stationary Early log Log Early stationary 
OD600 0.47 1.02 1.89 0.49 1.00 1.69 
Time (h) 2.0 2.7 4.0 4.9 6.0 7.3 
LeuRS level Low Low High N.D.+ N.D.+ N.D.+ 
 + Not detected. 
 
LeuRS in the media was detected only during the early stationary phase of E. coli that 
was grown in the rich LB media (Figure 4.15b).  In contrast, when E. coli was grown in 
M9 minimal media, the LeuRS signal was not detected throughout growth (Table 4.3).  
Analysis via Western blot using antibodies to the outer membrane protein A (OmpA) 
determined that OMVs were released continuously through each phases of E. coli growth 
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in enriched media.  In contrast, under conditions of minimal media, OMVs that were 
marked by OmpA were only detected in early stationary phase of E. coli growth. 
 
Figure 4.15 E. coli LeuRS is secreted at early stationary phase when grown in LB 
media.  a. E . coli MG1655 growth curve in LB and M9 media.  b. Western blot analysis 
of media recovered from E. coli grown in either rich or minimal media showed that 
LeuRS was detected in LB media mainly at the early stationary phase.  Growth media 
recovered at early log (ES), log (L) and early stationary (ES) phases were used to detect 
LeuRS and OmpA.  The OmpA signal represents the OMV level in the media.  c. LeuRS 
was secreted external to the OMVs. The LB media was recovered at the early stationary 
phase.  OMV-free media (OFM, concentrated by 10-fold), crude OMV (OMV, 
concentrated by 25-fold) and twelve fractions of buoyant ultracentrifugation were 
separated by SDS-PAGE and analyzed by Western blot using antibodies against LeuRS, 
MBP, OmpA and ribosomal protein S3.  LeuRS and MBP were detected mainly in the 
OMV-free media.  A small fraction of LeuRS was detected in the crude OMV sample and 
the 50% Optiprep region of buoyant ultracentrifugation tube.  OmpA and ribosomal 
protein S3 were detected mainly in the crude OMV and further isolated at 30-40% 
Optiprep region of the ultracentrifugation tube. 
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OMVs are small vesicles that are secreted from E. coli.  Proteomics analysis has 
indicated that they are comprised of diverse proteins and nucleic acids, including 
macromolecules that are involved in translation (Lee et al., 2007).  To determine if 
LeuRS is sequestered inside the OMV, we isolated OMVs via extended 
ultracentrifugation that established a density gradient using Optiprep/1X PBS commercial 
buffers.  Western blot analysis that probed OmpA showed that OMVs migrated to the 
lower density region of approximately 35% Optiprep due to their phospholipid content 
(Figure 4.15c).  The ribosomal protein S3 also co-migrated with the OMVs, indicating 
that either the isolated S3 protein or the entire ribosome was exported via the OMVs. 
Previously, proteomic profiling of E. coli OMV reported that ribosomal protein S3, as 
well as AlaRS, GlyRS and PheRS were found inside the OMV (Lee et al., 2007).  
However, in our experiment, LeuRS was isolated in the media, but external to the OMVs.  
Therefore, we hypothesized that LeuRS is secreted from the periplasmic space in an 
OMV-independent mechanism to the media. 
The LeuRS that is found in the media could originate from cell secretion or 
alternatively due to cell death.  We probed a series of additional proteins in E. coli strain 
MG1655 as internal standard controls via Western blot analysis. Neither G6PDH that 
resides in the cytoplasm, nor SecF that is located to the inner membrane, were detected in 
the media (Figure 4.16a,b).  Likewise AlaRS and ProRS were not found in the media 
(Figure 4.16c).  Only a periplasm-based protein MBP exhibited a similar pattern of 
localization to LeuRS when E. coli was grown in LB media (Figure 4.16a).  Thus, we 
hypothesize that LeuRS as well as MBP that is found in the media translocate from the 
periplasmic space to the media at early stationary phase.   
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Figure 4.16 Both LeuRS and MBP were detected in the LB media when E. coli 
strain MG1655 was grown to early stationary phase.  E. coli strain MG1655 was 
grown in LB and M9 media to early log (ES), log (L) and early stationary (ES) phases.  
Growth media was recovered and centrifuged to separate OMV-free media (a) from crude 
OMVs (b).  Western blot was used to detect LeuRS, G6PDH, MBP, OmpA and SecF in 
the media. Endogenous G6PDH, MBP, OmpA and SecF proteins were targeted as 
cytoplasm, periplasm, outer membrane and inner membrane biomarkers, respectively.  
Isolated periplasm (P), cytoplasm (C) and membrane (M) fractions of E. coli MG1655 
(grown in LB media to OD600 = 0.5) were used as internal standard controls.  c.  Western 
blot was used to detect ProRS, AlaRS and ribosomal protein S3 in the OMV-free media.  
Purified proteins and isolated periplasm, cytoplasm and membrane fractions were loaded 
on the left side as positive controls.   
 
Previously, we observed that LeuRS was enriched in the periplasmic space of the 
leucine auxotrophic E. coli JC1552 strain upon leucine starvation (Figure 4.8e).  Because 
E. coli MG1655 cells secrete LeuRS to the media at early stationary phase when nutrients 
are depleting, we wondered if the LeuRS that was translocated into the periplasmic space 
in JC1552 cells could be further secreted to the media.  The same protocol was used to 
induce leucine starvation of the E. coli strain JC1552 grown in minimal media that 
contained 2-200 µM leucine.  The OMVs were separated from OMV-free media by 
ultracentrifugation.  A western blot was used to detect LeuRS as well as internal standard 
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controls in both OMV-free media and OMVs.  However, no observable LeuRS signals 
were detected in the low-leucine media by Western blot (Figure 4.17).  It is possible that 
an extremely low amount of LeuRS that below Western blot detection limit, are secreted 
to the media upon leucine starvation, or that the secretion occurs in minimal amounts 
early in the growth when the cells first encounter missing or low levels of nutrients such 
as leucine.   
 
Figure 4.17 In leucine-auxotrophic E. coli JC1552, LeuRS was not detected in the 
media under leucine starvation stress.  E. coli strain JC1552 (leucine and arginine 
auxotrophic) cells were grown in M9 minimal media (supplemented with 10 amino acids 
including leucine and arginine) to early log phase before shifting to media with low 
leucine media.  Cells were allowed to grow for an additional 1.5 hours before harvest and 
the media was recovered.  The OMVs were separated from OMV-free media by 
ultracentrifugation.  The OMV-free media (a) and OMV (b) samples were analyzed by 
Western blot using antibodies against LeuRS, G6PDH, MBP, OmpA and SecF. 
Endogenous G6PDH, MBP, OmpA and SecF proteins were targeted as cytoplasm, 
periplasm, outer membrane and inner membrane biomarkers, respectively.  Isolated 
periplasm (P), cytoplasm (C) and membrane (M) fractions of E. coli MG1655 (grown in 
LB media to OD600 = 0.5) were used as internal standard controls. 
 
To systematically analyze LeuRS secretion during growth, we determined the levels 
of total protein (Figure 4.18) in the periplasmic space, cytoplasm and membrane.  When 
E. coli was grown in LB media from early log to log, then to the early stationary phase, 
total protein levels of cytoplasm and membrane decreased.  The low protein levels inside 
the cell indicate less active protein synthesis, which is likely due to depleting nutrients 
and saturating cell density in the media.  In contrast, the protein level of periplasmic 
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space increased during growth.  Because OMVs are typically composed of proteins from 
the periplasmic space or proteins that are embedded in the outer membrane (Lee et al., 
2007), we hypothesize that more OMV-associated proteins are actively translocated from 
the cytoplasm to the periplasmic space when OMVs are generated and released. 
 
Figure 4.18 Total protein level in the periplasmic space increased during growth. 
Total protein levels in the periplasmic space, cytoplasm and membrane are from about 
0.35 g MG1655 cell pellet grown in LB and M9 media.  The result was based on two 
independent experiments including cell culturing, sub-fractionation and protein 
concentration determination.  
 
The levels of individual proteins were also determined via Western blot (Figure 4.19).  
We particularly focused upon LeuRS, AlaRS, ProRS, Sec translocon proteins and internal 
standard control proteins.  Indeed, we observed decreasing LeuRS levels in the 
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periplasmic space when E. coli was grown from early log to early stationary phases 
compared to the LeuRS levels in the cytoplasm.  Because E. coli secretes LeuRS from the 
periplasmic space to the media at the early stationary phase, the decreasing levels of 
LeuRS support our hypothesis that the media-localized LeuRS originates from the 
periplasmic space.   The levels of all three AARSs, including LeuRS, AlaRS and ProRS, 
decreased in the cytoplasm, which likely reflected an overall slow down of protein 
synthesis.  However, the levels of membrane-localized AlaRS remained the same for 
unknown reasons. 
During growth of E. coli in LB media, the level of SecF associated with the 
membrane fraction decreased dramatically, while SecD and SecA only exhibited a slight 
decrease.  The level of membrane-localized LeuRS also decreased.  It is possible that 
when E. coli was grown to early stationary phase, less SecD and SecF were expressed on 
the inner membrane, which resulted in a less active transport of LeuRS to the periplasmic 
space. In contrast, the SecY level increased during growth.  Because SecY is an essential 
protein in Sec translocon, a high SecY level may indicate active protein translocation 
mediated by putative Sec translocon.  MBP and OmpA are two proteins that translocate 
across the inner membrane exclusively via canonical Sec translocon (Pogliano & 
Beckwith, 1994).  As expected, the levels of MBP and OmpA increased in the 
periplasmic space and membrane, respectively. The diverging rates of the increasing 
canonical Sec translocon-dependent translocation versus the decreasing SecDF-
dependent translocation further support our hypothesis that LeuRS transport likely occurs 
through a novel SecDF-dependent pathway.   
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Figure 4.19 Western blot of specific E. coli proteins at specific points of E. coli 
growth.  E. coli strain MG1655 was grown in LB media to early log (EL), log (L) and 
early stationary (ES) phases.  Cells were harvested and sub-fractionated to isolate 
periplasmic space, cytoplasm and membrane proteins. Each fraction (1 µg) was probed 
by antibodies to detect endogenous proteins.   
 
IV. 4  Discussion 
Eukaryotic AARSs have been shown to relocalize upon specific stimuli (Fu et al., 
2012; Wakasugi & Schimmel, 1999; Xu et al., 2012).  We developed a platform to 
systematically and efficiently sub-fractionate E. coli cells to recover proteins from the 
periplasmic space, cytoplasm and total membrane fractions as well as isolation from 
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OMVs and OMV-free media.  We also developed a powerful antibody to the CP1 domain 
of LeuRS to probe for small amounts of the protein that might reside in non-canonical 
compartments. Using the sub-fractionated samples of E. coli at different growth phases, 
specific proteins were detected and quantified by Western blot analysis.  Surprisingly, we 
found the housekeeping LeuRS protein exists not only in the cytoplasm, where it is 
required for protein synthesis, but small amounts can be found associated with the 
membrane, periplasmic space and external media.  The widespread distribution of LeuRS 
suggests potential alternate functions that are distinct from aminoacylation. 
Previously, E. coli LeuRS was reported to relocalize to the membrane upon leucine 
starvation or chloramphenicol treatment (Williamson, 1993).  We also observed 
relocalization of LeuRS.  However, in contrast, we observed that LeuRS dissociated from 
the membrane.  In addition, a substantial fraction of AlaRS was detected in the membrane 
fraction while LeuRS and ProRS primarily reside in the cytoplasm. 
Using a customized antibody that recognizes LeuRS CP1 domain in 
immunoprecipitation assays, we identified that SecD and SecF bind to LeuRS 
specifically.  By utilizing a SecDF-knockout strain, we determined that LeuRS 
translocation across the inner membrane is mediated through a novel SecDF-dependent 
mechanism.  During E. coli growth, the level of LeuRS decreases in the periplasmic 
space, probably due to lack of SecDF on the inner membrane. 
The transported LeuRS in the periplasmic space could be further secreted when the 
nutrients in rich media are depleting.  However, in minimal media, the endogenous 
LeuRS has an exceptionally low level in the periplasmic space.  Consistently, no LeuRS 
signals were detected during growth in minimal media (Table 4.4).  These results imply 
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that E. coli LeuRS dynamically distributes within the cell’s compartments in response to 
the nutritional changes (Table 4.4). 
 
Table 4.4  Dynamic distribution of aminoacyl-tRNA synthetases in E. coli 
AARS LeuRS LeuRS ProRS AlaRS3 
     Growth Media LB M9 LB LB 
Growth Phase1 EL L ES N/A2 N/A2 N/A2 
     Cytoplasm + + + + + + 
     Membrane + + + + - + 
     Periplasmic Space + + - - - - 
  Secretion at ES Phase - - + - - - 
 1  Early log (EL); log (L); early stationary (ES). 
 2  Not applicable. 
 3 A relatively high level of AlaRS is associated with the membrane. 
 
Human cytoplasmic LeuRS has been shown to be a leucine sensor upstream of the 
mTOR pathways (Bonfils et al., 2012; Han et al., 2012; Yoon & Chen, 2014), which 
responsively regulates translation and cell growth.  The leucine-bound pocket of LeuRS 
is responsible for transmitting the signal of intracellular amino acid level to mTOR.  
Because the leucine-binding pocket of LeuRS is highly conserved due to its fundamental 
role in tRNA aminoacylation and protein synthesis (Cusack et al., 2000), we 
hypothesized that E. coli LeuRS may also play a leucine sensor role.  
In our work, E. coli LeuRS is observed to dynamically relocalize in response to 
nutritional availability.  For example, at early stationary phase when nutrients are 
severely depleted from the LB media, LeuRS is secreted.  It is possible that E. coli 
LeuRS plays a secondary role as a leucine sensor to detect both intra- and extra-cellular 
amino acid levels.   
Ironically, the relocalization of LeuRS was not observed in minimal media.  Nor was 
LeuRS present in the periplasmic space. It is possible that this moonlighting function is 
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repressed to facilitate aminoacylation for translation of essential proteins.  The repression 
of LeuRS relocalization restricts most of LeuRS in the cytoplasm.  This would guarantee 
the minimal requirement for protein synthesis when E. coli is in the minimal media.  
However, in rich media, a small fraction of LeuRS is actively transported to the 
periplasmic space, where amino acid level is similar to the outside of the cell.  The 
leucine-bound LeuRS may activate downstream signaling pathways to regulate E. coli 
cell growth and metabolism.  At the early stationary phase, the secreted LeuRS may act 
as a signaling molecule in cell-cell communications. 	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Chapter V.  E. coli tRNALeu isoacceptors are selectively secreted and 
induce human colon cell migration  
V. 1 Introduction 
V.1.1 General overview of human microbiome  
The human body carries about 100 trillion indigenous microbes collectively, called 
the microbiome, which number about 10 times that of human cells (Ley et al., 2006; 
Savage, 1977), or about 1-3% of the total body mass. The microbiome colonizes on most 
human body surfaces, externally and internally.  Some examples are the skin, urinary, 
gastrointestinal and respiratory tracts (Sekirov et al., 2010). Among them, the 
gastrointestinal tract is the most heavily colonized organ (Neish, 2009). It is estimated 
that about 70% of the human microbiome resides in the colon, with densities of 
approximately 1012 cells/gram (O'Hara & Shanahan, 2006).  The gut microbiome is 
dominated by strict anaerobes, while facultative anaerobes (such as E. coli) and aerobes 
account for less than 1% of the total population (Gordon & Dubos, 1970). 
It has long been thought that humans are born germ free and the colonization of gut 
microbiome starts immediately after birth (Mandar & Mikelsaar, 1996).  The mother’s 
vaginal microbiome show similarities to the initially colonized intestinal microbiome of 
newborns (Mandar & Mikelsaar, 1996).  Recently, a unique bacterial community was 
identified in human placenta, which resembled the micribiome of the oral cavity 
(Aagaard et al., 2014). However, there was no evidences that the developing fetus had a 
direct contact with bacteria in the placenta (Wassenaar & Panigrahi, 2014). Depending on 
the baby’s living environment, diet, as well as development factor, the microbial 
composition can diversify widely before one year of age (Mackie et al., 1999).  
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Subsequently, the microbiome stabilizes through adulthood with continuous changes that 
are influenced by diet, environmental exposures and antimicrobial therapies (Mackie et 
al., 1999). 
The human host and its indigenous microbiome have co-evolved to provide 
significant health benefits.  As an example, the gut microbiome that is overlaid on the 
host cell serves as a physical barrier to competitively exclude invading pathogens.  The 
probiotic strain Lactobacillus secretes compounds that inhibit colonization of pathogenic 
E. coli and prevent Listeria infections (Corr et al., 2007).  Ruminococcus gnavus, isolated 
from human fecal samples, requires trypsin from host to produce a wide range of 
antimicrobials in a competitive manner (Dabard et al., 2001). 
An extremely complex network has been implicated amongst the host-microbiome-
pathogen relationships. Because of the vast growing role in signaling found for 
mammalian aaRSs and our discovery that E. coli LeuRS is secreted to the media (Chapter 
IV), we hypothesized that bacterial AARSs could have the capacity of signaling in the 
relationaships of the human microbiome.  Thus, we screened for bacterial AARS-
dependent human cell activities and determined that the tRNA co-factor induced human 
cell migration in certain cells. 
 
V.2 Experimental procedures 
V.2.1 Materials 
Human colorectal carcinoma cell line HCT116 (ATCC CCL-247), embryonic kidney 
cell line HEK293 (ATCC CRl-1573) and cervix adenocarcinoma cell line HeLa (ATCC 
CCL-2) were generous gifts from the laboratories of Dr. Steve Blanke, Dr. Jie Chen and 
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Dr. Lin-Feng Chen (University of Illinois).  Standard procedures for maintaining cultured 
cells were performed according to ATCC guidelines.  Purified yeast ribosome (80S) and 
hpk mRNA were kindly shared by Dr. Hong Jin (University of Illinois).  E. coli crude 
tRNA (MRE600, No.10109550001) was purchased from Roche.  E. coli ribosome 
(P0763S) was bought from New England Biolabs (NEB). Salmon sperm DNA (15632-
011) was acquired from Invitrogen. Decade RNA marker (AM7778) was obtained from 
Ambion.  Native E. coli tRNALys (R6018) and tRNAMet (R8019) were purchased from 
Sigma. 
The DNA probes to detect tRNA isoacceptors and RNA oligonucleotides that were 
added to the human cell culture were synthesized from IDT.  The DNA probes were 
designed to reversely complement the 5’-half of each tRNA molecule (Figure 5.1, Table 
5.1). 
 
Figure 5.1 Design of DNA probes to selectively identify E. coli tRNA isoacceptors. 
Synthesized DNA probes anneal to the tRNAs from 5’-end to the residue before entering 
to the anticodon loop.  Probes against tRNALeuCAG, tRNALeuCAA, tRNAAlaUGC, tRNAProCGG 
and tRNAIleGAU had lengths of 32 bp, 32 bp, 31bp, 32 bp and 32 bp, respectively. 
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Table 5.1 Sequence and GC content of each probe in Northern blot. 
Target tRNA 
isoacceptor 
Sequence (5’ to 3’) GC content 
(%) 𝐭𝐑𝐍𝐀𝐂𝐀𝐆𝐋𝐞𝐮    GCGAAGGUGGCGGAAUUGGUAGACGCGCUAGC 62.5 𝐭𝐑𝐍𝐀𝐂𝐀𝐀𝐋𝐞𝐮  GCCGAAGUGGCGAAAUCGGUAGACGCAGUUGA 56.3 𝐭𝐑𝐍𝐀𝐔𝐆𝐂𝐀𝐥𝐚  GGGGCUAUAGCUCAGCUGGGAGAGCGCCUGC 67.7 𝐭𝐑𝐍𝐀𝐂𝐆𝐆𝐏𝐫𝐨  CGGUGAUUGGCGCAGCCUGGUAGCGCACUUCG 65.6 𝐭𝐑𝐍𝐀𝐆𝐀𝐔𝐈𝐥𝐞  AGGCUUGUAGCUCAGGUGGUUAGAGCGCACCC 59.4 
 
V.2.2 Total RNA extraction and oligonucleotide radiolabeling  
In Chapter IV, E. coli cells were harvested at different growth phases and the 
periplasmic space, cytoplasm and membrane were sub-fractionated.  Growth media was 
also isolated, concentrated and filter-sterilized.  To each subcellular fraction of E. coli or 
concentrated media, final concentrations of 300 mM sodium acetate, pH 5.2 and 10 mM 
EDTA, pH 8.0 were added. Protein was removed by extraction with acidified 
phenol/chloroform/isoamyl alcohol mixture (125:24:1, pH 4.3) followed by ethanol 
precipitation.  Concentrations of the total RNA were determined based on absorption at 
260 nm using Nanodrop 2000 spectrophotometer (Thermo, Waltham, MA). 
For radioactive labeling, 5 µg total RNAs extracted from the sub-fractionated 
periplasmic space, cytoplasm and membrane were treated with 20 U calf intestinal 
alkaline phosphatase (CIP; New England Biolabs, Ipswich, MA) at 37 °C for 1 hour in 
water.  The CIP-treated RNAs were extracted and purified with phenol-chloroform 
[phenol/chloroform/isoamyl alcohol mixture (125:24:1, pH 4.3)], followed by ethanol-
precipitation at -20 °C overnight.  The precipitated tRNA pellet was washed twice with 
70% ethanol, vacuum-dried and resuspended in RNase-free water.  Concentrations of 
recovered RNAs were determined and 500 ng from each sample were labeled with γ-
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[32P]-ATP (6000 Ci/mmol, BLU002Z250UC, PerkinElmer) using 10 U T4 polynucleotide 
kinase (NEB, Catalog # M0201S) at 37 °C for 1 hour (Fang et al., 2012).  Likewise, 
About 40 pmol of DNA probe was [32P]-labeled using 40 U T4 polynucleotide kinase at 
37 °C for 1 hour as described above.  The labeled probes were purified from 
unincorporated γ-[32P]-ATPs by Chroma spin TE30 columns. 
V.2.3 Northern blot analysis of RNAs isolated from E. coli 
An aliquot of extracted 5 µg RNA was separated by electrophoresis on a 15% 
acrylamide-TBE gel containing 7 M urea.  Electrophoresis was carried out in 1X TBE 
buffer at 300 V for about 1 hour until the bromophenol blue dye reached the bottom of 
the gel. The RNAs were transferred to a nylon membrane (Hybond-N, Cat#RPN303N, 
GE Healthcare) in ice-cold 1X TBE at 80 V (400 mA) for 2 hours, before UV-
crosslinking in a UV Stratalinker 1800 (Stratagene).   In a 42 °C hybridization oven, the 
crosslinked nylon membrane was incubated in 10 ml pre-hybridization buffer 
(NorthernMax Prehyb/hyb buffer, Cat#AM8677, Ambion) for 2 hours with gentle 
rotation.  The nylon membrane was placed in a 50 ml Falcon tube with the side 
containing the RNA facing the interior. Radiolabeled DNA probe was heated at 95 °C for 
1 min and put on ice for 10 min before adding to the pre-hybridization buffer.  The nylon 
membrane was incubated with rotation in the Falcon tube at 42 °C overnight. 
On the next day, the nylon membrane was washed once with 50 ml 2X saline-sodium 
citrate (SSC) (diluted from Ultrapure 20X SSC, Cat#15557-044, Invitrogen), 0.1% SDS 
buffer with rotation for 15 min and then twice using 50 ml 0.1X SSC, 0.1% SDS for 15 
min at room temperature.  The wet membrane was covered with parafilm and exposed to 
the storage phosphor screen (Fuji film, BAS cassette2 2040) overnight.  The exposed 
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screen was scanned using a Storm 840 phosphorimager (Amersham Pharmacia Biotech).  
The density of each spot was quantified using ImageQuant 5.2 software (GE Healthcare). 
V.2.4 Human cell culture incubation with tRNA or oligonucleotides 
E. coli crude tRNA and in vitro transcribed full-length tRNAs were refolded by 
heating to 95 °C for 1 min, adding 1 mM MgCl2, and finally quick-cooled on ice for 10 
min. Other RNA oligonucleotides in 30 mM HEPES, pH 7.6, 25 mM KCl and 5 mM 
MgCl2 were heated at 85  °C for 5 min and quickly put on ice for 10 min to allow optimal 
refolding (Wright et al., 1993).   
Human cells were split in a 12-well tissue culture plate and grown for 48 hours 
(37 °C, 5% CO2) until confluence reached about 20-30%. Refolded tRNAs (10 µM, or 
0.26 mg/ml) were added to 0.5 ml media that was pre-warmed in a 37 °C water bath.  The 
old media in each well was carefully replaced with tRNA-containing media in a biosafety 
hood.  The plate was incubated again at 37 °C under 5% CO2.  Cell images were recorded 
every 24 hours using an Infinity 1 camera (Lumenera) hooked onto an optical microscope 
(VWR).  
Human cell number was counted using a hemacytometer (Cat#0267151B, Fisher 
Scientific). The p values were calculated using Graphpad t test calculator with input from 
three independent experiments. 
V.2.5 Con-focal microscopy analysis   
Cells were seeded in a Lab-Tek II chamber slide system (Thermo, 154534) and grown 
to 20-30% confluence.  Multi-layer cells were induced by adding 10 µM E. coli crude 
tRNA and incubated for about 4 days.  Cells were fixed on the slide in 4% formaldehyde 
solution, and then stained by 5 μg/ml Wheat Germ Agglutinin (WGA), Alexa Fluor 633 
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conjugate (ThermoFisher, W21404) and 10 ng/ml 4’, 6-diamidino-2-phenylindole (DAPI) 
(ThermoFisher, D1306) for 10 min each at 37 °C.  The prepared slide was stored in the 
dark prior to analysis using a Carl Zeiss LSM 700 confocal microscope.  The depth of 
each slice along Z-axis was fixed to 0.7 μm and yielding about 60 images that were 
captured for each object.  All 3D models were reconstructed using Imaris software 
(Oxford instrument). 
 
V.3 Results 
V.3.1  Selective secretion of tRNALeu isoacceptors at early stationary phase. 
As described in Chapter IV, when rich LB media was used, LeuRS was secreted from 
E. coli into the media at early stationary phase.  We wondered if tRNALeu was likewise 
secreted.  Total RNA from the periplasmic space, cytoplasm and membrane were 
isolated.  As found with the sub-fractionated protein samples, the recovered total RNA 
declined during growth as nutritional sources were depleted from the rich media.  In 
particular, the periplasmic space contained an exceptionally low level of RNA (about 1% 
of total RNA in cell) (Figure 5.2) compared to its relative protein level (about 8% of total 
protein in cell) (Figure 4.15).  It has been hypothesized that the cell phospholipid 
membranes can act as a strong barrier to the passive diffusion of nucleic acids (Dinger et 
al., 2008), which may result in the low level of RNA in the periplasmic space.  
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Figure 5.2 Total RNA in sub-fractionated periplasmic space, cytoplasm and 
membrane.  Total RNAs in the periplasmic space, cytoplasm and membrane were 
isolated from about 0.35 g MG1655 cell pellet grown in LB (early log phase: EL; log 
phase: L; early stationary phase: ES) and M9 early log phase media (M9_EL).  The insert 
is a blow-up representation of the periplasmic space RNA.  The result is based on two 
independent cell growth experiments.  
 
To visualize the composition of RNA in each E. coli subfraction, the total RNA was 
radiolabeled with  γ-[32P] at their 5’-terminus , followed by separation on a 15% 
denatured acrylamide gel (Figure 5.3).  As would be expected, RNAs isolated from the 
cytoplasm exhibited bands that were representative of tRNA (75-90 base pairs), 5S (120 
base pairs), tmRNA and 23S/16S RNA (> 150 base pairs).  Membrane-localized RNAs 
had a wide spectrum of sizes ranging from 10 to 150 base pairs, which could reflect 
mRNAs that co-localized with membrane-bound ribosome.  However, some major bands 
of less than 50 base pairs due to RNA interference.  Or alternatively, degradation in vivo 
or during the extraction process.  In contrast, in the periplasmic space, the majority of 
RNA lengths are below 40 base pairs. 
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Figure 5.3 Separation of RNA from E. coli sub-fractionated samples.  About 60 ng of 
radiolabeled RNA that was isolated from E. coli periplasmic space (P), cytoplasm (C) 
and membrane (M) were separated by electrophoresis. A Decade RNA marker (left side) 
was used as standard.  
 
Although tRNA had not been detected in the periplasmic space via radiolabeling, we 
hypothesized that small amounts could be co-localized with LeuRS that was secreted into 
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the media.  DNA probes were designed to anneal to the 5’-half of two of the five tRNALeu 
isoacceptors tRNALeuCAG and tRNALeuCAA.  In E. coli, tRNALeuCAG is the most frequently 
utilized of the five tRNALeu isoacceptors and represents about 7% of the total intracellular 
RNA.  The tRNALeuCAA is used in the cell at a similar level to the other three tRNALeu 
isoacceptors (Dong et al., 1996).  A second set of DNA probes was synthesized as 
controls to detect tRNAAlaUGC, tRNAProCGG and tRNAIleGAU (Figure. 5.1).    
Crude tRNA from E. coli was separated by electrophoresis on a denaturing 
acrylamide gel.  Analysis via Northern blot showed that each of the five probes bound in 
a linear manner to their tRNA targets with comparable affinities (Figure 5.4, Table 5.2). 
Our results suggest that about 72% of the RNA isolated from the cytoplasmic are tRNAs.  
According to Dong et al (1996), the in vivo concentration of each tRNA isoacceptor was 
determined in fast-growing E. coli (Table 5.2) similar to the work carried out herein.  
Therefore, the relative binding affinity (A) of each probe was calculated by dividing the 
quantified target tRNA density (D) by their respective concentrations (C; Table 5.2), 
which was similar with up to 4.6 fold difference as shown in equation V.1. 
 
                                                          A = D / C                                        (Equation 5.1) 
 
               
 Table 5.2 Relative binding affinities of each probe in Northern blot. 
tRNA Type tRNALeu tRNALeu tRNAAla tRNAPro tRNAIle 
Anticodon CAG CAA UGC CGG GAU 
E. coli Genome Copy Number 4 1 3 1 3 
Northern blot Density  
(2 µg RNA in Cytoplasm) 15 1.4 13 1.0 6.7 
in vivo Concentration1 (µM) 22.2 9.30 21.0 2.67 24.7 
Relative Binding Affinity2 4.6 1.0 4.2 2.5 1.8 
         1 (Dong et al, 1996) 
         2 “Relative binding affinity” is normalized to tRNALeuCAA data. 
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Figure 5.4 Radiolabeled probes binds to target tRNAs in a linear way. a. RNA from 
either crude E. coli tRNA (lane1, 1 µg; lane2, 0.2 µg; lane3, 0.04 µg) or the sub-
fractionated cytoplasm (lane4, 2 µg) was separated on a 15% denaturing gel. DNA probes 
designed to the 5’-half of specific tRNA isoacceptors was used in Northern blot analysis. 
b. Spot densities were quantified using ImageQuant 5.2 software (GE Healthcare). The 
signal of each tRNA is linearly correlated with the absolute amount. 
 
We also measured the relative levels of each of the five tRNAs within the E. coli 
periplasmic space, cytoplasm and membrane.  We loaded 5 µg total RNA of each 
subfraction onto a 15% denaturing gel and analyzed the tRNA isoacceptor levels via 
Northern blot (Figure 5.5). As expected, in the cytoplasm, the levels of tRNA 
isoacceptors are highly correlated with their respective genome copy numbers. As would 
be expected, the membrane fraction contains less tRNA.  Compared to the relative tRNA 
levels in the cytoplasm, tRNAAlaUGC was found at a relatively high level in the membrane, 
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consistent with AlaRS’s association with the membrane (Chapter IV).  Likewise, tRNAAla 
and tRNALeu were detected in the periplasmic space, even though the overall tRNA 
concentration was very low.  It is possible that tRNAAlaUGC and tRNALeu are selectively 
transported to the periplasmic space for unknown reasons.  Based on that the ratio of 
RNA in the periplasm, cytoplasm and membrane is about 1:30:50 (Figure 5.2), we 
calculated the relative levels of tRNALeuCAA in the periplasmic space, cytoplasm and 
membrane to be approximately 1:3000:200.   
 
Figure 5.5 Levels of tRNA isoacceptors in sub-fractionated E. coli. RNAs (5 µg) of 
each E. coli subcellular fraction (LB media, OD600=0.5) were separated on denaturing gel 
and analyzed by Northern blot using radiolabeled probes against respective isoacceptors.  
The signals of Northern blot spots were quantified by ImageQuant software.  The insert is 
a blow-up representation of the periplasmic space RNA.   
 
While the levels of tRNAs are very low in the periplasmic space, we wondered if they 
might pass through this compartment at least transiently, for secretion into the media 
along with LeuRS.  We extracted total RNA from OMV-free media (Chapter IV) at 
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different growth phases for E. coli that had been grown in LB enriched and M9 minimal 
media.  This included early log, log and early stationary phases as described in Chapter 
IV.  Northern blot analysis detected high levels of tRNALeuCAG and tRNALeuCAA in the 
media when E. coli was grown to early stationary phase in LB media (Figure 5.6).  
 
Figure 5.6 Detection of tRNALeuCAG and tRNALeuCAA in OMV-free media. a. E. coli 
MG1655 was grown in LB and M9 media to early log (EL), log (L) and early stationary 
(ES) phase.  Growth media was isolated and analyzed by Northern blot with the 
radiolabeled probes recognizing tRNALeuCAG, tRNALeuCAA, tRNAAlaUGC, tRNAProCGG and 
tRNAIleGAU. b. The quantified density of each spot was normalized to samples taken from 
fresh LB media.  Fresh LB media was used as control to test for yeast tRNAs from yeast 
extract that might be present in the LB media. 
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The levels of other tRNAs including tRNAAlaUGC, tRNAProCGG and tRNAIleGAU were also 
screened in the media via Northern blot analysis.  However, they were not detected in the 
media during growth. Because two tRNALeu but not the other three tRNAs were detected 
in the media, particularly at early stationary phase, we hypothesize that tRNALeu is 
selectively secreted by E. coli under certain conditions.  It is possible that tRNALeu is co-
secreted with LeuRS by E. coli to the media at early stationary phase as nutritional 
stresses emerge. 
To ensure that media-localized tRNALeu did not originate from small amounts of lysed 
cells, we compared the intra- and extra-cellular levels of each of the tRNA isoacceptors 
including tRNALeuCAG, tRNALeuCAA, tRNAAlaUGC, tRNAProCGG and tRNAIleGAU.  Since the 
tRNAPro gene has one copy number in E. coli genome, we used this to normalize each of 
the tRNA measurement.  By dividing the extra-cellular level of each tRNA isoacceptor at 
early stationary phase of LB media (Hernandez et al.) over its intra-cellular level at early 
log phase of LB media (Int), we calculated the relative fold of enrichment (F) of each 
isoacceptor in the media with respect to the enrichment factor of tRNAProCGG. 
 
                                              F =   𝑬𝒙𝒕  (𝒕𝑹𝑵𝑨𝒙)  /  𝑰𝒏𝒕  (𝒕𝑹𝑵𝑨𝒙)  𝐄𝐱𝐭  (𝐭𝐑𝐍𝐀𝐂𝐆𝐆𝐏𝐫𝐨 )/𝐈𝐧𝐭  (𝐭𝐑𝐍𝐀𝐂𝐆𝐆𝐏𝐫𝐨 )                        (Equation 5.2) 
 
A relative fold for enrichment of 1 reflects proportional release of tRNA caused by cell 
lysis while F<1 suggests a lack of secretion.  If F>1, then the media-localized tRNA is 
dominated by secretion.  Since tRNALeuCAA was enriched by 5-fold in the media, we 
propose that it is selectively secreted relative to the other isoacceptors that were tested 
(Figure 5.7).   
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Figure 5.7 tRNALeuCAA is likely to be secreted into the media.  The enrichment fold of 
each tRNA isoacceptor is calculated by dividing the extra-cellular level of each tRNA 
isoacceptors at early stationary phase of LB media (Figure 5.6) over its intra-cellular 
level at early log phase of LB media (Figure 5.5), followed by normalization to the 
enrichment fold of tRNAProCGG.   
 
 
V.3.2 E. coli tRNAs induce human colon carcinoma cells migration. 
Because E. coli is a pathogen, it is possible that the secretion of LeuRS and 
tRNALeuCAA would have an effect on host cells.  We also wondered if either the protein or 
tRNA could be part of an important signaling pathway for E. coli or even the diverse 
microbiome that it resides.  To test these hypotheses, E. coli crude tRNA, which contains 
a mixture of tRNA isolates, was incubated with three types of human cell lines. Colon 
carcinoma cell line HCT116 was selected because E. coli bacteria normally live in the 
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intestinal track (mainly in colon) of human and animals.  We also used HEK293(T) and 
HeLa cell lines as controls. 
In the presence of 10 µM E. coli crude tRNA, both HCT116 and HEK293 exhibited 
dramatic cell migration to form clumps of assembled cells (Figure 5.8).  In contrast, 
HeLa cell growth was significantly slowed when tRNA was introduced, resulting at least 
in part in cell death. When 10 µM E. coli crude tRNA and 10 nM ribosome were added in 
combination to each of cell culture, HCT116 and HEK293 but not HeLa cells migrated 
similarly (Figure 5.8; Table 5.3).  E. coli ribosomal proteins have also been reported to be 
secreted from the cell (Lee et al., 2007) Interestingly, the addition of the ribosome 
enhanced cell migration, such that the tightly assembled cells could be visualized as early 
as 72 hours.  We hypothesize that E. coli tRNA signals human cell migration in a cell 
type-dependent manner. 
 
Table 5.3  E. coli crude tRNA effects on human cells. 
Cell line Cell migration Growth slowed Cell number (tRNA treated / PBS control) 
HCT116 + - 95% 
HEK293T + + 66% 
HeLa - +* 44% 
  * E. coli crude tRNA induced cell death after 3 days treatment. 
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Figure 5.8 tRNA-induced human cell migration is specific to HCT116 and HEK293. 
a. Human cell line HCT116, HEK293 and HeLa were grown to 20% confluence before 
adding RNA.  Images were recorded using an optical microscope after 96 hours of 
treatment with crude 10 µM tRNA.  b. The cell numbers were determined using 
hemacytometer based on three independent experiments.  c.  Images of the cells were 
taken after 72 hours of treatment with 10 µM crude tRNA and 10 nM ribosome.  d. The 
cell numbers were determined as b. 
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The RNA-treated HCT116 cells were further investigated via a fluorescent 
microscope to better characterize the assembled clumps of cells (Figure 5.9a, b). After 4 
days of incubation with 10 µM E. coli crude tRNA and 10 nM ribosome, HCT116 cells 
were fixed and stained with DAPI to visualize the nuclei.  Multiple layers of cells were 
observed to pile irregularly but tightly to the center of the cell mass.  The areas 
surrounding the tightly piled cells were free of cells.  In contrast, untreated cells formed a 
single layer of cells as expected. 
 
Figure 5.9 tRNA-induced assembled HCT116 cells have a tightly piled morphology.  
HCT116 cells were treated with 10 µM E. coli crude tRNA and 10 nM ribosome for 4 
days to induce cell migration.  Untreated cells had a “single layer” while the treated cells 
developed “cell clumps”.  Cells were washed, fixed, DAPI stained and observed in bright 
field (a) or DAPI mode (b) using a fluorescent microscope. Alternatively, DAPI-stained 
cells were scanned along Z-axis under a Carl Zeiss LSM700 confocal microscope to 
reconstruct the 3D surface model (c) and 3D DAPI-stained nucleus model (d) using 
Imaris software. e. The hights of single layer and tRNA-induced assembled cells were 
determined based on DAPI signal along Z-axis. DAPI-stained cells were further stained 
by WGA (red) on the membrane.  The cells in a single layer (f) or assembled state (g) 
were scanned along Z-axis using a Carl Zeiss LSM700 confocal microscope. Images 
were generated using Zen software and cell heights were measured using Imaris software. 	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Based on the images scanned by confocal microscope, the three dimensional models 
of tRNA-dependent cell clumps as well as single-layered cells were reconstructed by 
stacking all the scanned images.  The heights of assembled cells were measured along the 
Z-axis based on the maximum distances between the DAPI stained nuclei.  On average, 
the clump-like masses were comprised approximately of two layers of irregularly piled 
cells (Figure 5.9e).  Less gap spaces between cells were observed on the surface of the 
clump (Figure 5.9c, d), which indicates tighter cell-cell connections toward the exterior 
of the cell.  Indeed, dual staining revealed that the cells were assembled and stacked so 
tightly that the WGA dye could not penetrate to stain the membrane at the center of the 
cell mass (Figure 5.9f, g).  In comparison, cells located to the surface of the cell mass 
were stained by both dyes.  It is possible that E. coli tRNA may activate certain human 
cell receptors to form a very tight external barrier for the cells. 
 
V.3.3 Human cell migration is dependent on tRNA. 
We observed HCT116 cell migration when E. coli crude tRNA was added to the cell 
culture (Figure 5.8a).  Since LeuRS was secreted to the media as described in Chapter IV, 
we also tested LeuRS, IleRS and AlaRS in the presence and absence of the tRNA and 
ribosome by incubating them with HCT116 cells but no effects were observed unless 
ribosome was present (Figure 5.10). Compared to the cells with E. coli crude tRNA only, 
ribosome-treated cells exhibited significant cell migration.  We wondered if ribosome is 
carrying extra tRNAs to enhance the cell migration effect. 
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Figure 5.10 Human colon cancer cell line HCT116 cell migration is specific to tRNA.  
HCT116 cells were grown to 20% confluence before adding 10 µM E. coli crude tRNA, 
10 nM ribosome (a), 100 nM BSA, LeuRS, IleRS, AlaRS (c), or combinations of RNA 
and protein molecules (b).  Pictures were taken by after 48 hours incubation using an 
optical microscope. 
 
We boiled the ribosome at 100 °C to denature ribosomal proteins.  The combination 
of boiled ribosome and tRNA still triggered significant cell migration into an assembled 
state (Figure 5.11a).  It is possible that the E. coli ribosomal RNA might collaborate with 
tRNA to induce cell migration.  However, when tRNA, but not ribosome, was lowered to 
1/10 in concentration, the effect disappeared (Figure 5.11b).  This result indicates that 
tRNA is the primary cause of cell migration.   We hypothesized that the ribosome may 
carry extra tRNAs that enhance promotes human cell migration. 
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Figure 5.11 E. coli crude tRNA but not ribosome has a dominant effect on HCT116 
cell migration.  a. HCT116 cells were grown to 20% confluence before adding 10 µM E. 
coli crude tRNA and 10 nM boiled ribosome to the cell culture.  Ribosome was boiled at 
100 °C for 5 min to denature ribosomal proteins.  b. The concentration of either tRNA or 
ribosome was lowered to 1/10 of the concentrations added above (tRNA: 1 µM; 
ribosome: 1 nM).  Pictures were taken after 5 days treatment using an optical microscope. 
 
 
Since E. coli tRNA triggered cell migration, we wondered if tRNA from other 
organisms would also impact human cells.  Yeast crude tRNA and ribosome were also 
added to HCT116 in a series of combinations. E. coli crude tRNA induced more clumps 
than yeast crude tRNA (Figure 5.12a) while ribosomes from both species exhibited no 
effect on HCT116 cells (Figure 5.12b).  The combination of E. coli crude tRNA and 
ribosome induced greater migration of the HCT116 cells than yeast crude tRNA and 
ribosome (Figure 5.12c).  When ribosome was swapped between species, moderate 
amount of clumps were induced.  We hypothesize that tRNA induces human HCT116 
cell migration in an E. coli-specific manner. 
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Figure 5.12 E. coli crude tRNA is more effective than yeast crude tRNA for 
induction of HCT116 cell migration.  a. HCT116 cells were grown to 20% confluence 
before adding 10 µM E. coli (Ec) or S. cerevisiae (Sc) crude tRNA to the cell culture.  b.  
E. coli or S. cerevisiae ribosome was added at concentrations of 10 nM.  c.  Combinations 
of 10 µM crude tRNA and 10 nM ribosome from either E. coli or yeast were added. 
Images were taken after 5 days treatment using an optical microscope.  Estimated cell 
clump number is labeled in bracket. 
 
 
Because both yeast and E. coli tRNA induced cell migration, we asked whether other 
RNA molecules and their derivatives would cause similar effects.  A highly structured 
65 bp hpk mRNA that can form stem-loop was used to mimic tRNA (Figure 5.13).  After 
4 days of treatment, hpk mRNA caused very little cell migration, compared to tRNA, 
emphasizing the importance of the tRNA secondary structure to induce migration.  
Likewise, salmon sperm DNA did not stimulate cell migration, supporting that the 
mechanism was RNA-based.  We tested single base pair dNTP, as well as NTP molecules 
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at the same concentration as tRNA, but no cell migration was observed.  Early cell death 
was observed when ATP but not GTP or AMP was added.  However, neither of them 
caused cell migration.  E. coli ribosome was added in combination with all the nucleic 
acids and enhanced cell migration as expected (Figure 5.14).  All these results support 
that the human cell migration effect is dependent on tRNA molecules. 
 
 
Figure 5.13 Secondary structures of hpk mRNA and tRNALeuCAA.  The hpk mRNA 
has two stable stem-loop structures. 
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Figure 5.14 E. coli tRNA specifically causes cell migration.  a. HCT116 cells were 
grown to 20% confluence before adding 10 µM E. coli crude tRNA or 0.26 mg/ml 
nucleic acids including hpk mRNA, salmon sperm DNA, dNTP, NTP, ATP, GTP and 
AMP.  b. E. coli ribosome (10 nM) was added in combination with tRNA and nucleic 
acids.  All images were taken after 4 days treatment by an optical microscope. 
 
Our collective data supports that tRNA acts as the primary mediator of HCT116 cell 
migration.  Because E. coli crude tRNA is a mixture of all isoacceptors, we isolated in 
vitro transcripts of different tRNA isoacceptors including tRNALeuCAA, tRNALeuCAG and 
tRNALeuUAA. In addition, we purchased native purified tRNALys and tRNAMet and 
confirmed their lengths by gel electrophoresis.  Each tRNA isoacceptor was added at 1 
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µM.  Even though this was estimated to be greater than the relative amount in 10 µM 
crude tRNA, the individual transcripts did not cause an effect (Figure 5.15).  Then we 
screened for cell migration using a higher concentration of tRNALeuUAA, which yielded a 
similar effect to crude tRNA (Figure 5.16). This suggests that tRNA-induced cell 
migration is correlated with tRNA concentration rather than isoacceptor specificity.  It is 
possible that other tRNA isoacceptors will also induce cell migration if used at higher 
concentrations.  
 
 
 
Figure 5.15 Individual E. coli tRNA isoacceptors did not cause cell migration.  E. 
coli crude tRNA (10 µM) (a) and individual tRNA isoacceptors including tRNALeuCAA, 
tRNALeuCAG, tRNALeuUAA tRNALys, tRNAMet (1 µM) (b) were added to HCT116 cell line. c. 
E. coli ribosome (10 nM) was added in combination with tRNA. Images were taken after 
3 days treatment by an optical microscope. 
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Figure 5.16 E. coli tRNALeuUAA caused the same effect as E. coli crude tRNA.  a. 
HCT116 cells were grown to 20% confluence before adding E. coli tRNA or in vitro 
transcribed tRNALeuUAA (10 µM). b. E. coli ribosome (10 nM) was added in combination 
with tRNA. Images were taken after 4 days treatment by an optical microscope. 
 
Because each of the tRNA isoacceptors that we tested similarly affect the migration 
of HCT116 cells, we hypothesized that a common tRNA feature might be important to 
the activity.  We designed three RNA oligonucleotides (Francklyn & Schimmel, 1989; 
Martinis & Schimmel, 1992) to mimic the functional domains of tRNALeuUAA.  The three 
oligonucleotides respectively contain the acceptor stem and co-axially stacked TψC 
stem-loop (minihelixLeu); D stem-loop and co-axially stacked anticodon stem (D-loopLeu); 
anticodon stem-loop and co-axially stacked D stem (AC-loopLeu) (Figure 5.17a).  Each 
forms a stem-loop that structurally mimics part of the L-shaped tRNA (Martinis & 
Schimmel, 1992). After 4 days treatment, all three oligonucleotides at 10 µM exhibited 
no observable effect (Figure 5.17b).  However, when we increased the concentrations to 
50 µM, each of the three oligonucleotides induced migration effects of human cells 
comparable to the E. coli crude tRNA (Figure 5.17c).  It is possible that the essential 
domains of tRNALeuUAA can cause human cell migration in a concentration-dependent 
manner. 
	   129	  
 
 
Figure 5.17 Oligonucleotides mimicking tRNALeuUAA functional domains induce cell 
migration in a concentration-dependent manner.  a. Sequences of three functional 
domains of tRNALeuUAA.  HCT116 cells were grown to 20% confluence before adding E. 
coli crude tRNA and the three oligonucleotides at 10 µM (b) or 50 µM (c).  “Refolding 
buffer” contained 1 mM MgCl2 that crude tRNA was dissolved in.  “Annealing buffer” 
contained 30 mM HEPES, pH 7.6, 25 mM KCl and 5 mM MgCl2 that the three 
oligonucleotides were dissolved in. Images were taken after 4 days treatment by an 
optical microscope. 
 
To further characterize the effect of tRNA on HCT116 cells, we added 10 µM E. coli 
crude tRNA to the cell culture, and monitored cell migration daily.  Cell assembly into 
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tightly packed masses was first observed after 3 days (Figure 5.18).  Since ribosome 
enhanced the cell migration effect to occur after 2 days (Figure 5.10), it is likely that 
ribosome enhancement is due to the addition of tRNA that associated with it, 
 
 
Figure 5.18 E. coli tRNA induces cell migration after 72 hours.  HCT116 cells were 
grown to 20% confluence before adding 10 µM E. coli crude tRNA. Images were taken 
daily using an optical microscope. 
 
V.3.4 E. coli tRNA induces HCT116 cell migration under starved conditions 
Human cell aggregation appeared in as little as 3 days in the presence of E. coli crude 
tRNA.  To test whether tRNA-dependent HCT116 cell aggregation was reversible, we 
replaced the tRNA media after 4 days with fresh media that lacked tRNA and ribosome. 
Surprisingly, the aggregated cells redistributed to form a single-layer that was 
reminiscent of control cells (Figure 5.19).  This suggests that tRNA is not likely to be 
internalized, but acts at the cell surface.  We also tested whether we could cycle the cell 
migration effect by replacing the media a second time with fresh media that again 
contained 10 µM E. coli crude tRNA and 10 nM ribosome.  HCT116 cells reassembled 
into a tight aggregate after 2 days (Figure 5.20a).  Media was also recovered that 
contained 10 µM E. coli crude tRNA and 10 nM ribosome and added to the freshly split 
HCT116 cells with low confluence.  The cells exhibited migration into tightly packed 
masses after 24 hours (Figure 5.20b).   
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Figure 5.19 tRNA-dependent aggregation of HCT116 cells disassembles upon 
addition of fresh media.  HCT116 cells were grown to 20% confluence before adding 
10 µM E. coli crude tRNA and 10 nM ribosome. After 4 days of incubation, the media 
containing RNA was replaced by fresh media (“Hour 0”) and grown for 18 hours (“Hour 
18”). 
 
 
 
 
Figure 5.20 Treatment with crude tRNA on both high and low confluence HCT116 
cells caused cell migration and aggregation effect.  a. HCT116 cells that had been 
grown to a high confluence were replaced with fresh media that contained 10 µM E. coli 
crude tRNA and 10 nM ribosome. b. HCT116 at a low confluence were replaced with 
used media that had been used to induce cell migration for 4 days (contained 10 µM E. 
coli crude tRNA and 10 nM ribosome). Images were taken daily after the media 
replacement using an optical microscope. 
 
We also tested if the migration effect can be reintroduced to cell aggregates in fresh 
media.  We added fresh media that contained 10 µM E. coli crude tRNA and 10 nM 
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ribosome to the HCT116 cells, which had been induced to form tightly packed masses 
(Figure 5.21).  Surprisingly, the clump-like cells disassembled to form single layer within 
24 hours, suggesting that fresh media can rescue the HCT116 cells from aggregation.  
However, as the nutrients in the media are depleted, cells assembled into a tightly packed 
mass again after 48 hours.  We hypothesize that E. coli tRNA can induce HCT116 cell 
migration under nutritional stresses. 
 
 
Figure 5.21 tRNA-dependent migration of HCT116 cells was rescued in fresh media 
after 24 hours but re-induced after 48 hours.  HCT116 cells at day 4 treated with 10 
µM crude E. coli tRNA and 10 nM ribosome until the migration effect occurred.  Fresh 
media with or without 10 µM E. coli crude tRNA and 10 nM ribosome was used to 
replace the old growth media on “Day 0”.  Images were recorded daily after the media 
was replaced. 
 	  	  
V.4 Discussion 
As E. coli begins to sense nutrient limits when it is grown in rich media, it begins to 
transit from exponential growth to stationary phase (Sezonov et al., 2007) that is 
concurrent with shifts in the metabolism.  At early stationary phase, we identified that 
tRNALeuCAA was selectively secreted into the media.  Amongst the five tRNALeu 
isoacceptors, tRNALeuCAA comprises 21.2% of all E. coli tRNALeu (Dong et al., 1996), 
which is the second highest concentration in vivo.  It recognizes leucine codon UUG, 
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which is used to translate about 11% of leucine residues (Maloy et al., 1996).  
Significantly, the concentration of tRNALeuCAA is higher than the required level to 
maintain protein synthesis, which is unique in five tRNALeu isoacceptors (Table 5.4).  It is 
possible that the extra tRNALeuCAA isoacceptors can be secreted without interrupting E. 
coli protein translation at early stationary phase.   
              Table 5.4 E. coli tRNALeu isoacceptor concentrations and usage percentage*. 
tRNALeu anticodon CAG CAA GAG UAG UAA 
Percentage of tRNALeu 49.5 21.2 10.5 7.4 11.4 
Codon recognition CUG UUG CUC  CUU 
CUA 
CUG 
UUA 
UUG 
Codon usage by tRNALeu (%) 55 11 20 58 22 
                  * Data adapted from Dong et al, 1996 and Maloy et al, 1996. 
Because LeuRS is also secreted (Chapter IV), it is possible that the specific secretion 
of tRNALeu and LeuRS provide important signaling mechanisms in response to stress 
based on depletion of nutrients.  We hypothesized that these signals could impact other 
bacterial cells.  Alternatively, since E. coli is embedded in the human microbiome, we 
wondered if tRNALeu and LeuRS could mediate interactions between E. coli and its host.  
Combinations of LeuRS and tRNALeu, as well as control proteins and nucleic acids 
showed tRNA specifically induced colon cell migration to form clumps of tightly 
aggregated cell masses that formed a dome-like structure.  The clump had multiple layers 
of tightly connected cells, forming a dome-like structure.  We hypothesized that E. coli 
tRNA triggered cell migration by introducing the cell-cell connection via an unknown 
mechanism.   
We observed that the tRNA-induced cell aggregation could be rescued by fresh 
media.  However, when E. coli tRNA was present in the media, the cell migration effect 
re-occurred after 24 hours.  It is possible that when human cells are undergoing 
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nutritional stress, as a response, the colon-embedded E. coli would also sense the stress 
stemming from starvation.  As a result, E. coli would secrete its tRNALeu to the 
surrounding microenvironment in colon niches.    
The secreted tRNA may function as a signaling molecule to tightly pack colon cells.  
This morphological change may protect colon cells from damages caused by lack of 
nutrient.  In addition, the reversibility of the cell migration effect also shed a light on the 
potential clinical use of tRNA molecules to treat colon diseases. 	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Chapter VI. Conclusions 
 
AARSs have long been used as antimicrobial drug targets due to their fundamental 
roles in protein synthesis. Drugs that mimic the substrates or intermediates of pathogen’s 
AARSs have been developed.  For example, pseudomonic acid resembles the isoleucyl-
adenylate intermediate to inhibit bacterial IleRS (Fuller et al., 1971; Hughes & Mellows, 
1978). 
An antifungal drug AN2690 was reported to block aminoacylation by trapping 
LeuRS/tRNALeu complex in the editing conformation (Rock et al., 2007).  Multiple 
resistance mutants are found within the LeuRS editing pocket.  But some of them, such as 
K510E, are located outside of the editing pocket. Combining biochemical analysis, 
computational simulation and X-ray crystallography, I found the resistance mechanism of 
K510E was introduced by locking a critical tyrosine residue in an inactive state.  Based 
on this, a novel editing mechanism using this “tyrosine switch” was discovered specific 
to eukaryotic and archaeal LeuRS.   
The antifungal drug AN2690, or Kerydin as its commercial name, has been on the 
market to treat fungal toenail disease in patients.  Because of the different amino acid 
editing mechanisms used in bacterial and non-bacterial LeuRS, we anticipate that 
AN2690 can be optimized to specifically kill bacteria, without causing significant side 
effects to human cells. 
AARSs can be ideal enzymes for scaffolding that harbor diverse binding capacities to 
amino acid, tRNA and ATP, which are three fundamental molecules to life.  Using all 
three of them, AARSs play critical roles in protein synthesis to produce and proofread the 
aminoacyl-tRNAs. However, cells have taken advantage of these binding interactions to 
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other purposes.  Even using the leucine-binding pocket alone, LeuRS can sense the 
intracellular leucine level and render the signal to downstream partners in mTOR 
pathway (Bonfils et al., 2012; Han et al., 2012).  In another example, resveratrol binds to 
the tyrosine-binding pocket of TyrRS and redirects the protein to nucleus, activating 
downstream key stress signaling pathways such as PARP-1 (Sajish & Schimmel, 2015).   
It is also possible that the tRNA and ATP binding pockets are involved in non-
translational functions.  For example, multiple human AARSs such as TyrRS (Fu et al., 
2012) and LysRS (Yannay-Cohen et al., 2009) are relocalized to cell nucleus.  TyrRS 
(Wakasugi & Schimmel, 1999), LysRS (Park et al., 2005), GlyRS (Park et al., 2012) and 
ThrRS (T. F. Williams et al., 2013) are secreted extracellularly especially under stress. I 
hypothesized that AARSs in bacteria cells may also relocate under stress.  Gram-negative 
bacteria E. coli was chosen as my model organism because it was reported that E. coli 
LeuRS redistributed to the cytoplasmic membrane upon leucine starvation or 
chloramphenicol treatment (Williamson, 1993).  To detect endogenous E. coli LeuRS, a 
customized antibody against its editing domain (α-CP1Leu) was raised and purified.   
As my first trial, a gradient of H2O2 was added to the E. coli culture to induce stress.  
However, Western blot result showed that LeuRS levels in the cell lysates did not change 
significantly.  I thought this was reasonable because of its housekeeping role.  However, I 
asked the question of whether the subcellular localization of LeuRS would change under 
certain stresses? Instead of using the time-consuming sucrose gradient centrifugation 
(Williamson, 1993), I adapted a published protocol (Thein et al., 2010a) using ultra-
centrifugation to separate membrane from soluble (including periplasm and cytoplasm) 
fractions. Surprisingly, a Western blot using α-CP1Leu showed that LeuRS level 
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decreased in the membrane fraction upon nutritional or antibiotic stresses.  Although this 
was opposite to Williamson’s result, it still indicated a LeuRS relocalization event in 
response to stress.  Due to the constant levels of LeuRS in the soluble fraction, which is 
dominated by cytoplasm, I wondered if the membrane-dissociated LeuRS could be 
transported across the inner membrane.  Using an osmotic shock method (Levin, 1996) to 
isolate proteins within the periplasmic space, I determined its LeuRS level upon leucine 
starvation.  Compared to normal-growing cells, the starved E. coli had a higher LeuRS 
level in the periplasmic space.  This was the first time that an AARS was shown to be in 
the periplasmic space.  AlaRS was also identified in the periplasmic space via mass 
spectrometry followed by immunoprecipitation using α-CP1Leu (Appendix 2), indicating 
the potential interaction between LeuRS and AlaRS in E. coli periplasmic space. 
How does LeuRS get transported across the inner membrane to the periplasmic 
space?  To answer this question, I performed immunoprecipitation assays using isolated 
E. coli membrane fraction with α-CP1Leu.  Two Sec translocon proteins, SecD and SecF, 
were co-immunoprecipitated with the antibody-bound LeuRS, as detected by both mass 
spectrometry and western blot.  In E. coli, the Sec translocon is responsible for transport 
of most secretive proteins across the inner membrane (Lycklama & Driessen, 2012) via 
the SecYEG channel.  However, our Western blot showed LeuRS had no interaction with 
SecY.  It is possible that LeuRS transportation is mediated through SecDF. To test this, I 
determined the LeuRS level in the periplasmic space when SecDF were knocked out in E. 
coli.  As expected, less LeuRS was found in the periplasmic space in the SecDF knockout 
E. coli. 
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Although SecDF knock-out strains are severely defective in protein translocation and 
grow slowly at 37 °C (and not at all at lower temperatures) (Pogliano & Beckwith, 1994), 
they are non-essential to the reconstituted translocase (Akimaru et al., 1991; Brundage et 
al., 1990). The protein SecD and SecF each contain 6 trans-membrane domains and large 
periplasmic loops.  Deletions of the periplasmic loops lead to more severe translocation 
deficiencies both in vivo and in vitro (Nouwen et al., 2005).  Several functions of SecDF 
have been proposed, including a proton motive force-driven conformational change that 
dynamically assists the translocating protein movement (Tsukazaki et al., 2011).  
However, their detailed function and mechanism remain “mysterious” (Beckwith, 2013).  
Based on my collective data, I hypothesize that small amount of LeuRS can be 
transported to the periplasmic space in a SecDF-dependent mechanism. 
Because of the relocalization effect of LeuRS upon leucine starvation, I became 
interested in systematically determining LeuRS levels in the periplasmic space, 
cytoplasm and membrane during growth in LB and M9 media.  Interestingly, when E. 
coli was grown in M9 minimal media, the LeuRS level in the periplasmic space was 
exceptional low (Figure 6.1).  In LB enriched media, the LeuRS level in the periplasmic 
space decreased dramatically when cells entered the early stationary phase.  This made 
me think LeuRS may need to escape from E. coli periplasmic space, especially when the 
surrounding nutrient level is low (Interstella, film).  The media at different growth phases 
was isolated and analyzed by Western blot using α-CP1Leu.  As expected, I found LeuRS 
detected mainly at the early stationary phase of LB media (Figure 6.1).  In contrast, no 
LeuRS signals were observed at any growth phases of M9 media.  Considering the 
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LeuRS level changes in the periplasmic space, I hypothesize the dynamic distribution of 
LeuRS is linked to certain types of signaling pathways. 
 
Figure 6.1.  E. coli LeuRS/tRNALeu secretion hypothesis. (Top) In LB media, small 
fractions of LeuRS are translocated to the periplasmic space via a SecDF-dependent 
mechanism.  At early stationary phase (E.S.), LeuRS assists tRNALeu secretion into the 
media.  (Bottom) In M9 media, LeuRS is mainly involved in protein translation without 
entering to the periplasmic space or being secreted. 
 
What is the physiological reason for E. coli to secret LeuRS?  Based on its tRNA 
binding capacity, I wondered if LeuRS can assist tRNALeu secretion.  Total RNAs from 
the E. coli periplasmic space, cytoplasm and membrane were extracted and analyzed by 
Northern blot.  The tRNA concentrations in the periplasmic space were determined at an 
extremely low level, indicating the difficulty for tRNAs to pass through the periplasmic 
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space.  The levels of five tRNA isoacceptors were measured in the growth media by 
northern blot.  Interestingly, two tRNALeu isoacceptors showed disproportional high 
levels in LB media at the early stationary phase, when LeuRS was mainly detected, too.  
Considering the high levels of RNase in the periplasmic space (Luhtala & Parker, 2010; 
Zhu et al., 1990) to scavenging nucleic acids, I hypothesize that LeuRS can facilitate 
tRNALeu secretion by protecting it from RNase cleavage in the periplasmic space (Figure 
6.1). 
Even though LeuRS is transported to the periplasmic space across the inner 
membrane, it remains unclear how E. coli LeuRS associates to the membrane.  The total 
membrane fraction of E. coli was isolated that comprises both inner and outer membranes.  
Further separation of these membranes would tell the exact localization of LeuRS.  We 
hypothesize that the membrane-localized LeuRS is also likely due to its association with 
the periplasic domain of SecDF (Tsukazaki et al., 2011) (Figure 6.2).  Although the 
LeuRS level in the periplasmic space is relatively low when E. coli is grown in the 
minimal media, it is possible that LeuRS is transported to the periplasmic space and then 
anchored to the SecDF proteins.  The periplasmic domain of SecDF may regulate release 
of LeuRS back to the periplasmic space from the exterior of inner membrane.  Likewise, 
certain protein may associate with LeuRS at the interior of the outer membrane and 
facilitate LeuRS secretion to the media.  
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Figure 6.2.  Alternate E. coli LeuRS/tRNALeu secretion hypothesis. (Top) In LB media, 
small fractions of LeuRS are translocated to the periplasmic space and secreted to the 
media at early stationary phase.  The periplasm-localized LeuRS could either associate 
with the periplasmi domain of SecDF on the exterior of the inner membrane, or associate 
with the interior of the outer membrane.  (Bottom) In M9 media, LeuRS is mainly 
involved in protein translation without entering to the periplasmic space or being secreted.  
In both LB and M9 media, some LeuRS proteins may associate to the interior of the inner 
membrane. 
 
What is the ultimate aim for E. coli to secret tRNAs?  Since E. coli strain was isolated 
from human colon, it is possible that the secreted tRNAs can cause effects on human 
colon cells.  When E. coli crude tRNA or tRNALeuUAA were added into the human cell 
culture, colon cells became clumpy after 3-4 day treatment.  The cells migrated from 
surrounding area to form a dome-like structure and tightly packed.  I hypothesize that 
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secreted E. coli tRNAs can activate certain human cell receptors such as toll-like 
receptors (Diacovich & Gorvel, 2010), which in turn triggers downstream signaling 
pathways to promote cell clumping.  The clumping caused by overlaid cells might be a 
potential defensive strategy during starved conditions. 
In summary, I discovered a tyrosine-switch regulated editing mechanism in 
eukaryotic and archaeal LeuRS.  The mechanistic differences of amino acid editing can 
be used to design new generations of antibiotics without causing major side effects.  Also, 
I observed a dynamics subcellular distribution of E. coli LeuRS, which may assist 
tRNALeu secretion under nutritional stress.  The secreted tRNA may be recognized by 
host cell receptors to cause cell clumping.  This potential inter-species communication 
using tRNA molecules could be a promising lead in characterizing microbiome networks. 	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Appendix A.  Binding partners of LeuRS in E. coli membrane fraction determined 
using immunoprecipitation followed by mass spectrometry*. 
Protein Molecular Mass (Da) Matches Score
Ribosomal protein L19 13125 40 1257
Deoxyribose-phosphate aldolase 27838 4 132
Ribosomal protein S3 26021 43 574
Pyruvate dehydrogenase 99605 17 502
Ribosomal protein L1 24700 15 347
Dihydrolipoyl dehydrogenanse 50630 10 330
Tryptophananse 52682 14 290
ElaB 10435 4 159
Acetaldehyde dehydrogenase 96432 8 149
DEAD/DEAH box helicase gi|585364477 70517 7 145
DnaK 69085 6 143
Chorismate synthase 39172 6 122
Leucyl-tRNA synthetase 97143 6 115
SecD 66446 3 106
Glycine dehydrogenase 104334 5 105
Serine endoprotease DegP gi|41761 51190 7 101
Heat shock protein GrpE 21842 1 98
DNA topoisomerase IV, subunit B 70256 4 98
NADH dehydrogenase 47325 6 97
Isocitrate lyase 47488 4 95
SecF 35307 1 93
Ribosomal protein S1 61122 5 85
Enoyl-ACP reductase 27715 3 85
UDP-N-acetyl-D-mannosaminuronic acid transferase 27869 2 83
DnaJ 41103 3 77
Elongation factor P 20860 2 74
Catabolite gene activator protein gi|2098296 23494 2 73
Ribosomal protein L17 12744 9 72
Initiation factor 3 20491 3 69
Trigger factor gi|147989 47994 5 68
endoribonuclease L-PSP gi|6573316 13611 2 65
Hypothetical protein gi|446088404 21130 3 63
PTS glucose transporter subunit IIA 18109 6 62
Ferric uptake regulator gi|446053846 16785 3 61
Thioredoxin 15984 2 59
Adenine phosphoribosyltransferase 19847 2 56
Gns gi|446941942 6816 2 56
PTS mannose transporter subunit IIAB 34997 7 55
Ribosomal protein S12 13659 7 55
Heat shock protein HSP31 31243 2 54
GMP synthase 60184 3 54
Ribosomal protein L30 6510 5 53
RbsD 4337 1 50
Transcription termination factor Rho 46654 3 50
Hypothetical protein gi|445948744 10621 2 50
Oligopeptidase A 77034 1 49
YobA 9134 4 49
Hslv gi|3114398 20048 1 47
Ribosomal pseudouridine synthase B 32668 4 46
FtsZ 40272 1 45
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Appendix B.  Binding partners of LeuRS in E. coli periplasmic space fraction 
determined using immunoprecipitation followed by mass spectrometry*. 
 
 
Protein Molecular Mass (Da) Matches Score
FKBP%type*peptidyl%prolyl*cis%trans*isomerase 28608 24 423
Periplasmic*beta%glucosidase 86020 16 394
transpeptidase*YbiS 32818 14 257
D%galactose%binding*periplasmic*protein 35606 5 168
Hypothetical*protein*gi|693207313 38602 5 153
Hypothetical*protein*gi|672834184 55393 3 131
TolB 42745 3 121
Enolase 46417 5 108
Metal%binding*protein*ZinT 25458 2 103
Hypothetical*protein*gi|12512834 17521 2 101
Fumarate*hydratase*class*I,*aerobic 60217 3 99
TolC 46838 5 98
Succinyl%CoA*ligase*subunit*beta 41309 1 95
Phosphoglycerate*kinase 41165 2 93
Glycerol*kinase 56254 2 92
Ecotin 16155 2 91
Peptidyl%prolyl*cis%trans*isomerase 28234 2 88
Hypothetical*protein*gi|754648936 33910 4 89
ORF_o259a*gi|537048 28234 2 88
Serine*hydroxymethyltransferase 45454 2 86
Etta 62204 3 83
Ribosomal*protein*S4 23324 4 83
Leucyl4tRNA9synthetase 97222 5 75
HSP31 31174 2 73
Thiol*peroxidase 17824 4 72
Ribose*5%phosphate*isomerase*A 25585 4 70
Isocitrate*lyase 47510 3 70
Alanyl4tRNA9synthetase 96003 5 69
Acid%resistance*protein 12061 1 68
Peptide9ABC9transporter9substrate4binding9protein 49688 2 65
Hypothetical*protein*gi|692993272 8311 4 65
Glucose%1%phosphatase 45981 2 56
Rnase*I 29625 5 55
Ribosomal*protein*S16 14696 1 60
3%oxoacyl%ACP*synthase 42832 2 59
Glutathionylspermidine*synthase 58389 2 58
NAD*synthetase 30662 2 55
Carbonic*anhydrase 25156 1 54
Hypothetical*protein*gi|486206600 20929 2 53
LolA 20310 1 53
Enoyl%ACP*reductase 27715 1 51
Hypothetical*protein*gi|585279908 15590 2 51
Uracil*phosphoribosyltransferase 22518 3 46
Outer*membrane*protein*A*precursor 36282 2 46
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Appendix C.  Binding partners of LeuRS in E. coli cytoplasm fraction determined 
using immunoprecipitation followed by mass spectrometry*.  
* In Appendix 1-3, LeuRS is highlighted in red color.  Interesting proteins are highlighted    
in green color. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Molecular Mass (Da) Matches Score
D"ribose"binding,protein 28457 2 159
Ribosomal,protein,L24 11178 4 114
Hypothetical,protein,gi|447058407 8279 3 95
Carbon,storage,regulator,CsrA 6800 4 94
Ribosomal,protein,L22 12215 9 91
Serine,endoprotease,DegP,(HtrA) 45725 3 81
Transcriptional,regulator,gi|545230458 23316 3 72
Endoribonuclease,L"PSP 13602 2 70
Ribosomal,protein,S14 11286 6 68
Ribosomal,protein,S3 27463 4 65
Hypothetical,protein,gi|446035099 12233 1 62
FtsZ 40272 1 57
Co"chaperon,GroES 5622 3 53
CspC 7497 3 52
Hypothetical,protein,gi|490303626 6680 1 48
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Appendix D.  Strain frozen stocks in -80 °C freezer. 
Box$1 $Plasmid$/$Strain$name Host$cell Description
1 pHZCaLRSWT Rosetta
AN3945pet21b5at5Nhel5and5Xhol5sites,545
amino5acid5variables5included
2 pHZCaLRSK510A Rosetta
3 pHZCaLRSK510D Rosetta
4 pHZCaLRSK510E Rosetta
5 pHZCaLRSK510R Rosetta
6 pHZScK507E
AN3545ANA318*5CDC605K507E5(AN16775
resistant5mutant5C10)5Vol525Page511
7 pHZCaK510E AN3695ATCC59002852690.45LeuRS5(K510E)
8 pHZScLRSD419A BL21+ yeast5cytoplasmic5LeuRS5D419A
9 pHZScLRSWT Rosetta From5Jaya5WT5Sc5LeuRS5p32YLY2Y3
10 pHZScLRSK507A DH5a
11 pHZScLRSK507D DH5a
12 pHZScLRSK507E DH5a
13 pHZScLRSK507R DH5a
14 p14bMBymCP1YNYC5B BL21
Shortest5yeast5mito5LeuRS5CP15in5Jaya's5JBC5
paper,5pET14b5Ile260YGlu4315NdeI_XhoI
15 p14bMBymCP1+(NC)5B BL21
2nd5shortest5yeast5mito5LeuRS5CP15in5Jaya's5
JBC5paper,5pET14b5Trp238YLeu4425NdeIY
XhoI
16 pHZCaLRSK510AY2 DH5a
17 pHZCaLRSK510DY2 DH5a
18 pHZCaLRSK510EY2 DH5a
19 pHZCaLRSK510RY2 DH5a
20 T75RNAP
21 PUC5185vector DH5a
22 pHZCatRNAUUA DH5a C.5albicans5tRNAleu
23 pHZCaLRST321A Rosetta
24 pHZCaLRS5K510E/T321A Rosetta
25 pHZCaLRS5E320K/K507E Rosetta
26 pHZCaLRS5E320R/K507E Rosetta
27 ScmLeuRS5WT5 BL21 pET515b
28 Scm5tRNAleu DH5a
29 ymCP1Ybeta5ext BL21
longest5yeast5mito5CP15in5Jaya's5JBC5paper,5
pET14b5Lys232YTyr4525NdeIYXhoI
30 pCaLeuRSCP1K510A BL21 It5is5K510E5actually
31 pCaLeuRSCP1K510E BL21 It5is5K510A5actually
32 CCA5adding5enzyme5 BL21 From5Li5Li
33 Bs5CCA5adding5enzyme BL21 Kan+5From5Li5Li
34 pCaLRSCP1WT BL21
Amp+5From5Cusack's5group,5see520095JMB5
paper
35 Ec5Ntase5WT BL21 Amp+5From5XiangYlei5Yang's5group
36 pHZ5CaLRSD422A Rosetta
37 pHZCaLRSY487F Rosetta
38 pHZCaLRSY487A Rosetta
39 pHZ5CaLRSY487E Rosetta
40 pHZ5CaLRSL317T Rosetta
41 pHZ5CaLRST316S Rosetta
42 pBETeCP1Y13Y6 BL21
Lab5inventory5Box58Y125EcLeuRSCP15domain5
construct
43 pHZ5CaLRS5T316V Rosetta
44 pHZ5CaLRS5F491A Rosetta
45 pHZ5CaLRS5Y487F/T316V Rosetta
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Appendix D.  Strain frozen stocks in -80 °C freezer (Continued). 
 
 
Box$1 $Plasmid$/$Strain$name Host$cell Description
46 pHZ&CaLRS&Y487A/L317T Rosetta
47 pHZ&CaLRS&Y487E/&T316S Rosetta
48 MG1655&E.coli No&antibiotics&needed
49 p32MBymLeuRSdCP1&(2A) BL21+
ymLeuRSdCP1&from&Michal&1AQ54&in&Q20&
706aa&2Along,&pETQ32&Ek/LIC&vector
50 p15MTVecLeuRSdCP1&(3A) BL21+
EcLeuRSdCP1&from&Michal&Box4Q53&in&Q80,&
pET&15b
51 p28&MtbLeuRS BL21 Kan+&from&Dickon&Alley&pet28a&NdeI_Xho1
52 MG1655&from&Jiqiang&Ling No&antibiotics 20131221,&use&this
53 KY2350&proteaseQdeficient&strain& No&antibiotics from&Jiqiang&Ling,&20131221
54 EcLRS&from&Lucy&Amp+ BL21 20141126made
55 BW25113 BW25113 CGSC#7636&Keio&Collection
56 CV514 CV514 CGSC#5540&Keio&Collection
57 JC1552 JC1552 CGSC#4273&Keio&Collection
58 JW3745Q2 JW3745Q2 CGSC#10733&Keio&Collection
59 JW5605Q1 JW5605Q1 CGSC#11483&Keio&Collection
60 JW5807Q2 JW5807Q2 CGSC#11943&Keio&Collection
61 JW2786Q1 JW2786Q1 CGSC#10181&Keio&Collection
62 JW3419Q1 JW3419Q1 CGSC#11894&Keio&Collection
63 JW3420Q1 JW3420Q1 CGSC#10543&Keio&Collection
64 JW3421Q1 JW3421Q1 CGSC#10544&Keio&Collection
65 JW3422Q2 JW3422Q2 CGSC#10545&Keio&Collection
66 JW3423Q1 JW3423Q1 CGSC#10546&Keio&Collection
67 JW3425Q1 JW3425Q1 CGSC#10547&Keio&Collection
68 JW1995Q1 JW1995Q1 CGSC#9644&Keio&Collection
Box$2. $Plasmid$/$Strain$name Host$cell Description
1 CG2 CG2 CGSC#7149&Keio&Collection
2 JW3142Q6 JW3142Q6 CGSC#10387&Keio&Collection
3 JW3584Q1 JW3584Q1 CGSC#10640&Keio&Collection
4 KJ173 KJ173 CGSC#7145&Keio&Collection
5 KJ184 KJ184 CGSC#7146&Keio&Collection
6 KJ185 KJ185 CGSC#7147&Keio&Collection
7 JP91 Kan+,&from&Joe&Pogliano 20141203,&Joeseph&A.&Pogliano1994&EMBO&J
8 JP135 Kan+,&from&Joe&Pogliano 20141203,Joeseph&A.&Pogliano1994&EMBO&J
9 JW0233Q2 JW0233Q2 CGSC#8468&Keio&Collection
10 JW2806Q1 JW2806Q1 CGSC#10193&Keio&Collection
11 SX1025 SX1025 CGSC#12580&Keio&Collection&20150122
12 DY330 DY330 From&Emili&lab,&20150212,&no&antibiotics
13 pET546 DH5a
Arnold&Dressien&lab,&see&Nouwen&and&
Driessen2002
14 pET552 DH5a
Arnold&Dressien&lab,&see&Nouwen&and&
Driessen2002
15 pET560 DH5a
Arnold&Dressien&lab,&see&Nouwen&and&
Driessen2002
16 pET584 DH5a
Arnold&Dressien&lab,&see&Nouwen&and&
Driessen2002
17 pET20bAlaRSEcoli BL21
From&Paul&Schimmel&lab,&express&E.coli&
AlaRS
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Appendix E.  Plasmid frozen stocks in -20 °C freezer.  
 
 
 
 
 
 
 
 
Box1 Plasmid,name Description Additional,information
1 C.$albicans$LeuRS$WT pet21b$Amp+ pHZCaLRSWT
2 C.$albicans$LeuRS$K510A pet21b$Amp+ pHZCaLRSK510A
3 C.$albicans$LeuRS$K510D pet21b$Amp+ pHZCaLRSK510D
4 C.$albicans$LeuRS$K510E pet21b$Amp+ pHZCaLRSK510E
5 C.$albicans$LeuRS$K510R pet21b$Amp+ pHZCaLRSK510R
6 Yeast$cytoplasmic$LeuRS$WT From$Jaya
7 Yeast$cytLeuRS$K507A
8 Yeast$cytLeuRS$K507D
9 Yeast$cytLeuRS$K507E
10 Yeast$cytLeuRS$K507R
11 E.$coli$LeuRS$YDD
12 Yeast$cyt$tRNAleu megaprep
13 E.coli$cyt$tRNAleu megaprep
14 T7$RNAP$WT
15 C.$albicans$LeuRS$D422A pHZ$CaLRSD422A
16 C.$albicans$LeuRS$CP1$domain From$Andres,$2009$JMB$Cusack pCaLRSCP1WT
17 C.$albicans$cyt$tRNAleu pUC$57 pHZCatRNAUUA
18 empty
19 CCA$adding$enzyme From$Li
20 E.$coli$Ntase From$XiangleiWYang$lab
21 Ec$CP1 pBETeCP1W13W6$E.coli$LRS$CP1$domain pet15b$NdeI_BamHI
22 C.albicans$LRS$T316V pHZ$CaLRS$T316V
23 C.albicans$LRS$F491A
24 C.albicans$LRS$DM1 Y487F/T316V pHZ$CaLRS$Y487F/T316V
25 C.albicans$LRS$DM2 Y487A/L317T
26 C.albicans$LRS$Y487F pHZCaLRSY487F
27 C.albicans$LRS$DM3 Y487E/T316S
28 C.albicans$LRS$Y487A pHZCaLRSY487A
29 C.albicans$LRS$Y487E pHZ$CaLRSY487E
30 C.albicans$LRS$L317T
31 C.$albicans$LRS$T316S pHZ$CaLRST316S
32 HHWtRNApheWHDV From$Germany$Group map$in$notebook
33 YmLRS$dCP1$(2A) From$Michal's$W80$Box$10W45 sequencing$result$confirmed
34 YmLRS$dCP1$(2A$long) From$Michal's$W80$Box$10W46 sequencing$result$confirmed
35 Mtb$tRNAleu From$Andres$201311
36 YmLeuRS$CP1$WNWC Jaya's$paper$shortest$ymLRSCP1 Ile260$to$Glu431$56ng/ul
37 YmLeuRS$CP1$+N+C Jaya's$paper$2nd$shortest$ymLRSCP1 Trp238$to$Leu442$63$ng/ul
38 YmLeuRS$CP1$beta$ext jaya's$paper$longest$ymLRSCP1 Lys232$to$Tyr$452$71ng/ul
39 YmLRS$dCP1$(2A$long) same$as$No.34$sequencing$result$confirmed 54$ng/ul
40 YmLeuRS$sequencing$primer Fw850 10$ng/ul
41 p15bEcLeuRS from$Lucy 20141203
42 pRHFN1 Box12W62,$Rachel$Hellmann 20150103
43 pRHD391A Box12W69,$Rachel$Hellmann 20150103
44 pGP1W2 Box3W13 20150104
45 pETW20bWAlaRSWE.coli$ From$Schimmel$lab 20150723
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Appendix G.  Topology file of Ile-AMP (named IPO) in MD simulation. 
 
 
 
RESI IPO         -1.00  !  ILE bould to O2' of AMP ribose, constructed by Ade,NTER,
5PHO,ILE,Hanchao
                        !  Zhao, 20130308
GROUP  !-1.00
ATOM C5'  CN8B   -0.08  !
ATOM H5'  HN8     0.09  !               
ATOM H5'' HN8     0.09  !             H61-N6-H62
ATOM P    P       1.50  !                 |
ATOM O1P  ON3    -0.82  !                C6
ATOM O2P  ON3    -0.82  !               // \
ATOM O5'  ON2    -0.62  !              N1   C5----N7
ATOM O5T  ON4    -0.68  !              |    ||    \\
ATOM H5T  HN4     0.34  !              |    ||     C8--H8
GROUP  !0.00            !              C2   C4     / \
ATOM C4'  CN7     0.16  !             / \\  / \   /    \
ATOM H4'  HN7     0.09  !            H2  N3     N9      \ 
ATOM O4'  ON6B   -0.50  !                                \
ATOM C1'  CN7B    0.16  !                                  \
ATOM H1'  HN7     0.09  !                                    \
GROUP   !0.00           !          H5T-O5T    H5' H4'  O4'   |     
ATOM N9   NN2    -0.05  !               |      |    |  /   \  |      
ATOM C5   CN5     0.28  !           O2P-P-O5'--C5'--C4'      C1'--H1'
ATOM N7   NN4    -0.71  !               |      |      \     /
ATOM C8   CN4     0.34  !               O1P  H5'' H3'-C3'--C2'--H2''
ATOM H8   HN3     0.12  !                            /      |
ATOM N1   NN3A   -0.74  !                           O3'     O2'
ATOM C2   CN4     0.50  !                           |       |
ATOM H2   HN3     0.13  !                          H3T      |          HG21
ATOM N3   NN3A   -0.75  !                                   C==O      /
ATOM C4   CN5     0.43  !                             HT1   | HA   CG2-HG22
ATOM C6   CN2     0.46  !                               \   | /   /  \
ATOM N6   NN1    -0.77  !                           HT2--N--CA  /      HG23
ATOM H61  HN1     0.38  !                               /   | /
ATOM H62  HN1     0.38  !                             HT3   CB--HB       HD1
GROUP                   !                                    \          /
ATOM C2'  CN7B    0.14  !                                     CG1-----CD--HD2
ATOM H2'' HN7     0.09  !                                     / \       \
ATOM O2'  OP     -0.34  !                                   HG11 HG12    HD3
ATOM C    CCP     0.63  ! 
ATOM O    OCP    -0.52  ! 
GROUP                   !
ATOM N   NH3    -0.30
ATOM HT1 HC     0.33
ATOM HT2 HC     0.33
ATOM HT3 HC     0.33
ATOM CA  CT1    0.21
ATOM HA  HB     0.10
GROUP                   
ATOM CB   CT1    -0.09  
ATOM HB   HA      0.09  
GROUP                   
ATOM CG2  CT3    -0.27  
ATOM HG21 HA      0.09
ATOM HG22 HA      0.09
ATOM HG23 HA      0.09
GROUP   
ATOM CG1  CT2    -0.18
ATOM HG11 HA      0.09
ATOM HG12 HA      0.09
GROUP   
ATOM CD   CT3    -0.27
ATOM HD1  HA      0.09
ATOM HD2  HA      0.09
ATOM HD3  HA      0.09
GROUP                   !0.00
ATOM C3'  CN7     0.14
ATOM H3'  HN7     0.09
ATOM O3'  ON5    -0.66
ATOM H3T  HN5     0.43
BOND O1P  P     O2P   P    O5T  P   H5T  O5T   P    O5'
BOND O5'  C5'       C5'  C4'       C4'  O4'       C4'  C3'       O4'  C1'
BOND C1'  N9        C1'  C2'       N9   C4        N9   C8        C4   N3
BOND C2   N1        C6   N6
BOND N6   H61       N6   H62       C6   C5        C5   N7
BOND C2'  C3'       C2'  O2'       O2'   C        
BOND CB   CA    CG1   CB   CG2 CB   CD CG1
BOND N     CA   C   CA   
BOND CA  HA     CB    HB   CG1  HG11  CG1  HG12  CG2  HG21
BOND CG2  HG22  CG2  HG23  CD  HD1   CD  HD2   CD   HD3
BOND N   HT1   N   HT2    N   HT3
BOND C3'  O3'       O3'  H3T 
BOND C1'  H1'       C2'  H2''      C3'  H3'       C4'  H4'       C5'  H5'
BOND C5'  H5''      C8   H8        C2   H2
DOUBLE  N1  C6      C2   N3        C4   C5        N7   C8
DOUBLE  O   C
IMPR N6   C6   H61  H62        C6   N1   C5   N6 
IMPR C    O2'  CA   O 
DONO H5T  O5T
IC O5'  C5'  C4'  C3'    1.4401  108.83   60.00  116.10   1.5284 !gamma
IC C5'  C4'  C3'  O3'    1.5160  116.10  140.00  115.12   1.4212 !delta
IC C4'  C3'  O3'  H3T    1.5284  111.92  155.00  119.05   1.6001 !epsilon
IC O4'  C3'  *C4' C5'    1.4572  104.06 -120.04  116.10   1.5160
IC C2'  C4'  *C3' O3'    1.5284  100.16 -124.08  115.12   1.4212
IC C4'  C3'  C2'  C1'    1.5284  100.16  -30.00  102.04   1.5251 !puck
IC C3'  C2'  C1'  N9     1.5284  101.97  147.80  113.71   1.4896
IC O4'  C1'  N9   C4     1.5251  113.71  -97.2   125.59   1.3783 !chi
IC C1'  C4   *N9  C8     1.4896  125.97 -179.94  106.0    1.367  
IC C4   N9   C8   N7     1.376   106.0     0.0   113.6    1.312  
IC C8   N9   C4   C5     1.367   106.0     0.0   105.6    1.382  
IC C8   N7   C5   C6     0.0       0.0   180.0     0.0    0.0
IC N7   C5   C6   N1     0.0       0.0   180.0     0.0    0.0
IC C5   C6   N1   C2     0.0       0.0     0.0     0.0    0.0
IC N9   C5   *C4  N3     1.376   105.6  -180.0   126.9    1.342  
IC C5   N1   *C6  N6     1.409   117.6  -180.0   121.2    1.337  
IC N1   C6   N6   H61    1.337   121.2     0.0   119.0    1.01   
IC H61  C6   *N6  H62    1.01    119.0   180.0   119.00   1.01   
IC C5   N1   *C6  N6     1.409   117.6  -180.0   119.0    1.337  
IC N1   C6   N6   H61    1.337   119.0     0.0   119.0    1.01   
IC H61  C6   *N6  H62    1.01    119.0   180.0   121.00   1.01   
IC N9   N7   *C8   H8    0.0       0.0   180.0     0.0    0.0
IC N1   N3   *C2   H2    0.0       0.0   180.0     0.0    0.0
IC C1'  C3'  *C2' O2'    1.5284  102.04 -114.67  110.81   1.4212 
IC O4'  C2'  *C1' H1'    0.0       0.0  -115.0     0.0    0.0
IC C1'  C3'  *C2' H2''   0.0       0.0   115.0     0.0    0.0
IC C2'  C4'  *C3' H3'    0.0       0.0   115.0     0.0    0.0
IC C3'  O4'  *C4' H4'    0.0       0.0  -115.0     0.0    0.0
IC C4'  O5'  *C5' H5'    0.0       0.0  -115.0     0.0    0.0
IC C4'  O5'  *C5' H5''   0.0       0.0   115.0     0.0    0.0
BILD C4'   C5'  O5' P      0.0000  000.00 -146.00   000.00   0.0000
BILD C5'   O5'  P   O5T    0.0000  000.00  -46.90   000.00   0.0000
BILD O5T   O5'  *P  O1P    0.0000  000.00 -115.82   000.00   0.0000
BILD O5T   O5'  *P  O2P    0.0000  000.00  115.90   000.00   0.0000
BILD H5T   O5T  P   O5'    0.0000  000.00  -95.20   000.00   0.0000
IC HT1  N    CA   C     0.0000  0.0000  180.0000  0.0000  0.0000
IC HT2  CA   *N   HT1   0.0000  0.0000  120.0000  0.0000  0.0000
IC HT3  CA   *N   HT2   0.0000  0.0000  120.0000  0.0000  0.0000
IC N    C    *CA  CB    1.4542 106.3500  124.2200 112.9300  1.5681
IC N    C    *CA  HA    1.4542 106.3500 -115.6300 106.8100  1.0826
IC N    CA   CB   CG1   1.4542 112.7900  180.0000 113.6300  1.5498
IC CG1  CA   *CB  HB    1.5498 113.6300  114.5500 104.4800  1.1195
IC CG1  CA   *CB  CG2   1.5498 113.6300 -130.0400 113.9300  1.5452
IC CA   CB   CG2  HG21  1.5681 113.9300 -171.3000 110.6100  1.1100
IC HG21 CB   *CG2 HG22  1.1100 110.6100  119.3500 110.9000  1.1102
IC HG21 CB   *CG2 HG23  1.1100 110.6100 -120.0900 110.9700  1.1105
IC CA   CB   CG1  CD    1.5681 113.6300  180.0000 114.0900  1.5381
IC CD   CB   *CG1 HG11  1.5381 114.0900  122.3600 109.7800  1.1130
IC CD   CB   *CG1 HG12  1.5381 114.0900 -120.5900 108.8900  1.1141
IC CB   CG1  CD   HD1   1.5498 114.0900 -176.7800 110.3100  1.1115
IC HD1  CG1  *CD  HD2   1.1115 110.3100  119.7500 110.6500  1.1113
IC HD1  CG1  *CD  HD3   1.1115 110.3100 -119.7000 111.0200  1.1103
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Appendix H. Copyright release form. 
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Author: Hanchao  Zhao,  Andres  Palencia,
Elena  Seiradake,  et  al
Publication: ACS  Chemical  Biology
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If  you're  a  copyright.com
user,  you  can  login  to
RightsLink  using  your
copyright.com  credentials.
Already  a  RightsLink  user  or
want  to  learn  more?
PERMISSION/LICENSE  IS  GRANTED  FOR  YOUR  ORDER  AT  NO  CHARGE
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(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright
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One-time permission is granted only for the use specified in your request. No additional
uses are granted (such as derivative works or other editions). For any other uses, please
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Appendix I.  “0186” slows deacylation by the LeuRS CP1 domain with no inhibition 
of aminoacylation. 
	  
Materials 
 
Calf liver crude tRNA was purchased from Novagen (San Diego, CA).  Radiolabeled 
[14C]-leucine (NEC279E250UC, 328 mCi/mmol) and [3H]-isoleucine (TRQ40314, 
97 Ci/mmol) were obtained respectively from PerkinElmer and Amersham. 	  
Methods 
 
Aminoacylation assay.  Each aminoacylation reaction contained 50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (HEPES), pH 7.6, 30 mM KCl, 
30 mM MgCl2, 0.02% BSA, 1 mM dithiothreitol (DTT), 4 mg/ml calf liver crude tRNA 
(Pang & Martinis, 2009), 40 μM [14C]-leucine (164 mCi/mmol), 100 nM human 
cytoplasmic LeuRS and varying concentrations of compound “0186” dissolved in 
dimethyl sulfoxide (DMSO).  Reactions were incubated at 30°C for 20 min before adding 
4 mM ATP.  Aliquots of 5 μl were taken at different time points and quenched on 
Whatman filter pads, which were pre-soaked with 5% trichloroacetic acid (TCA) and 
dried.  The pads were washed three times for 10 min each in ice-cold 5% TCA, and then 
once in cold 70% ethanol.  The washed pads were dried under a heat lamp and put into 
scintillation vials with 3 ml ScintiSafe Econo F fluid (Fisher Scientific).   The 
radioactivity was quantified by a Beckman LS 6000IC scintillation counter (Beckman 
Coulter, Fullerton, CA) 
 
Isolation of mischarged tRNALeu.  8 μM transcribed C. albicans tRNALeuUAA (Zhao et 
al., 2015) at was aminoacylated by 5 μM C. albicans LeuRS D422A mutant in a reaction 
containing 60 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 3 μM [3H]-isoleucine 
(97 Ci/mmol) and 4 mM ATP.  The reaction was carried out at 37°C for 3 hours and then 
quenched with 0.18% acetic acid.  Protein was removed by a phenol:chloroform:isoamyl 
alcohol mixture (125:24:1, Fisher Scientific, Fair Lawn, NJ) at pH 4.3.  The aqueous 
layer was ethanol precipitated, washed by 80% ethanol and resuspended in 50 mM KPi, 
pH 5.0. 
 
Deacylation assays.  Deacylation reactions contained 60 mM HEPES, pH 7.7, 10 mM 
KCl, 10 mM MgCl2, 8 μM [3H]-Ile-tRNALeu.  Human cytoplasmic LeuRS was incubated 
with “0186” or DMSO at 30 °C for 20 min before addition of the enzyme at 100 nM in 
each reaction.  Aliquots of 5 μl were taken at different time points and quenched on 
Whatman filter pads that were pre-soaked with 5% TCA.  The pads were washed and 
analyzed as described above. 
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Result 
 
1. Aminoacylation Assays. 
 
Table I.1. Triplicated data of tRNALeu aminoacylation by human cytoplasmic    
LeuRS in the presence of “0186”.*	  	  
	  
 Charged tRNALeu (pmol) 
Time (min) LeuRS LeuRS +1 μM 0186 LeuRS+10 μM 0186 LeuRS+100 μM 0186 
Assay No. 1 2 3 1 2 3 1 2 3 1 2 3 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 10.97 9.62 8.76 11.46 9.98 11.37 9.54 9.01 9.58 7.81 8.28 7.09 
5 23.60 24.52 21.23 25.43 20.95 22.08 24.63 20.90 20.93 19.63 20.97 18.64 
10 37.40 32.65 34.74 41.37 33.65 35.41 39.04 33.78 37.88 32.28 33.89 32.47 
20 38.64 36.20 41.19 40.01 37.18 40.19 38.21 39.07 41.65 40.03 37.89 39.16 
	  * Three replicates were carried out for each concentration of “0186”. 
 
 
	  
Figure I.1.  Aminoacylation of tRNALeu by human cytoplasmic LeuRS in the 
presence of “0186”.  Abbreviations for LeuRS aminoacylation in the presence of varying 
concentrations of “0186” as follows: No “0186” (●, circle); 1 μM “0186” (▼, inverted 
triangle); 10 μM “0186” (▲, triangle); 100 μM “0186” (n, square). Error bars are based 
on reactions repeated at least in triplicate. 
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2. Deacylation Assays. 
 
   Table I.2. Triplicated data of Ile-tRNALeu deacylation by human cytoplasmic 
LeuRS in the presence of “0186”.* 
 Percentage of Ile-tRNALeu 
Time(min) No Enzyme LeuRS LeuRS+1 mM 0186 LeuRS+10 mM 0186 LeuRS+100 mM 0186 
Assay No. 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
1 103.6 103.5 102.1 66.5 67.9 74.9 78.4 75.7 72.5 83.4 74.7 74.3 85.6 86.5 89.6 
2 97.1 107.4 98.2 56.3 56.7 50.9 63.2 60.4 50.5 60.6 75.5 69.8 78.0 64.1 81.6 
4 91.8 105.1 95.8 45.8 42.1 39.0 56.4 53.7 36.5 55.4 58.9 50.7 64.3 65.3 63.9 
6 91.4 99.4 84.8 37.0 42.8 31.4 48.1 47.9 36.6 49.1 58.1 41.6 59.5 66.5 56.1 
10 88.2 96.7 93.6 36.0 41.5 27.1 45.9 48.7 31.2 42.2 54.5 36.3 51.4 55.6 44.2 
    * Three replicates were carried out for each concentration of “0186”. 
 
 
	  
Figure I.2.  Deacylation of mischarged tRNALeu by human cytoplasmic LeuRS in the 
presence of “0186”.  Abbreviations for LeuRS aminoacylation in the presence of varying 
concentrations of “0186” as follows: No Enzyme (u, diamond); No “0186” (●, circle); 
1 μM “0186” (▼, inverted triangle); 10 μM “0186” (▲, triangle); 100 μM “0186” (n, 
square).  Error bars are based on reactions repeated at least in triplicate.	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Table I.3. Rate constant in deacylation assays with varying concentrations of 
“0186”.* 
“0186” (μM) 0 1 10 100 No Enzyme 
K (rate constant) 0.60 ± 0.07 0.60 ± 0.11 0.43 ± 0.09 0.30 ± 0.07 0.09 ± 0.23 
*. K (rate constant) is calculated to fit into one-phase exponential decay via Graphpad 6. 	  	   Reference	  	  Pang,	  Y.L.,	  &	  Martinis,	  S.A.	  (2009).	  A	  paradigm	  shift	  for	  the	  amino	  acid	  editing	  mechanism	  of	  human	  cytoplasmic	  leucyl-­‐tRNA	  synthetase.	  Biochemistry,	  
48(38),	  8958-­‐8964.	  Zhao,	  H.,	  Palencia,	  A.,	  Seiradake,	  E.,	  Ghaemi,	  Z.,	  Cusack,	  S.,	  Luthey-­‐Schulten,	  Z.,	  &	  Martinis,	  S.	  (2015).	  Analysis	  of	  the	  resistance	  mechanism	  of	  a	  benzoxaborole	  inhibitor	  reveals	  insight	  into	  the	  leucyl-­‐tRNA	  synthetase	  editing	  mechanism.	  
ACS	  Chem.	  Biol.,	  10(10),	  2277-­‐2285.	  
 	  
